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=P53 is an important gene in the control of cellular proliferation, apoptosis and DNA repair, and loss of
wild-type p53 gene function has been demonstrated to be the most common type of event arising
during the development of many human malignancies. My aim therefore, was to generate an
-experimental system in which it would be possible to externally control p53 gene expression and thus
^examine phenotypic consequence following introduction of wild-type p53 gene expression in an
otherwise p53 null environment. Following recent advances in the field of inducible promoter
technology, I attempted to render p53 expression inducible utilising several of the current promoter
systems of choice via both targeting and transgenic approaches.
"Using a double replacement targeting approach, I attempted to replace the p53 promoter region with
inducible promoter sequence. Targeting constructs were designed to produce a mutant p53 locus,
which would then subsequently allow the rapid and simple introduction of a variety of transcriptional
-regulatory sequences. Following the introduction of the first stage targeting vector into ES cells,
southern analysis demonstrated that 1 clone from 508 HAT resistant clones possessed a recombinant
p53 locus.
In a parallel approach, I used one of the candidate promoter systems to generate an interferon a/(3
inducible p53 transgene. Sarcoma cells, derived from an engineered homozygous p53 deficient
mouse, were established as lines in vitro and stably transfected with this construct. Analysis of
resultant inducible clones demonstrated little significant transgene mediated effect upon tumour cell
cycle, however, a clear transgene dependent apoptotic phenotype was observed following UV
-irradiation.
To test the possible extent of therapeutic benefit resulting from the introduction of p53 gene expression
into p53 null tumour cells in vivo, 5 x 106 inducible sarcoma cells were injected sub-cutaneously into
the flanks of SCID animals. Tumours grew at the site of injection within 3 weeks, at which time the
animals were injected intra-peritoneally with synthetic double stranded RNA (pI:pC) to induce
■transgene expression. No p53 protein could be detected in these tumour samples by either western or
immuno-histochemical analyses. Subsequent re-establishment and analysis of cell lines derived from
these tumours indicated that selection for a final presenting tumour cell with lost or silenced p53
transgene expression can occur during the clonal expansion of inoculated ID cells growing in vivo.
Following pI:pC injection of SCID mice, an acute apoptotic phenotype was observed in the crypt
compartments of the small intestine which resulted in the death of approximately 20% of all injected
animals. It is known that levels of interferon a/p are elevated during graft versus host response, but
these cytokines had previously been described as exerting a proliferative effect upon colonic crypt
cells. Observation of small intestine epithelia, 6 hours post-injection, clearly shows the underlying
biological process responsible for this phenomenon is however apoptosis. Further experimentation
would suggest that this intestinal phenotype is NK cell mediated and is most severe in T and B cell
deficient animals.
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CHAPTER 1
One of the greatest challenges to face biomedical science this century has been to
develop the ability to effectively cure inherited and acquired human genetic
disease. In order to understand fully the molecular nature underlying the biology
of human genetic disease, a prerequisite before such a therapeutic goal can be
considered feasible, scientists have found it necessary to employ the use of
experimental animals as model systems. Observations recorded in the course of in
vitro experimentation with mammalian cell lines, although certainly highly
informative as regards cellular biology, cannot be directly extrapolated as being of
relevance to the genetic disorder in vivo. The model species of choice in this field
of experimental science is for many reasons the common house mouse, Mus
musculus.
The biology of this species is of far more physiological relevance to human
biology than that of the other "classical" genetic model systems, such as E. coli
and D. melanogaster. The mouse's small size, fertility and short gestation period
make their practical handling and storage convenient for often necessary large
scale breeding programmes. Moreover, the existence of many inbred laboratory
mouse strains has generated a resource of greater than 1000 spontaneous,
radiation or chemically induced mutant lines (Doolittle et al, 1996). This has
enabled researchers in the past to map the genes implicated in disease to specific
chromosomal loci, thus deriving the first genetic linkage maps. However, it is
most certainly the technological advances made in the past two decades that have
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been instrumental in fixing the mouse as the mammalian system of choice in the
modelling of human disease.
Despite the complexity of the murine genome (~3 x 109 base pairs (bp)/haploid
genome), parallel breakthrough advances in Embryonal Stem cell (ES cell), gene
targeting and gene cloning technologies mean that it is now possible to modify
specifically the expression of any known gene and analyse phenotypic
consequence on virtually any inbred or outbred genetic background. In addition,
the ever-improving resolution of genetic linkage and physical maps of the murine
genome is greatly facilitating the identification of candidate disease genes of
interest. It is predicted that the mouse genome will be fully sequenced by the year
2003 (Jordan and Collins, 1996).
(l.i.l) The Origins of the Laboratory Mouse
th
The origins of mouse genetics began formally at the turn of the 20 century. It
was at this time that researchers first recognised the need for a higher
homogeneity of genetic background in the experimental mouse. Strains of mice
with inbred backgrounds were required to fix alleles and permit controlled
scientific experimentation exploring the genetics of disease traits. In 1909, Little
began breeding the first inbred mouse strain, DBA (d, dilute; b, brown; a, non-
agouti), with the intention of investigating the genetics of cancer susceptibility
loci.
Inbred strains of mice are created following approximately 20 consecutive rounds
of brother x sister mating (Hogan et al, 1995). There now exist approximately
478 strains of inbred mice (Festing, 1998) and many of the lines found in the
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laboratory today share their origins from the 1920's and 30's, from within the
laboratories of Little, Strong and MacDowell.
In the 1940's, Snell pioneered the development of the congenic strain and these
mice were initially bred in an attempt to identify loci influencing tissue
transplantation. Congenic strains are constructed by backcrossing one inbred line
carrying a locus, phenotypic trait or mutation of interest onto another inbred strain
background. The desired trait is selected at each of approximately 10
backcrosses. After this breeding programme is complete, the resultant mouse
differs from the parental mouse statistically by approximately 20cM of DNA,
from within which, is encoded the trait of interest. These mice have proved
invaluable in the mapping of polymorphic disease and marker loci (for review see
Frankel, 1995).
Recombinant Inbred (RI) strains, originally derived by Taylor and Bailey during
the 1970's, have also proved invaluable in the study of polygenic disease. These
mice are created via the systematic inbreeding of randomly selected pairs from the
F2 generation resulting from an original cross of two different inbred mouse
strains. Thus, RI strains comprise an overall 50:50 genetic contribution from both
initial inbred parental lines, but all different strains originating from the F2
intercrosses, exhibit a random combination and segregation of individual loci.
These animal strains have been successfully employed to examine the complex
genetics underlying the diseases of epilepsy (Frankel et al, 1994), atherosclerosis
(Justice et al, 1992) and substance abuse (Crabbe et al, 1994).
A modification of the RI approach, termed the Recombinant Congenic (RC)
approach was pioneered by Demant during the mid 80's {Demant and Hart,
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1986). Following the breeding of two inbred strains, RC mice are produced by
initially backcrossing the resultant F i generation two times, followed by repeated
brother x sister mating. The result of this breeding programme is that the RC
strain is composed of approximately 12.5% of the donor genome, randomly
distributed through 87.5% of the background genome. This increases the
comparative probability of disease locus segregation in comparison to the RI
strains and thus permits finer mapping of complex traits. The RC approach has
been most extensively employed in mapping tumour susceptibility genes of colon
(Moen et al, 1996) and lung cancer (Finjeman et al, 1995), and investigating the
genetics underlying the T-cell response to selected cytokines (Lipoldova et al,
1995).
Figure l.i.a on the next page illustrates the conventional breeding programmes
used in the development of laboratory mouse strains.
KEY
A. Single cross between two inbred laboratory strains.
B. 10 conventional backcrosses and phenotypic selections, onto one of the
parental inbred genetic backgrounds to produce a congenic strain.
C. Production of the F2 generation following Fi (brother x sister) mating.
D. Randomly selected brother x sister mating originating at the F2 generation, for
more than 20 generations to produce a recombinant inbred strain.
E. 2 backcrosses onto one of the inbred parental backgrounds, producing the N3
generation.
F. Randomly selected brother x sister mating between N3 generation mice for
more than 20 generations to produce a recombinant congenic strain.
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(l.i.2) Manipulation of the Murine Genome
The ability to modify the specific expression of a single allele on an inbred
genetic background has rapidly accelerated our understanding of many diverse
aspects of mammalian molecular biology, including the genetics of disease. The
application of transgenic technology, originating in the late 70's and early 80's,
has enabled researchers to introduce foreign DNA into the mammalian germline;
thus permitting the passage of introduced DNA through generations of inbred
genetic stocks.
Transgene technology has not been confined solely to the laboratory mouse and
has been utilised to produce transgenic strains of other mammalian and
domesticated species e.g. sheep, cow and chicken. These species however have
been primarily developed within the biotechnology industry, with potentially
massive commercial impact, in an attempt to improve the yield and quality of
meat sold in the marketplace, or as 'bio-reactors' for the production of
pharmacologically active peptides.
Transgenic technology has however been applied mostly in studies of phenotypic
consequence following the introduction of foreign gene expression in mice.
Further, this technology has proved useful in functional studies of the regulatory
promoter sequences responsible for conferring either temporal or tissue specific
patterns of reporter gene expression.
Pronuclear injection is the most commonly used approach to generate transgenic
animals (Hogan et al, 1995). This method involves the direct microinjection of
foreign DNA into the pronucleus of a fertilised egg (Gordon et al, 1980) and is
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successful at producing stable transgenic mouse lines at a frequency of between
10-40% (i.e. between one and four transgenic mice are produced from
approximately every ten pronuclear injections (Hogan et al, 1995)).
Transgenic animals produced in this manner characteristically possess multiple
copies of the introduced DNA, arranged tandemly in a head-to-tail array,
integrated randomly at a single chromosomal locus (Lacy et al, 1983). This
appears to be the result of extra-chromosomal homologous recombination (ECR)
arising between individual transgene copies immediately upon injection and prior
to integration (reviewed in Bollag et al, 1989).
The efficiency of ECR does not appear to be affected by the concentration of
injected transgenic DNA (it has been proposed that every transfected molecule
may undergo at least one ECR event (Folger and Capecchi, 1985)) and can occur
within very short lengths (<100bp) of homology (Rubnitz and Subramani, 1984).
Further, rates of ECR can be demonstrably enhanced in yeast following the
generation of a double-strand break within the sequence of introduced DNA (Orr-
Weaver et al, 1981).
In light of these observations, it is highly likely that rates of ECR between
transfected DNA transgenes are enhanced as a result of their preparation prior to
introduction as opposed to the amounts introduced. Transgenic DNA is routinely
linearised and removed from associated plasmid sequence prior to injection as
prokaryotic sequence elements have been demonstrated to influence transgene
expression negatively in vivo (Chada et al, 1985), (Hammer et al, 1987).
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The integration of transgenic DNA into the host cell's genome occurs in most
cases as a unique and rapid event following microinjection. It has been reported
that up to 80% of transgenic mice produced by this technique possess the
introduced DNA in all of their cells, i.e. integration occurs prior to pronuclear
division. The remaining proportion of transgenic animals exhibit mosaicism of
transgene expression resulting from delayed integration and require one round of
breeding and selection before possessing the introduced DNA in every cell
(Wilkie et al, 1986).
Infection of pre-implantation embryos with recombinant retrovirus is another
common approach used to introduce foreign DNA into the animal germline.
Rudolph Jaenisch produced the first transgenic animal in 1976 via this method, by
directly exposing a pre-implantation stage mouse embryo to Moloney leukaemia
virus (M-MuLV) (Jaenisch, 1976). In addition to simple exposure, another
commonly used method of infecting animal embryos with retrovirus is to co-
cultivate them in the presence of virus producing cells (Jahner et al, 1982). All
resultant transgenic animals generated by these methods are mosaic for presence
of the transgene (i.e. both somatic and germ cells from the same animal possess
variable transgene copy number, ranging from zero to many copies).
Variation of titre and exposure time of retrovirus in contact with the animal
embryo can influence resultant transgene copy number (Coffin et al, 1998). Long
exposure times with high titre viral stocks can result in the super-infection of
embryonal cells. Unlike the unique chromosomal integration event associated
with multiple transgene copy number following pronuclear injection, retroviral
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super-infection results in high copy numbers of transgene per cell, randomly
integrated at independent chromosomal loci. The generation of single copy
transgenic animals can be achieved relatively easily however, and so can enable
the phenotypic characterisation of gene dosage effects in vivo.
The main advantage of recombinant retroviral gene delivery over pronuclear
injection is that the introduction of foreign DNA is permissible with later stage
embryos (between days 8 to 14 p.c.). This allows DNA to be introduced at
different stages of embryonal development but, as a downside to this, viral
integration occurs predominantly in somatic cell lineages as opposed to the
germline (Soriano et al, 1986).
Unlike pronuclear injection however, retroviral gene delivery is limited by the
maximum size of transgenic DNA the virus can effectively package and therefore
introduce into the germline (maximum limit approximately 8Kb). In addition, as
a result of producing a significantly higher frequency of mosaic animals, there is
much greater variability in resultant transgene expression levels and pattern
between animals produced in an identical manner.
The advent of ES cell technology has enabled further means of generating
transgenic mice (see section l.i.5). Transgenic DNA can randomly integrate
within the ES cell genome following conventional in vitro transfection protocols.
Stable recombinant cells can then be selected in antibiotic containing media and
the relative levels of transgene expression can be determined in vitro, prior to
blastocyst injection and whole animal generation.
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(l.i.3) Transgene Expression
The in vivo expression pattern of a transgene can be influenced by the choice of
promoter sequence used to regulate transgene expression. Promoters of viral
origin have been demonstrated to drive the overexpression of a construct in both a
global (CMV) and tissue specific fashion (M-MuLV LTR in macrophages (Lang
et al, 1987)). Promoter sequences derived from mammalian constitutively
expressed (housekeeping) genes (e.g. (3-actin), also direct transgene
overexpression to all tissues.
Other commonly used promoter types confine transgene expression to specific
tissue types (e.g. a-crystallin to the lens (Goring et al, 1987), (3-lactoglobulin to
mammary epithelial cells (Simons et al, 1987)). These tissue specific promoters
are especially useful in transgenic studies when the global expression of a
transgene results in either a dominant deleterious phenotype or when phenotypic
consequence is of interest only in a specific cell type in vivo.
Inducible promoters are a further class of promoter type now commonly used in
transgenic experimentation. These promoter sequences have been derived from
viral, prokaryotic and eukaryotic genes and conditionally direct transcription in
the presence of an inducing molecule or following environmental stimulation.
Although transgenic DNA is present within the genome at all times, this
technology permits the induction (or ablation in conjunction with cre/loxP
technology, for review see (Porter, 1998)) of transgene expression at any stage of
embryonal or adult development.
The development of inducible gene expression technology is of obvious
advantage regarding conventional transgenic experimentation. Conditional
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transgenics are a powerful tool in the development of animal models of acquired
genetic disease. The expression of many loci implicated in acquired genetic
disease, in non-hereditary cancers for example, are proving to also be essential for
embryonic development (for review see Copp, 1995). Thus, cancer research will
benefit greatly from these promoter types, as it is now possible to model oncogene
activation and tumour suppressor ablation in a highly specific manner in adult
animals.
In addition, this technology has also greatly simplified the identification and
validation of transgene dependent phenotype, both in vitro and in vivo. The nature
of several of these promoters will be discussed in greater depth later in this
chapter (section l.i.8).
(l.i.4) The Problem with Transgenes
A common problem affecting the expression of foreign DNA in all transgenic
animal lines generated by random integration is termed the position effect. As
transgenic DNA randomly recombines within the host cell's genome, host DNA
sequence and conformation in proximity to the site of transgene integration can
influence transgene expression. Tocal chromatin structure and transcriptional
interference from adjacent promoter sequence elements can both positively and
negatively influence transgene expression. Position effect is often manifested by
poor reproducibility in detected transgene expression level and pattern in
transgenic animals generated in an identical fashion. To by-pass these problems,
transgene expression patterns should be fully characterised in the initial founder
lines, with desired levels selected and bred.
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A relatively infrequent problem associated with the random integration of foreign
DNA into the genome of a host cell is that of gene disruption. If the transgene
integrates within a promoter/enhancer region of a host gene or within an open
reading frame, the expression of that allele will be altered, even ablated. Random
transgene mediated mutagenesis and gene disruptions have been reported to occur
at a rate of approximately 5% of all integration events (Hogan et al, 1995). It is
therefore important to make phenotypic comparisons between identically
generated transgenic animals before determining whether any observable
phenotypic modifications are transgene dependent.
The major limitation of transgene technology is that DNA can only be introduced,
not removed from the animal germline. With the possible exception of
introducing dominant-negative mutant transgenes (Harvey et al, 1995) or anti-
sense expression constructs (Katsuki et al, 1988), which are both of highly
variable efficiency, it is not possible to completely ablate specific wild-type gene
expression using conventional transgenic approaches.
Parallel breakthroughs in ES cell and homologous recombination technologies
however have made it practically possible to knock out gene expression routinely
and have revolutionised mammalian genetic research.
(l.i.5) ES Cells
Embryonal Stem (ES) cells were first described by two independent groups in
1981, as permanent pluripotent cell lines derived from the inner cell mass (ICM)
of 3.5 d.p.c. (Days Post Coitum) mouse embryos (Martin, 1981), (Evans and
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Kaufman, 1981). Like Embryonal Carcinoma (EC) cells, ES cells can be
maintained,, essentially indefinitely, in an undifferentiated state in culture. To
achieve this, ES cells were traditionally cultured on mitotically inactivated
embryonic fibroblasts (Evans and Kaufman, 1981) or in media conditioned by EC
or BRL (Buffalo Rat Liver) or bladder carcinoma cells (Martin, 1981), (Smith and
Hooper, 1987), (Williams et al, 1988). ES cells have now also been demonstrated
to retain their morphology and pluripotency when cultured in media supplemented
with a single active peptide, e.g. Leukaemia Inhibitory Factor (LIF) (Smith and
Hooper, 1988), (Williams et al, 1988), Ciliary Neurotrophic Factor (CNTF) (Wolf
et al, 1994), or Human Oncostatin M (OSM) (Gearing and Bruce, 1992).
Upon withdrawal from these culture conditions in vitro, ES cells spontaneously
differentiate into a wide variety of cell types. ES cells plated at low density
characteristically differentiate into endoderm and mesoderm-like cells (Mummery
et al, 1990), whereas cells grown at a higher density characteristically start to
differentiate and form suspension aggregates termed embryoid bodies (similar to a
6 d.p.c. stage embryo). If these aggregates of cells re-attach to the tissue culture
plate, further differentiation will occur, resulting in a wide range of cell types
within a few weeks (reviewed Hooper, 1992).
The most important property of ES cells however, which is distinct from EC cells,
is the ability to colonise both somatic and germline tissues at high efficiency
following direct injection back into host blastocysts (Bradley et al, 1984). In
practical terms, this enables the genomic manipulation of large numbers of cells,
thereby permitting selection of relatively rare events, the phenotypic
consequences ofwhich can be analysed in many diverse cell and tissue types.
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(l.i.6) Basic Models of Homologous Recombination
Homologous recombination (HR) is defined as the exchange of genetic material
between two DNA entities entirely upon the basis of their sharing lengths of
homologous sequence. This process occurs naturally within eukaryotic organisms
during meiosis, mitosis and DNA repair and its mechanisms have been exploited
by researchers in a technique termed gene targeting (see section l.i.7), which
allows very precise modification of the genome (Hooper, 1992).
HR can occur in mammalian cells between introduced DNA molecules (extra-
chromosomal recombination, ECR, reviewed in Bollag et al, 1989), between
homologous sequences within the same chromosome (intra-chromosomal
recombination) or on different chromosomes (inter-chromosomal recombination)
or between introduced DNA sequences and host chromosomal sequences
(reviewed in Hooper, 1992).
Different homology requirements have been reported (both in total length and in
total un-interrupted length) for the ability of DNA molecules to homologously
recombine in the various ways listed above (reviewed in Hooper, 1992).
However, only the considerations and requirements for efficiently achieving HR
between introduced DNA sequences and host chromosomal sequences will be
discussed further in this chapter (see section l.i.7).
Much of the research investigating the underlying mechanisms of homologous
recombination have been carried out either in bacteria, fungi or yeast, primarily
because of the low complexity of their genomes and in the latter cases, the ease
through which they can be grown, both mitotically and meiotically. Many of the
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principles of HR, derived from the use of these organisms, have also proven
applicable to the observed HR occurring within mammalian cells.
In general, homologous DNA sequences can exchange information through either
reciprocal or non-reciprocal recombination. Reciprocal recombination involves a
balanced swap of nucleotides between sequences, whilst non-reciprocal
recombination (or gene conversion) involves a unidirectional exchange of
nucleotides. Both forms of HR are often observed to occur simultaneously at
adjoining sequences and models have been proposed accordingly to attempt to
explain their underlying molecular mechanisms.
(l.i.6a) Reciprocal Recombination
Figure l.i.b illustrates the model proposed by Holliday to explain the mechanism
of reciprocal homologous recombination (Holliday, 1964). Although updated and
modified, most notably in the models by Meselson & Radding (section l.i.6b) and
by Szostak & Stahl (section l.i.6c), this model has been included to explain the
concepts of heteroduplex DNA formation and the Holliday Junction, concepts
which are universal to all of the above proposed models ofHR.
In this schematic, the bold pairs of black and blue lines signify two double
stranded molecules of homologous DNA. At point (A), both homologous sections
of DNA pair to form a synaptic complex where both form single-strand nicks at
homologous positions in strands of like polarity (B). Strand invasion occurs at the
sites of DNA breakage (i.e. the free ends of both nicked DNA duplexes invade
each other simultaneously) and become covalently sealed to form a structure
termed the Holliday Junction (C). The Holliday junction can subsequently diffuse
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along the length of DNA by a process termed branch migration, forming a stretch
of heteroduplex DNA (i.e. a length of double stranded DNA composed from two
different DNA molecules) as it proceeds (D). An alternate depiction of the
Holliday junction following branch migration is shown in (E). Resolution of this
structure can arise from diagonal cleavage at either points (F) or (G), resulting in
the generation of'non-crossover' or 'crossover' products respectively.
Since this model was proposed in the mid-60's, Holliday structures have been
directly visualised in E. Coli using electron microscopy, thus providing part
corroboration for the molecular mechanisms discussed here (Potter and Dressier,
1979).
(l.i.6b) Meselson & Radding's Model of Homologous Recombination
Meselson & Radding proposed this revised form of the Holliday model in 1975
{Meselson and Radding, 1975} in light of observations that HR rarely occurs in a
reciprocal manner, and so to convincingly model the mechanisms underlying gene
conversion.
As depicted in figure 1 .i.c, at point (A), both homologous sections ofDNA pair to
form a synaptic complex where only one forms a single-strand nick (B), which
subsequently invades the other intact homologous duplex, displacing a D-loop
(C). The D-loop structure is degraded at (D), and an asymmetric heteroduplex is
generated (i.e. only the recipient chromatid possesses heteroduplex DNA) as a
result of DNA synthesis on the donor duplex and degradation on the recipient
chromatid. Ligation occurs at (E) forming a Holliday junction which is resolved
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as in the previous model, either without cross-over to generate the products at (F)
or with crossover to generate the products at (G).
(l.i.6c) The Double Strand Break Repair Model ofHR
The Double-Strand Break-Repair (DSBR) model ofHR was initially proposed by
Szostak & Stahl to explain observable increases in recombination rates in yeast
following the introduction of double-strand DNA breaks (Szostak et al, 1983).
This model is similar to the other models mentioned in section l.i.6, in that
recombination is again initiated through the invasion of a single DNA strand into
homologous recipient duplex DNA to produce heteroduplex DNA.
As depicted in figure 1 .i.d, at point (A), both homologous sections ofDNA pair to
form a synaptic complex where one strand forms a double strand break, which is
subsequently enlarged to a double strand gap as a result of exonuclease
degradation (B). One of the free ends generated at point (B), invades the other
duplex molecule to displace a D-loop structure on the recipient duplex (C), which
extends as result of DNA synthesis primed from the initial invading strand (D).
Also at point (D), the extended D-loop structure base pairs with homologous
single-stranded DNA generated from the original degraded double strand break
generated at point (B). Covalent linkage occurs at point (E) to form two Holliday
junctions, both of which can diffuse by branch migration. In addition, the
displaced D-loop, base-paired to the original donor duplex molecule, acts as a
primer from which DNA synthesis can be initiated. Resolution of the two
Holliday junctions generated at point (E) can result in the generation of four
recombination products. (Fi) results from double non-crossover; (Fii) results from
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crossover at the left, but non-crossover on the right; (Fiii) results from non-
crossover on the right, but crossover on the left; and (Fiv) results from crossover
at both junctions. Note that the gap resulting from endonuclease degradation of
the original donor molecule at point (B) has been replaced by sequences derived
from the recipient DNA molecule.
HR can also occur in mammalian cells in a non-conservative manner (i.e. two
homologous DNA sequences recombine to generate a single species and a
resultant net loss of DNA). A further model of FIR, termed the single-strand
annealing (SSA) model, was proposed by Lin in 1984 in an attempt to explain the
generation of non-conservative extra-chromosomal HR products, arising from the
introduction of double-strand DNA breaks within homologous sequences (Lin et
al, 1984). The mechanisms of SSA are distinct from the models discussed above
and are not included within this chapter as this model ofHR does not appear to be
able to explain the majority of recombination products that arise following HR
between introduced DNA sequences and host chromosomal sequences i.e.
products that arise during gene targeting (see section l.i.7).
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Gene targeting is the term used to describe homologous recombination (HR)
between DNA vector and host cell genomic sequence. Via application of ES cell
and HR technology, it is now possible to introduce virtually any genetic
modification into the animal germline, ranging from the subtle introduction of
point mutations and small scale deletions (for review see Brandon et al, 1995,
Bedell et al, 1997 (parts I and II)), through to a full spectrum of gross
chromosomal alterations (Ramirez-Solis et al, 1996).
(l.i.7a) Basic Targeting Strategy
The simplest targeting strategy involves the inactivation of a target gene via the
insertion of a positive selectable marker (e.g. a neomycin resistance cassette).
Utilising an O-type (insertion type) targeting vector, linearised within the region
of sequence homology, a single recombination event occurring at the vectors free
ends will result in an insertion event at the target chromosomal locus. The result
of such homologous recombination will be a duplication of the homologous
sequence separated by plasmid vector sequence (see figure 1 .i.e).
Q-Type (replacement type) vectors are also commonly utilised to ablate gene
expression and require two sections of homologous sequence. Homologous
recombination between vector and host DNA, occurring within both sections of
homology, will delete all host chromosomal DNA residing between crossover
events and replace them with intervening vector sequence (also see fig. 1 .i.e). It is
possible to select for replacement type events if the targeting vector possesses a
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positive selectable marker residing between both portions of homologous vector
sequence.
It has been observed that decreasing the length of one "arm" of homologous
vector sequence does not significantly affect resultant replacement targeting
frequency (Thomas and Capecchi, 1987) provided that the length of homology
remains greater than 470bp (Hasty et al, 1991(A)). This evidence indicates that
perhaps only one recombination event is required between host chromosomal and
replacement type vector sequences to produce the desired recombination event.
Subsequent branch migration of a single crossover event and resolution within the
other region of homologous vector sequence could account for the observed





(l.i.7b) Factors Affecting Targeting Efficiency
Compared to the frequency of random integration, the successful gene targeting of
a locus in mammalian cells is a relatively rare event. Following the transfection
of a targeting construct into ES cells, approximately 10"3 mammalian cells exhibit
random integration, whilst only around 10"6 cells exhibit successful homologous
recombination (Waldman, 1992). Further, large variability is often observed
between the efficiencies of HR at independent loci following similar targeting
experimental methodologies in mammalian cells.
The most likely explanation for this intrinsic variability of success in targeting
experimentation is the complexity of the higher eukaryotic genome. The
organisation of the genome creates variability in both chromatin composition and
conformation, and therefore in loci accessibility. The frequency of HR is
reportedly enhanced when targeting actively transcribing loci (Mansour et al,
1988), presumably as a result of a looser DNA: histone conformation, however
this is by no means a prerequisite for gene targeting (Smithies et al, 1985),
(Jeannotte et al, 1991).
Within practical limits, the greater the length of homology utilised in the targeting
construct, the greater the frequency of observed HR although gene targeting has
been achieved in mammalian cells with constructs containing as little as 1.3Kb
overall homology (Hasty et al, 1991 (A)). Targeting experimentation at the hprt
locus however, has demonstrated that as the length of homology increases,
resultant targeting frequency also increases in either an exponential (Thomas and
Capecchi, 1987), (Deng and Capecchi, 1992), or in a linear manner (Hasty et al,
1991 (A)). Whilst this may suggest the use of very large pieces of homology in
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targeting vector construction, no further improvement in targeting frequency was
observed once overall homology lengths exceeded 14Kb in length (Deng and
Capecchi, 1992). The use of isogenic DNA has also enhanced HR frequency in
targeting experimentation (te Riele et al, 1992). Incorporating homologous DNA
from the same lab strain as that of the target ES cells, reduces the number of
single base pair polymorphisms, thus maximising the length of uninterrupted
sequence homology.
Linearisation of the targeting vector prior to transfection is also thought to
enhance targeting efficiency following demonstrable enhancement of HR
frequency in both fungi and extra-chromosomal recombination in mammalian
cells (for review see Orr-Weaver, 1985).
(l.i.7c) Selection ofComplex Targeting Strategies
The first gene targeting experiments using ES cells were aimed at modifying the
hypoxanthine-guanine phosphoribosyltransferase locus (HPRT) (Thomas and
Capecchi, 1987), (Doetschman et al, 1987). This gene located on the X-
chromosome (therefore present only as a single copy in males), confers resistance
to HAT (see section 5.ii.4) and so permitted the selection of desired targeting
event above the predominant background of non- and illegitimately recombinant
clones.
Since this time, strategies have evolved that permit the selection of increasingly
complex HR events at other non-selectable loci. The transfection of DNA
containing a positive selectable marker (e.g. neo' cassette, conferring resistance to
G418 (Southern and Berg, 1982)), enables the selection of cells in vitro which
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contain a stably integrated copy of that DNA. This comprises the basis of
targeting experimentation at non-selectable loci.
The co-introduction of a negative marker gene (e.g. HSV/k, or Diptheria A toxin),
enables enrichment of the targeting event by selecting for homologous over non¬
homologous stable recombination (Mansour et al, 1988), {Le Mouellic et al,
1992), (McCarrick et al, 1993). If positioned outwith the two portions of
homology in a conventional replacement type vector, the majority of illegitimate
recombinant clones possess both positive and negative selection markers and
hence do not survive negative selection. Only clones that have undergone a
double HR, or a single HR and branch migration event, will solely possess the
positive selection marker gene and survive negative selection. PNS (positive-
negative selection) is commonly reported to enrich for the desired targeting event
by between 2 and 20 fold (Mombaerts et al, 1991).
Additional targeting strategies have been developed for when the desired genetic
modification is subtler than complete ablation of gene expression.
The "Hit and Run" targeting strategy (see fig. l.i.f) utilises a conventional
insertion type vector and enables the introduction of subtle deletions or point
mutations into the mammalian genome (Hasty et al, 1991(B)).
Both positive and negative selection cassettes are positioned adjacent to one
another in a conventional insertion type vector, thus enabling both the
conventional selection of stably recombinant clones, as well as the selection of
clones that have undergone a second, intrachromosomal HR event. The resolution
of this strategy, following the second round ofHR, can result in either the removal
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of duplicated and selective marker sequences leaving the target locus modified
and intact, or in reversion back to the original wild-type allele.
A further strategy, termed double replacement targeting (see fig. l.i.g), requires
the generation of two replacement type targeting vectors and sequential targeting
(Stacey et al, 1994). As essentially any number of second round targeting vectors
can be constructed, this strategy is especially useful in comparative studies when
the generation of multiple clonal lines containing different modifications at the
same locus is desirable.
In the initial vector, both positive and negative selection marker cassettes are
positioned between both portions of homologous sequence in a replacement type
vector. Successfully targeted cells from this stage are then re-targeted with the
second construct. Typically, the second vector contains identical sequence
homology as the first, but in place of the selectable cassettes is sequence
containing the desired genetic modification. Cells successfully targeted for a
second time can also be selected, as they will have replaced both positive and
negative marker cassettes with the desired modifier sequence.
More recently, a modified gene targeting procedure was reported to be so efficient
(10"' cells are targeted) that selectable markers were not required to enrich for
targeting events (Templeton et al, 1997). Through modification of ES cell
electroporation conditions (standard method for transfecting targeting constructs)
and plating methodology, the plating efficiency of electroporated ES cells has
improved from 3% without selection (Reid et al, 1991), to between 94.2% and
99.2% efficiency. This data suggests that the intrinsic rate of HR in ES cells is in
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reality very high, but that existing methodology is inefficient at producing
targeted clones.
Fi 1 i fIg -1-
"HIT AND RUN" TARGETING STRATEGY
70
. l.i.g
DOUBLE REPLACEMENT TARGETING STRATEGY
(l.i.8) Inducible Promoter Systems
Conditional gene expression has proved a valuable tool in the analysis of gene
expression in mammalian experimental systems. In studies of oncogenicity, cell
cycle or in the expression of dominant lethal alleles it is often undesirable to have
continuous transgene expression, so the ability to introduce transgene expression
rapidly and in a controlled fashion can be greatly beneficial in these experimental
circumstances (see section l.i.2).
The generation of recombinant transgene expressing adeno- and retroviral vectors
does permit highly efficient gene transfer and expression in vitro, however their
effectiveness at delivering efficient and stable transgene expression in vivo can be
highly variable. In terms of reproducibility therefore, inducible promoter systems
are superior to viral transduction as cells stably transfected with an inducible
transgene can be fully characterised with regard to their expression patterns in
vitro, prior to application in vivo.
The ideal conditional expression system should not permit gene expression in the
absence of inducer, yet should enable high levels of gene expression upon
stimulation in a rapid and dose-responsive manner. The means of induction
should also be non-toxic and should exert no other pleiotropic effects upon the
cell. Further, the expression system of choice should be easy to establish and
rapid to optimise both in vitro and in vivo.
A number of inducible promoter systems have been derived and developed from
viral, pro- and eukaryotic genes to achieve such goals (see table l.i.a), but
unfortunately as yet no developed conditional expression system meets all of the
above criteria.
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Table l.i.a Currently Available Inducible Promoter Systems
Promoter Inducer Number of
Components
Origin Reference
MT Heavy Metals 1 Human McNeall et al, 1989
MMTV Steroid Hormones 1 Virus Lee et al, 1984
6-16 Interferon a/p 1 Human Kerr et al, 1991
Mxl Interferon a/p 1 Mouse Hug et al, 1988
Lac operon IPTG 2 E.Coli Hu et al, 1987
Tet operon Tetracycline 2 E.Coli Gossen et al, 1993
Ecdysone Muristerone A 2 or 3 Drosophila No et al, 1996
Gal/ER™ Tamoxifen 2 Yeast/Human Webster et al, 1988
For the purposes of the experimental work described subsequently within this
thesis, both the interferon a/p responsive 6-16 promoter and the tetracycline
inducible promoter were selected from the available systems detailed in table l.i.a
to regulate the expression of the tumour suppressor gene p53. These individual
systems and the rationale underlying their selection are discussed in greater detail
within sections l.i.8a, 8b and 8c.
(l.i.8a) Interferon Inducible Promoter Systems
Interferon type I (interferon a/[3) inducible promoters drive the expression of
genes following interaction between secreted interferon a/p (see section l.i.8b)
and its receptor. The application of these inducible promoters to drive transgene
expression in mammalian cells are most likely universal as many mammals
produce interferon a/p in response to viral infection and the interferon a/p
receptor has so far been found to be present on all normal and malignant human
32
tissues, numbering between 100 to 2,000 functional receptors per cell (Merlin et
al, 1985). Binding of type I interferons (interferon a/(3) to this receptor results in
the specific transcriptional upregulation of several gene products via activation of
the ISGF-3 (Interferon Stimulated Gene Factor-3) protein complex.
The ISGF-3a component of this complex is initially located in the cytoplasm of
the cell and is made up of three proteins, namely p84, p91 (STATloc/p
heterodimer) and pi 13 (STAT2) (Fu et al, 1990 and Fu et al, 1992). Following
the binding of ligand to the interferon a/(3 receptor, the ISGF-3a complex
becomes activated following phosphorylation of specific tyrosine residues,
mediated primarily through JAK1 and Tyk2 protein kinase activity. Activated
ISGF-3a then translocates to the nucleus where it associates with the DNA-
binding protein ISGF-3y (p48) to complete the formation of functional ISGF-3
protein complex (Schindler et al, 1992).
Activated ISGF-3 directly transactivates the expression of genes by binding to a
sequence-specific DNA element termed the ISRE (Interferon Stimulable
Response Element). This element is highly conserved among many species which
respond to interferon a/(3 and is found in the promoter sequences of all interferon
oc/[3 stimulated genes (Witt et al, 1996).
Two other proteins, IRF-1 (Interferon Regulatory Factor-1) and IRF-2, operate
antagonistically to modulate ISGF-3 mediated activation of gene expression by
also binding to ISRE sequences. IRF-1 expression has been demonstrated to
positively influence interferon a/p mediated induction of gene expression, whilst
expression of IRF-2 has been shown to repress the effects of IRF-1. A further
negative regulator of interferon a/p induced gene expression, which also operates
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through binding to ISRE sequence, is the protein ICSBP (Interferon Consensus
Sequence Binding Protein). The expression of this protein is induced by
interferon y, but has only been detected in macrophage and lymphocyte cell
lineages (for review see Witt et al, 1996).
Two independent interferon inducible promoter systems have been developed and
described to date, the murine Mxl promoter and the human 6-16 promoter. The
Mxl gene was initially discovered as an interferon a/(3 inducible transcript that
inhibited the replication of influenza virus in cultured cells (for review see
Arnheiter et al, 1990). The Mxl promoter region has since been fully
characterised (Hug et al, 1988) and has been used to drive the expression of
foreign transgenes in an inducible manner both in vitro and in vivo (Kuhn et al,
1995).
The human 6-16 gene has been shown to be expressed in response to interferon
a/(3 in all human cell types analysed to date (Kelly et al, 1985), (Kelly et al,
1986). The function of 6-16 protein is currently unknown, but knockout analyses
have shown that the expression of this gene is not essential for conferring the
interferon type I induced "anti-viral" state upon the cell (Porter and Itzhaki, 1993
and section 1 ,i.8b). No known murine homologue exists.
The 6-16 promoter region consists of both TATA and GCAAT boxes, potential
SP1 binding sites as well as a tandemly duplicated interferon (IFN) response
element (IRE). Residing within each IRE is a 13bp consensus IRSE sequence,
which confers interferon type I inducibility to the promoter (Whyatt et al, 1993).
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Two variants of the 6-16 promoter exist, one long (6-16l) and one short (6-16s)
The 6-16s version is reported to be less leaky than the 6-16l when in the non-
induced state, but the 6-16l version has been demonstrated to induce higher levels
of transgene expression upon induction (Whyatt et al, 1993).
One obvious advantage of utilising the 6-16 promoter as a means of achieving
conditional transgene expression is that only one component is required.
Transgene expression can be rendered inducible by simply positioning 6-16
promoter sequence in a 5' position relative to transgene ORF (open reading
frame). This feature enables the researcher to rapidly generate and optimise
inducible transgene expression both in vitro and in vivo. Further, levels of
transgene expression have been shown to be dose-responsive with respect to the
concentration of inducer (i.e. absolute levels of transgene expression positively
correlate through a range of interferon a/(3 concentrations). Whilst this is unlikely
to be precisely manipulatable in vivo, this could potentially be useful when
physiological levels of transgene expression are required, or in instances when it
is desirable to modulate expression levels within the course of the same
experiment in culture.
One of the major drawbacks from using this conditional expression system
however is that in addition to inducing transgene expression, interferon a/(3
confers other pleiotropic effects upon the cell (see section l.i.8b). All transgene
induction experiments utilising this system must therefore be tightly controlled in
order to enable differentiation between interferon a/(3-mediated and transgene -
mediated effects upon the cell.
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(l.i.8b) The Molecular Basis of the Interferon a/(3 Response
Interferon a/(3 comprises a family of related peptides that are produced primarily
in response to viral or microbial infection by all differentiated mammalian cell
lines analysed to date (14 interferon a proteins and 1 interferon (3 protein
presently identified; reviewed by Witt et al, 1996).
The most potent in vivo inducer of type I interferons so far identified in the mouse
is the synthetic double stranded RNA (dsRNA) molecule polyinosinic acid:
polycytidylic acid (pI:pC) (Field et al, 1967). It is hypothesised that this reagent
mimics a viral dsRNA genome or viral replication intermediate and so
consequently induces a strong interferon a/p cellular response.
Interferon a/(3 can induce the expression of between 20 to 100 downstream genes
(Sen and Ransohoff, 1993), many of uncharacterised function, but their
cumulative effect results in the inhibition of general protein synthesis, a decrease
in the rate of cellular proliferation and in a general systemic enhancement of cell-
mediated cytotoxicity (Haines et al, 1991).
As many viruses utilise host cell machinery to replicate, it is proposed that
interferon a/p-mediated cellular responses serve to inhibit the expression of viral
genes (and consequently viral replication) within infected cells. In addition,
interferon a/p can promote the removal of infected cells by signalling to and
enhancing NK cell and macrophage activity (Reid et al, 1981), (Basham et al,
1984, (A) and (B)), thus further inhibiting the progression of viral infection within
a tissue.
The antiviral and antiproliferative effects elicited directly through interferon a/p
and indirectly by dsRNA have been shown to be at least part modulated through
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the induction and activation of three independent gene products; 2', 5'
oligoadenylate synthetase (2-5A synthetase), dsRNA protein kinase (PKR) and
dsRNA-specific adenosine deaminase (dsRAD).
Interferon a/p can indiscriminately repress both viral and cellular gene expression
(and consequently cell-cycle progression) through the induction of 2-5A
synthetase expression. Once expressed, this enzyme converts free monomeric
ATP into 2', 5' linked oligoadenylates (2-5A). 2-5A binds to and activates the
otherwise latent endonuclease RNase L, which subsequently degrades both host
and viral RNA within the cell. It should be noted that the cellular consequences
associated with the presence of 2-5A in the cell are transient as a result of the
inherent instability of this compound (for review see Player and Torrance, 1998).
PKR is a serine/threonine protein kinase implicated in both the transcriptional
regulation of interferon a/p induced genes via direct interaction with the
transcription activator STAT 1, and in the inhibition of protein synthesis via
phosphorylation of eIF-2 (eukaryotic Initiation Factor 2).
Inactive PKR binds to STAT1, inhibiting the ability of this protein to form the
DNA-binding complex associated with the transactivation of those genes
possessing the ISRE sequence element within their promoters. PKR becomes
activated by autophosphorylation following binding to dsRNA. Once activated,
PKR dissociates from STAT1 and phosphorylates the a subunit of eIF-2, which in
turn binds to the guanine nucleotide exchange factor eIF-2B, thus preventing
further initiation of protein synthesis within the cell (Farrell et al, 1977).
A further gene induced by interferon a/p, associated with mediation of the 'anti¬
viral' state but not anti-proliferative state, is an enzyme termed dsRNA-specific
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adenosine deaminase (dsRAD) (Patterson et al, 1995). The activity of this
enzyme catalyses the conversion of adenosine to inosine in dsRNA viral genomes
through hydrolytic deamination (O'Connell, 1997). Upon reverse transcription of
the viral genome, converted inosine residues base pair to cytidine and so dsRAD-
mediated editing of the viral genome appears as a conversion from adenosine to
guanosine, thus effectively mutagenising viral ORFs.
The cellular effects conferred by interferon a/(3 as described, has resulted in the
use of this reagent as a means of treating more than a dozen human malignancies
(Witt et al, 1996). It could be hypothesised upon this basis therefore that
utilisation of either Mxl or 6-16 promoter sequences to drive the expression of
tumour suppressor genes within a tumour cell environment may impart greater
anti-tumour effect than either reagent in isolation (see section 2.i.l).
(l.i.8c) Tetracycline Inducible Promoter System
The tetracycline inducible promoter system utilises components originating from
the tetracycline-resistance (Tet) operon derived from the E. coli TnlO transposon.
Similar in modality to the Lac repression system, the tetracycline inducible system
consists of a repressor molecule (tetR) which binds with high specificity to a
DNA consensus operator sequence (tetO) (Kleinschmidt et al, 1988). In the
absence of the anti-biotic tetracycline (Tc), the tetR molecule binds as a dimer
with high affinity to tetO sequence, sterically inhibiting transcriptional initiation
at the Tet operon. At very low concentration (0.1 |lg ml"1), Tc can bind to and
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induce conformational change within the tetR molecule, in turn lowering the
affinity between tetR and tetO, thus releasing transcriptional repression.
Initial applications of this prokaryotic repression system consisted of stably
transfecting the tetR molecule into higher eukaryotic cells, along with a reporter
transgene construct driven by a composite viral/ tetO promoter (for review see
Gossen et al, 1993). This approach was unsuccessful at achieving transcriptional
repression however, due to inefficient expression and resultant low cellular
concentration of the tetR molecule. High concentrations of the tetR molecule
have since been demonstrated to be toxic in mammalian cells (Shockett et al,
1995), therefore it is likely that these early studies were self selecting for poor
tetR mediated repression.
The generation of a fusion protein with the C-terminal portion of VP 16
(immediate early gene transactivator molecule derived from herpes simplex virus)
and the tetR molecule coupled the properties of strong transcriptional
transactivation with highly specific protein/DNA interaction (Gossen and Bujard,
1992). This protein, termed tTA (tetracycline responsive transactivator), binds to
tetO sequences in the absence of tetracycline and activates gene expression.
Following random mutagenesis of the tTA molecule, a protein which differed
from the wild-type by only 4 amino acids, termed the rtTA, was demonstrated to
possess reverse characteristics and only bind to tetO sequences in the presence of
tetracycline (Gossen et al, 1995). The development of both Tet-on (rtTA) and
Tet-off (tTA) systems (Clontech) offer a greater degree of flexibility in the control
of transgene expression in comparison with other inducible systems. Both
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systems share a common inducer molecule, upon administration of which, will
either switch on or off transgene expression.
Differential induction response kinetics have been reported through use of
derivative tetracycline antibiotics as inducer molecules. The best to date
(doxycycline) exhibited 100-fold greater efficiency in transgene induction than Tc
(Gossen et al, 1995).
In comparison to the other systems listed in table l.i.a, the Tet system currently
enables the greatest degree of flexibility in terms of experimental design. Further,
the relationship between Tc (and related derivatives) and the tetR molecule is
highly specific and the effective concentration of inducer has not been reported to
elicit any other gross pleiotropic effects within mammalian cells (see section
2.i.l).
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(l.ii) The Molecular Basis of Cancer
The dynamics of cellular flux within a tissue are basically modulated by two
distinct classes of genes, namely the oncogenes and the tumour suppressor genes.
The homeostatic maintenance of cell number within a tissue is finely balanced
between the active processes of cellular proliferation and cell death, with
conversion to malignancy typically associated with lesions affecting the genes
intrinsic to both of these processes.
Oncogenes encode a class of proteins that act to promote cell growth through
stimulation of the cell cycle or through inhibition of cell death. This class
typically comprises of extracellular growth factors, cell surface receptors,
intracellular signal transducing molecules and nuclear effectors (Weinberg, 1995).
Inhibitors of apoptosis, such as Bcl-2, are also included in this classification group
(Kroemer, 1997).
Conversely, tumour suppressor genes act to restrain the expansion of cell numbers
within a tissue. Despite present debate surrounding what actually does and does
not constitute a "real" tumour suppressor gene (Clurman and Groudine, 1997), it
is generally accepted that this class of genes predominantly comprises of proteins
that inhibit cell cycle progression. This class may possibly also include genes that
enhance apoptosis and those that recognise and repair mismatched DNA.
In a normal healthy individual, these two classes of genes work in synchrony to
preserve genomic integrity and regulate cell turnover within tissue. However, the
relationship between the acquisition of lesions that affect these two gene classes
and the malignant conversion of a cell is both complex and highly tissue specific.
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The advent of both transgenic technology and novel molecular techniques within
the past decade has enabled the specific investigation of oncogene and tumour
suppressor gene loci within animal model systems, which in turn has served to
rapidly advance our understanding of tumourigenic processes.
One could predict that a lesion arising within a single cell in vivo causing the
over- or disregulated expression of an oncogene would result in an increased rate
of cellular proliferation. The result of such a selective growth advantage over
neighbouring wild-type cells would be the clonal expansion of affected cells
within the tissue. Indeed, elevated expression levels of the oncogene c-Myc are
observed at high frequency in many diverse tumour types (Spencer and Groudine,
1991) and therefore must be an important event in the malignant conversion of a
cell.
C-Myc over-expression within cultured fibroblasts has been demonstrated to be
sufficient to drive both normally cycling and quiescent cells into a continuous
proliferative state, wherein they no longer respond to normal growth arrest signals
(Eilers et al, 1989). The overexpression of c-Myc in otherwise wild-type
fibroblast or haematopoietic cells however, does not result in an increase in cell
number when growth factors are limiting (Evan et al, 1992), (Askew et al, 1991).
Despite a marked increase in the rate of cellular proliferation, a correspondingly
high rate of apoptosis is also observed.
The generation of a transgenic c-Myc overexpressing mouse, the E^-Myc mouse
(Harris et al, 1988), was designed to model the human B-cell malignancy
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Burkitt's lymphoma and has been used to examine the in vivo consequences of c-
Myc overexpression targeted to B cell lymphocyte lineages.
B-cell lymphomas were observed in 90% of these animals following a latency
period of approximately 5 months. During this period, increasing numbers of
large proliferating B lymphocyte lineages were detected in the blood, but so too
were very high levels of apoptosis. Analysis of bone marrow at the time when the
tumour had developed still exhibited high levels of apoptosis within the tissue.
This model supports the notion that the overexpression of an oncogene, in this
instance c-Myc, drives tumourigenesis in combination with other genetic changes,
and further demonstrates that these events occur within an environment
characterised by high levels of proliferation and apoptosis.
Indeed, the tumourigenic effects conferred by c-Myc may be considered to arise
as a direct consequence of increased cell turnover. Assuming that the mutation
rate per cell cycle remains unaltered, hyperproliferating cells will accumulate
more mutations over a set time period than normally proliferating cells.
In addition to exposing a given cell population to a greater range of mutations, c-
Myc overexpression also places increased selective pressure for mutations that
inhibit the elimination of cells through apoptosis (e.g. those resulting in the
overexpression of Bcl-2). Failure to eliminate such cells through apoptosis would
likely result in their rapid expansion and possibly lead to tumour formation.
This theory has been partly substantiated in vivo through the development of mice
overexpressing both c-Myc and Bcl-2. Such animals were strongly predisposed to
a rapidly emerging undifferentiated haematopoietic leukaemia (Strasser et al,
1990).
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Genetic lesions resulting in loss of tumour suppressor gene function would also be
predicted to confer selective growth advantage to the cell. Hypothetically, the
selective advantage gained through loss of cellular proliferative restraint would
result in the clonal expansion of affected cells within a tissue comprised of
otherwise normal cells. These unrestrained proliferating cells could subsequently
gain further selective advantage following the acquisition of genetic lesions that
confer oncogene overexpression (i.e. those genes that enhance the rate of cellular
proliferation).
In a normal diploid organism, whilst a single mutational event may be sufficient
to confer gene overexpression, two mutational events are required to ablate gene
expression in most instances. This "two-hit" tumour suppressor gene inactivation
model was initially proposed by Knudson with regard to the retinoblastoma
susceptibility gene, pRb (Knudson, 1971). This gene has since become the
classical paradigm for tumour suppressor gene classification.
Human Rb heterozygotes develop retinoblastomas at almost 100% incidence and
osteosarcomas to a lesser extent, predominantly during their early childhood.
Further, loss of Rb gene function is frequently associated with tumours of the
lung, breast, prostate and bladder in humans (Knudson, 1993).
Knudson proposed that two mutational events are required (one of which being
inherited in cases of familial retinoblastoma) before the tumour suppressor
function of pRb is ablated and individuals become predisposed to tumourigenesis.
Thus, if ablation of tumour suppressor gene function is implicated as a key event
in a proportion of tissue specific tumourigeneses, then it could be postulated that
the re-introduction of tumour suppressor gene function into such tumour cells
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could constitute an effective treatment. At the least, one could predict
enhancement of conventional cancer treatment. An obvious candidate tumour
suppressor gene for such replacement type gene therapy would be p53.
(l.ii.l) P53
David Lane discovered the tumour suppressor gene p53 in 1979, as a gene coding
for a protein tightly associated in a complex with the SV40 large T antigen (Lane
and Crawford, 1979). Initial p53 expression studies showed that many
immortalised and primary human tumour cell lines expressed elevated levels of
p53 relative to the amounts expressed in normal wild-type cells (Zakut-Houri et
al, 1983). The notion that p53 possessed cellular transformation associated
properties was supported by further experimentation which demonstrated that
elevated levels of p53 expression could co-operate with activated Ha-Ras and
transform primary fibroblast cells in culture (Eliyahu et al, 1985).
Much evidence has since been accumulated however to firmly prove that the true
physiological role of p53 is as an inhibitor of cellular transformation through the
ability to preserve genomic integrity at times of cellular stress. Activated p53
suppresses cell transformation primarily through the ability to initiate cell cycle
arrest or apoptosis in response to many stimuli including DNA damage, low
oxygen conditions and inappropriate proliferative signals to mention but a few.
Elegant animal models have also demonstrated that p53 dysfunction is commonly
associated with either tumourigenesis or tumour progression in many different
tissue and cell types. Indeed, lesions affecting wild-type p53 gene expression
have been scored as being the most commonly detected across a wide spectrum of
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human malignancies (Hollstein et al, 1994). All these aspects of p53 biology will
be reviewed in the remaining sections of this chapter.
It was not discovered until years later that the early p53 overexpression
experiments had been performed using mutated p53 gene sequences (Finlay et al,
1989). Therefore, in addition to simple abrogation of p53 expression, the nature
ofmutational event can also potentially confer a selective growth advantage to the
cell. This perhaps goes some way to explaining why genetic alterations at this
locus are so commonplace in malignancy and has further emphasised the
importance of elucidating the nature of p53 mediated tumour suppression.
(l.ii.2) P53 Structure and Function
P53 is a 53KDa phosphoprotein comprising of 393 amino acids that can be
roughly subdivided into three separate functional domains. The amino- (N-)
terminal portion (amino acids 1-43) comprises a transcriptional transactivation
domain (Unger et al, 1992); the central core region (amino acids 102-292)
comprises a sequence specific DNA binding domain (Wang et al, 1993); and the
carboxy- (C-) terminal portion (amino acids 300-393) comprises both
tetramerisation and non-sequence specific DNA binding domains connected by a
short flexible linker sequence (Ko and Prives, 1996), (Jeffrey et al, 1995).
Functionally active p53 predominantly exists in a tetrameric conformation within
the cell nucleus and has been ascribed a multitude of biochemical properties and
interactions that can influence the cellular response to stimuli promoting genetic
instability.
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(l.ii.2a) The Core Domain
One clear means by which activated p53 influences cellular fate is through both
the transcriptional activation and suppression of a specific set of downstream
target genes. X-ray crystallography has determined that p53 folds and
oligomerises in such a way as to form a surface capable of binding DNA with
contact at both major and minor grooves (Cho et al, 1994). P53 specifically
recognises a tandem repeat of the 10-mer 5 RRRCa/tt/aGYYY3 (el-Diery et al,
1992), present as a motif in the promoter region of multiple genes, onto which it
can bind with high affinity (for a more detailed review see Levine, 1997). Once
bound to its recognition sequence, p53 exerts influence on the expression of
downstream genes through interaction between its N- terminal domain and
components of the basal transcriptional machinery (see section l.ii.2b).
Point-mutation analyses of p53 alleles originating from human tumour samples
have shown clustering, or mutational hotspots, affecting amino acid residues
located within this sequence specific DNA binding domain. These studies also
highlight that point mutations affecting either the N- or C- terminal domains are
rare in comparison, implying that the integrity of the core domain is essential for
tumour suppression functionality (Ko and Prives, 1996).
All p53 alleles possessing point-mutation(s) within this central core domain can
be classified as either contact mutant alleles (as they possess altered amino-acid
residues that directly contact DNA) or as conformational mutant alleles (as they
possess alteration of amino-acid residues affecting protein folding; Cho et al,
1994).
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Contrary to Knudson's "Two-Hit" tumour suppressor inactivation model, often
cells possessing one point-mutated and one wild-type p53 allele possess
attenuated p53 dependent responses. This dominant-negative effect, of mutant
over wild-type capability, has been shown to be at least partly the result of altered
tetrameric complex conformations. Hetero-oligomerisation between mutant and
wild-type protein affects the ability of tetrameric p53 to bind specific DNA
sequences and consequently to transactivate gene expression (Chene, 1998).
Clearly therefore, certain point-mutated alleles confer potentially more serious
tumourigenic consequences than others, and Harvey et al have proposed a grading
classification system of p53 point-mutants accordingly (Harvey et al, 1995).
Several conformational mutant alleles have proven useful as experimental tools in
the elucidation of p53 dependent cellular responses. Such an example is a mutant
form of p53 that differs from wild-type only at position 135, where it possesses a
valine residue instead of an alanine. The result of this single amino-acid
substitution is a p53 mutant protein that adopts mutant conformation at 37°C, but
assumes wild-type conformation at 32.5°C (Milner and Medcalf, 1990). Although
certain differences must exist at the level of general cellular metabolism between
these two temperatures, this temperature sensitive (ts) mutant p53 allele has
proven useful in transgenic studies with regard to the elucidation of p53
dependent responses and in observing how modulation of these responses affects
tumorigenic consequence (Harvey et al, 1995).
Further evidence arising from experimentation with SV40 large T-antigen stress
the importance of p53's ability to bind sequence specific DNA in achieving
tumour suppression. Expression of SV40 large T-antigen, within a wide range of
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primary cell lines, results in cell immortalisation through the binding and
functional inactivation of both p53 and Rb tumour suppressor genes. Functional
inactivation of the former is achieved through binding of the large-T antigen to the
central core domain of p53. One could therefore argue upon this basis that
disruption of this region is a key event leading to the immortalisation of the cell
(Holley and Lawlor, 1997).
(l.ii.2b) N-Terminal Domain
The ability of activated p53 to initiate growth arrest, DNA repair and apoptosis
have all been shown to be at least partly influenced by the ability of p53 to
transactivate the expression of specific genes. The N- terminal, or transcriptional
activator domain of p53 has been shown to bind to various proteins associated
with the basal transcriptional machinery including TBP (TATA-binding protein)
(Horikoshi et al, 1995), as well as TAFn40 and TAF]]60 (TATA-associated
factors; Thut et al, 1995) and p300/CBP (Gu and Roeder, 1997 and Lill et al,
1997). The nature of several of these transcriptionally activated genes has
provided insight into many of the biochemical mechanisms underlying p53
mediated tumour suppression (see sections l.ii.5a and 5b).
P53 is also known to repress the expression of certain genes, although the
mechanisms through which this is achieved remain to be fully clarified. Further
insight regarding how p53 inhibits tumourigenesis has however been gained
through the identification of several genes that appear to be repressed in this
manner. Amongst these are cellular oncogenes (c-fos, c-jun) and inhibitors of
apoptosis (Bcl-2) (Donehower and Bradley, 1993 and Miyashita et al, 1994).
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A distinction has previously been made between genes that utilise either TATA or
Inr (initiator) elements to define their transcriptional initiation site, where gene
members of the former group appear to have their transcription repressed in a p53
dependent manner, whilst those genes in the latter group do not (Mack et al,
1993).
The exact mechanism through which this distinction is made by p53 remains to be
clarified, although a p53 mutant (Q22, S23) has been shown to no longer possess
the ability to repress transcription (Sabbatini et al, 1995). This mutant retains the
ability to bind TBP but is unable to bind the TAF proteins, thus implicating
interaction between p53 and TAFs as essential for p53 dependent transcriptional
repression.
Experimental evidence has also been recorded that describes efficient p53
dependent repression of TATA-less promoters (Iotsova et al, 1 9 96),
(Gopalkrishnan et al, 1998). These examples may be exceptions to the general
rule, but it is more probable that our understanding of this aspect of p53 biology is
incomplete.
The cellular oncogene mdm2 has been demonstrated to inhibit p53 mediated
growth arrest and apoptosis by binding to and blocking the transcriptional
transactivating N- terminal domain of p53 (Oliner et al, 1993), (Chen J. et al,
1996). Indeed, so efficient is mdm2 at ablating wild-type p53 gene function that
analyses of mdm2 overexpressing cell lines rarely exhibit evidence for further
genetic alteration at the p53 locus (Leach et al, 1993).
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P53 is known to transcriptionally activate the expression of mdm2, and as mdm2
can ablate the transactivational capability of p53, this creates an autoregulatory
feedback situation whereby the expression of both gene products are mutually
regulated. Mdm2 mediated control of p53 mediated transactivation has been
shown to be of key importance during embryonic development as mdm2 deficient
murine foetuses are aborted immediately after implantation in a p53-dependent
fashion (Montes de Oca Luna et al, 1995), (Jones et al, 1995). All progeny foetus
nullizygous for both mdm-2 and p53 were viable however, thus demonstrating
that negative regulation of p53 is essential for normal embryonic development.
Further stressing the importance of the transactivation domain with regard to
inhibiting cell immortalisation was the demonstration that adenoviral ElB-55Kd
protein can block the p53 dependent apoptotic response observed in cultures of
cells in an ElA conferred hyperproliferative state, through direct interaction with
p53's N- terminal domain (Debbas and White, 1993). Binding of ElB-55Kd to
p53 still permits sequence specific binding to DNA, but rather than just physically
blocking interaction between p53 and basal transcription factors, the binding of
ElB-55Kd is the equivalent of attaching a strong transcriptional repressor domain
to the N- terminus of p53 (Yew et al, 1994). Consequently, cells co-expressing
both adenoviral El A and ElB-55Kd proteins exhibit a high frequency of
transformation in culture (Debbas and White, 1993).
(l.ii.2c) C- Terminal Domain
The C- terminal domain of p53 contains both the regions necessary for protein




Monomer units of p53 protein initially form homodimer complexes through direct
interaction between their respective tetramerisation domains (amino acids 320-
360). Functional p53 tetramers subsequently form as a result of p53 homodimer
dimerisation, again as a result of direct interaction within this region of the C-
terminal domain (Jeffrey et al, 1995).
The non-sequence specific DNA binding region within the C- terminal domain of
p53 (amino acids 363-393) confers ability to bind to both damaged DNA and
denatured DNA templates, thus perhaps implicating a role for p53 in the detection
or 'sensing' of DNA damage within the cell (Levine et al, 1997). This molecular
sub-domain also enables p53 to re-anneal both complementary RNA and single
stranded DNA (Wu et al, 1995).
A role for p53 in promoting the repair of damaged DNA template has already
been established through demonstration that p53 can both directly interact with
components of the DNA repair machinery and can positively influence the
expression of genes which are involved in DNA repair (see section l.ii.5a).
Further, mapping to the central core domain, p53 has also been shown to possess
3' to 5' exonuclease activity (Mummenbrauer et al, 1996), thus perhaps
implicating the direct involvement of p53 in excision repair.
In addition to these functional aspects, this portion of the C-terminal domain
seems to be able to exert influence on the affinity of p53 for its target DNA
sequences, as deletion of these 30 amino acid residues results in a molecule
constitutively active for DNA binding (Hupp et al, 1993). Further, a naturally
occurring splice variant of p53 has been identified in the mouse, which expresses
an alternative C- terminus (Kulesz-Martin et al, 1994). This splice variant
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accumulates in G2, can no longer reanneal single stranded DNA (Wu et al, 1995),
but appears to be constitutively active for DNA binding (Wu et al, 1994).
A recently published body of work now suggests that the allosteric modification
of specific residues within this domain can shift p53 from a latent, low-affinity
DNA binding state to an active high-affinity DNA binding state (Muller-Tiemann
et al, 1998). These modifications will be discussed in greater detail within section
l.ii.4c.
(l.ii.3) Activation of p53 Dependent Responses
In the absence of cellular stress, p53 has a very short half-life (t between 5 and
40 minutes; Reihsaus et al, 1990) and appears to be rapidly turned over in normal
cells, predominantly through ubiquitin-dependent proteolysis (for review see
Brown and Pagano, 1997).
Amounts of p53 protein accumulate within the cell in response to a multitude of
stimuli including those that result in the physical damage, the inappropriate
proliferation, or in the metabolic stress of the cell. Exposure to UV-C, ionising
irradiation, (Maltzman and Czyzyk, 1984 and Kastan et al, 1991), selected
chemotherapeutic drugs (Zhan et al, 1993), hypoxia, heat shock (Graeber et al,
1994), disorganisation of microtubules (Tishler et al, 1995), exposure to specific
cytokines (Eizenberg et al, 1995), deprivation of cytokines (Canman et al, 1995),
oncogene overexpression (Wagner et al, 1994) and depletion of rNTP's (Linke et
al, 1996) have all been demonstrated to stabilise p53 and induce p53 dependent
cellular responses in a variety of cell and tissue types.
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Expression levels of p53 are barely detectable in normal cells in vivo, but rise
rapidly in a tissue specific manner following stimulation (Midgely et al, 1995).
Immunohistochemical analysis ofmouse tissue following genotoxic insult showed
a strong accumulation of p53 protein in spleen, thymus, bone, and small intestine
(Midgely et al, 1995 and Clarke et al, 1994). P53 stabilisation has also been
demonstrated in human skin following exposure to normal sunlight (Hall et al,
1993).
To test p53 transactivation functionality in vivo, transgenic animal models have
been constructed to express a lacZ reporter gene in a p53 dependent manner
(Gottlieb et al, 1997 and Komarova et al, 1997). Following y-irradiation, sites of
maximal reporter expression largely concurred with sites of maximal p53
stabilisation in adult mice. Interestingly however, although both red and white
compartments of the spleen exhibiting high levels of p53 stabilisation in response
to DNA damage, reporter gene expression was only detected in the red
compartment. This observation perhaps indicates the involvement of a co-factor
or allosteric modulator regulating p53 transactivation capability in a cell-type
specific manner (e.g. p33ING1; Garkavtsev et al, 1998).
The exact mechanisms underlying the increase of p53 protein in response to
stimulation are complex and remain only partially understood. It is currently held
that post-translational modification of translated p53 protein is of the greatest
significance in explaining how intracellular levels of p53 rise and become
activated in response to stimulation. Comprehension of the mechanisms
influencing p53 gene expression at all levels must be prerequisite however before
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it is possible to fully appreciate how the amounts and activation-state of p53
protein are regulated in the cell.
(l.ii.4) Regulation of p53 Expression
The wide-ranging and potentially severe cellular consequences associated with
p53 activation imply that levels of p53 protein must be strictly controlled within
the cell. Yet, failure to rapidly promote p53 expression in response to genotoxic
stress could result in the propagation ofmutant cells, with potentially tumorigenic
consequence.
The regulation of p53 gene expression has been demonstrated at multiple levels,
presumably both as a means of ensuring against the inappropriate activation of
p53 dependent pathways in the cell, but also to make provision for a rapid cellular
response to DNA damage or cellular stress.
(l.ii.4a) Transcriptional Regulation
The promoter region of p53 lacks both TATA and GCAAT boxes (Bienz-Tadmor
et al, 1985), which is a feature typically associated with constitutively expressed
or "housekeeping" genes (Reynolds et al, 1984). Mapping to nucleotides -2 to
+5bp (relative to the start of exon 1) is a consensus initiator (Inr) element, which
has previously been demonstrated to position the transcriptional start site of other
genes also lacking a TATA box (O'Shea-Greenfield and Smale, 1992).
The entire 216bp length of exon 1 is non-translated sequence and contains
extensive dyad symmetry. Transcription of this sequence is putatively involved in
the formation of a stable mRNA stem loop structure, implicated in the post-
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transcriptional regulation of p53 expression (Mosner et al, 1995). The formation
of this stable mRNA hairpin structure has complicated the accurate definition of
p53 transcript initiation site. SI nuclease protection and primer extension studies
suggest three major transcriptional initiation sites at +1, +61 and at +105bp, the
latter position being the most frequently used (see figure l.ii.a) (Bienz et al, 1984
and Tuck and Crawford, 1989).
P53 transcription levels in murine fibroblasts have been shown to be upregulated
following exposure to the phorbol ester TPA and serum stimulation. The former
response is understood to be mediated by a novel AP-1 like transcription factor,
termed PF1 (p53 Factor 1), which binds to a closely conserved variant of the AP-1
consensus sequence (at -64 to -57bp), to which AP-1 itself cannot bind (Ginsberg
et al, 1990).
The latter response may be mediated through a helix-loop-helix binding motif,
from +70 to +75bp, which once bound to the transcription factor USF, can
enhance basal transcription 5-fold (Ronen et al, 1991). Transient overexpression
of c-myc has also been demonstrated to enhance p53 expression via this promoter
element (Reisman et al, 1993).
Expressed p53 protein has also been shown to exert positive feedback by
influencing transcription from its own promoter (Deffie et al, 1993). The
sequence element at nucleotides +55 to +66bp consists of a NF-kB motif,
containing a one nucleotide variant of the p53 DNA binding consensus sequence
as defined by el-Diery (el-Diery et al, 1992). Although p53 protein does not
physically bind with this sequence, reporter studies indicate that following p53
overexpression transcriptional activity increases via this sequence element. This
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implies the involvement of p53 as an interacting component of the stress-induced
NF-KB-mediated transcriptional response.
Fig l.ii.a
PROMOTER REGION OF MURINE P53 GENE
7
Exon 1 with three major
transcriptional start sites shown
KEY FACTOR SITE BINDING SEQUENCE (5' TO 3')
H PF-2 -195 to -170bp GGTCCACTTACGATAAAAACTTAATT
CD PF-1 -64 to -57bp CTGACTCT
CD SP-1 -49 to -44bp CCCGCC
m NF-1 +1 to +14bp TGGCGACTATCCAG
NF-B +55 to +66bp GGGACTTTCCCC
CD ETF +63 to +66bp CCC
CD HLH +70 to +75bp CACGTG
A sequence element identified at nucleotides -195 to -170bp has been
demonstrated to be essential for p53 expression, binding to an as yet
uncharacterised transcription factor, termed PF2, (p53 factor 2) (Hale and
Braithewaite, 1995). In addition, an ETF binding site at +63 to +66bp (Hale and
Braithewaite, 1995), and a NF-1 binding site present at nucleotides +1 to +14bp
(Ginsberg et al, 1990), also influence p53 basal expression. A putative SP1
binding site at nucleotides -49 to -44bp has also been identified, but it remains
S7
unresolved as to whether this transcription factor actually binds and influences
p53 gene expression.
(l.ii.4b) Post-Transcriptional Regulation
Following serum stimulation of resting fibroblasts to re-enter cell cycle, p53
protein levels rise and reach maximal levels of expression significantly faster than
corresponding levels of p53 mRNA or other housekeeping genes. In addition,
when cultured in the presence of the transcriptional inhibitor actinomycin D, these
cells exhibited a rapid rise in p53 protein levels (within 1 hour) following y-
irradiation. These results would implicate the involvement of some form of post-
transcriptional mechanism(s) in the regulation of p53 expression (Mosner et al,
1995).
Kozak proposes that 5' stem loop structures in mRNA are important for the
translational regulation of vertebrate mRNAs (Kozak, 1991). The fact therefore
that the p53 transcript from man, rat and mouse all contain highly conserved dyad
sequence symmetry at their 5' untranslated ends suggests that these sequences are
of evolutionary relevance and further analysis has implicated them in the
regulation of p53 translation (Mosner et al, 1995).
Initial studies of the 5' UTR (Un-Translated Region) of p53 predicted the
formation of a stable stem loop structure between -216 and -108 base pairs
(Bienz-Tadmor et al, 1984), possessing a free energy of -56 kcal/mol. Stem loop
structures with a free energy of-50 kcal/mol require RNA helicase activity for
dissociation and are sufficient to profoundly inhibit translation (Kozak, 1991). A
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further putative stem loop structure was identified from between -216 and +284
base pairs with a predicted free energy of-170 kcal/mol (Mosner et al, 1995).
P53 can bind RNA, possesses RNA*RNA re-annealing activity and displays
helicase inhibitory effects (Oberosler et al, 1993). P53 has also been
demonstrated to preferentially bind to the 5' UTR of its own mRNA in
competitive binding assays, directly implicating a role for the fully translated
product in "masking" the translation of its own message (Mosner et al, 1995).
It is proposed that upon genotoxic stress, p53 protein can be synthesised quickly
from the existing pool of masked mRNA, by-passing the requirement for
additional transcription. In addition, p53 protein previously bound to and
repressing the transcription of its own message can be immediately recruited to
the nucleus without the requirement for additional translation, thus facilitating a
rapid cellular response to DNA damage.
Additional sequences identified within the 3' UTR of human p53 mRNA have
been demonstrated to increase the rate of translation from p53 mRNA following y-
irradiation (Fu and Benchimol, 1997).
(l.ii.4c) Post-Translational Regulation
From examination of the regulatory mechanisms discussed so far, p53 appears to
be produced constitutively at low levels, to assume a latent (non-DNA binding)
state and to be rapidly turned over within non-challenged cells. P53 dependent
responses following challenge coincide with increased levels of p53 within the
cell nucleus and in a conformational shift towards a more actively DNA binding
state. Stabilisation and activation of p53 can be achieved through both the post-
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translational modulation of p53 phosphorylation and acetylation states and
additionally through specific protein: protein interactions.
Although levels of p53 protein increase in response to many stimuli (discussed in
section l.ii.3), the mechanisms through which stabilisation occurs appear to be
partially shared, partially 'challenge' specific and by inference in certain contexts,
cell-type specific.
Treatment of cells with y-irradiation or topoisomerase inhibitors (e.g. etoposide),
leads to the formation of double strand DNA breaks, which in turn results in
increased intracellular levels of p53 and induction of p53 dependent cellular
responses (Nelson and Kastan, 1994). Indeed, it has been proposed that a single
double strand DNA break is sufficient to stabilise p53 in normal human
fibroblasts (Di Leonardo et al, 1994).
A candidate molecule involved in linking the recognition of physical DNA
breakage to p53 (and thus implicated in the stabilisation of p53) is the protein
kinase ATM (ataxia-telangiectasia). Cells deficient in ATM exhibit a delayed p53
dependent response to y-irradiation and double strand breaks, indeed MEF cells
deficient in both ATM and p53 no longer arrest at Gj-S in response to y-
irradiation (Kastan et al, 1992 and Xu et al, 1998).
ATM appears to both directly phosphorylate p53 at serine 15, and to indirectly
dephosphorylate at serine 376, following exposure to y-irradiation (Siliciano et al,
1997 and Waterman et al, 1998). Phosphorylation of serine 15 has previously
been shown to increase both the stability and activity of p53, possibly through
decreasing efficiency of mdm2 binding (Shieh et al, 1997), whilst
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dephosphorylation at serine 376 has been implicated in the enhancement of
sequence specific binding (Waterman et al, 1998).
Despite the ability of ATM -/- MEF cells to activate p53 dependent pathways in
response to y-irradiation, albeit with reduced efficiency (SI5 can still be
phosphorylated in ATM -/- cells; Siliciano et al, 1997), it remains clear that ATM
kinase plays an important role in both the identification of DNA double strand
breaks and in activating p53 correspondingly.
Further kinases implicated in signalling double stranded DNA breaks to p53 are
DNA-PK and associated Ku autoantigen. These proteins have also been
demonstrated to phosphorylate p53 at serines 15 and 37 in response to DNA
double strand breaks (Shieh et al, 1997), but the relevance of their activity has yet
to be demonstrated in vivo.
Exposure of cells to UV-C irradiation results in the generation of thymidine
dimers, although the generation of these per se appears to be insufficient to
stabilise p53. However, DNA strand breaks generated from excision repair or
resulting from the replication of DNA through these genetic lesions appear to
stabilise p53 (Nelson and Kastan, 1994). In addition, UV induced lesions can
result in the stalling of transcription complexes, a molecular event that appears
sufficient to stabilise p53 (Ejungman and Zhang, 1996).
Unlike the DNA lesions induced by y-irradiation, ATM kinase does not signal UV
induced damage to p53. Residue S15 is still phosphorylated in response to UV
damage, although the UV-damage specific kinase responsible for this
modification remains to be identified (Giaccia and Kastan, 1998).
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In less specific terms, the phosphorylation of several amino-acid residues within
the C- terminal portion of p53 has been proposed as a potential control mechanism
regulating the switch from latent to active DNA binding form. Phosphorylation of
amino acid residue S378 by Protein Kinase C (PKC) (Takenaka et al, 1995) or
S392 by Casein Kinase II (CKII) (Hupp et al, 1992), have been demonstrated to
stimulate the sequence specific DNA binding by p53. Microinjection of the C-
terminal specific antibody pAb421 has also been demonstrated to activate p53
following binding to its epitope (Hupp et al, 1993).
A further residue phosphorylated by CKII (S386) was shown to stimulate p53
mediated repression of downstream target loci in vitro (Hall et al, 1996). A
summary of established p53 modifications is listed in table l.ii.a.
Table l.ii.a
STIMULUS MODIFIER MODIFIED TYPE OF
PROTEIN RESIDUES MODIFICATION
Etoposide CK I S6 + S9 Phosphorylation
y-irradiation DNA-PK S15 + S37 Phosphorylation
y-irradiation ATM +ATR S15 Phosphorylation
y-irradiation ATM S376 De-phosphorylation
y-irradiation CAK S33 Phosphorylation
UV-C 9 S15 + S33 Phosphorylation
Gi of cell cycle cdk2 +cdc2 S315 Phosphorylation
Phorbol ester PKC S378 Phosphorylation
- CK II S386 + S392 Phosphorylation
y-irradiation and UV-C p300 L382 Acetylation
y-irradiation and UV-C PCAF L320 Acetylation
Table l.ii.a summarises the stimuli, effector kinase/acetylase molecules, p53 residues modified
and the type of modification events demonstrated to effect either p53 conformation or stability.
Where known, the context in which these modifications arise is discussed in the main text and the
appropriate references are cited therein.
P300 and pCAF mediated acetylation of residues within the C- terminal domain of
p53 have also been shown to enhance sequence specific binding of p53 in
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response to both y-irradiation and UV induced DNA damage (Gu and Roeder,
1997 and Lill et al, 1997). Evidence has also been presented which shows that
p53 protein previously phosphorylated by DNA-PK is more efficiently acetylated
than unmodified p53 protein (Sakaguchi et al, 1998). This would suggest that p53
phosphorylation and acetylation states might have combinatorial or additive
effects with regard to the regulation of p53 specificity and action within the cell.
Further research within this area may lead to the identification of the p53
modification states that 'decide' cellular outcome in response to activation, or
indeed may lead to an explanation regarding the basis of certain tissue specific
differences in p53 dependent outcome following activation.
In addition to stabilisation following sustenance of DNA damage, p53 protein is
stabilised and activated in the cell following inappropriate overexpression of
certain oncogenes. A recently published body of work has highlighted a key role
for p 1 9arf in this context.
P19arf is one of two alternative tumour suppressor transcripts encoded by the
murine INK4A locus, and cellular levels are known to rise in response to the
overexpression of certain oncogenes (e.g. c-myc, ElA, E2F) in the absence of
corresponding levels of growth factor stimulation (Quelle et al, 1995). Induction
of pl9ARi in this manner has been demonstrated to stabilise levels of p53 in vivo
and induce either growth arrest at both Gi and G2 stages of the cell cycle or
apoptosis (Kamijo et al, 1997 and Zindy et al, 1998).
Overexpression of pl9ARF cannot induce growth arrest or apoptosis in p53 -/-
MEF cells however and so appears to be entirely dependent upon p53 to exert its
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effect upon the cell (Kamijo et al, 1997). Further, the role played by pl9ARF, as a
'sensor' of inappropriate hyperproliferative signals within the cell, appears to be a
specific means of p53 activation as pl9ARF -/- MEF cells respond as wild-type
MEF cells when exposed to both ionising and UV-C irradiation (Kamijo et al,
1997) i.e. pl9ARF does not influence the stabilisation of p53 in response to DNA
damage.
The means by which the pl9ARF gene product stabilises expression levels of p53
are now becoming clear. In addition to blocking p53 mediated gene
transactivation (as mentioned in section l.ii.2b), a further consequence of the
interaction between mdm2 and p53 is an increase in the rate of proteosome
mediated degradation of p53 (Kubbutat et al, 1997). The N- terminal portion of
pl9ARF can bind to the C- terminal portion of mdm2 and it appears that this
interaction results in a reduction of the rate of proteosomal degradation of p53.
Amounts of p53 rise within the cell as a consequence of this decrease in
degradation rate (Zhang et al, 1998 and Pomerantz et al, 1998).
Several putative mechanisms have been proposed to explain how interaction
between pl9ARI and mdm2: p53 reduces the rate of p53 degradation. Some
experimental evidence appears to suggest that binding of pl9ARF to mdm2: p53
results in a modification of mdm2's ability to poly-ubiquitinate p53. Also
suggested is a pl9ARF dependent mechanism whereby binding of pl9ARF blocks
nuclear export of the mdm2: p53 protein complex, thus ensuring that p53 protein
remains localised in a separate sub-cellular compartment from the proteosome
(Pomerantz et al, 1998 and Roth et al, 1998).
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Finally, direct interaction with HIF-a (Hypoxia Induced Factor a) results in the
stabilisation of p53 protein in cells growing under hypoxic conditions (An et al,
1998) and further, direct interaction with ref-1 in response to oxidative stress
appears to activate sequence specific DNA binding of p53 (Jayaraman et al,
1997). The mechanisms underlying both these observations are presently not
known.
(l.ii.5) Mediation of Growth Arrest, DNA Repair and Apoptosis
Although the general processes influencing both the stabilisation and activation of
p53 are becoming apparent, little is currently known regarding how p53 activation
can result in different cellular end-points in response to stimulation.
The extent of stimulation seems to influence the cellular response to activated p53
as several studies have highlighted that either growth arrest or DNA repair occur
at low levels of DNA damage, whilst apoptosis seems to be the predominant
response to sustenance of high levels ofDNA damage (Chen X et al, 1996 and Li
and Ho, 1998). This view is almost certainly too simplistic however, as even
following exposure to equivalent doses of DNA damaging agents different cell
types exhibit different p53 dependent responses. For example, human fibroblasts
predominantly enter growth arrest at Gi-S of the cell cycle following exposure to
5 Gy of y-irradiation whilst intestinal crypt epithelia apoptose (Di Leonardo et al,
1994 and Clarke et al, 1994).
Further, the means through which p53 becomes stabilised and activated is also
certainly of relevance with regard to cellular outcome. Depletion of intracellular
rNTP level is known to induce p53 stabilisation, but these cells predominantly
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exhibit a proliferative arrest rather than committing to apoptosis (Linke et al,
1996). Conversely, p53 activated in response to inappropriate oncogene
overexpression predominantly initiate apoptosis (Hermeking and Eick, 1994).
As will be discussed in sections l.ii.5a and l.ii.5b, p53 mediated growth arrest
requires the ability of p53 to transcriptionally activate the expression of
downstream loci, whereas p53 mediated apoptosis can occur in the absence of
downstream gene transactivation. Some experimental evidence exists to suggest
that the ability of p53 to transactivate downstream gene expression requires the
presence or 'assistance' of protein co-factors. In this respect, the coexpression of
P33ing has been demonstrated to be essential in achieving p53 dependent growth
arrest in response to DNA damage (Garkavtsev et al, 1997). Further, the addition
of exogenous pl9ARF into otherwise pl9ARF deficient MEF cells proved to be
essential for p53 mediated gene transactivation of a p53-reporter transgene
(Kamijo et al, 1997). Certainly the hypothetical existence of tissue specific co-
factors is an attractive means of explaining the observed tissue-specific
differences in p53 dependent outcome resulting from identical challenge.
Finally, as discussed in section l.ii.4c, allosteric modification p53's C- terminal
domain can increase the affinity of p53 for its cognate target sequence. Although
yet to be directly proven, it is highly probable that p53 dependent cellular
outcomes can also be regulated at this level.
(l.ii.5a) Growth Arrest and DNA Repair
DNA damaged wild-type cells can 'choose' between p53 mediated growth arrest
or death. Those that arrest at a cell cycle checkpoint, predominantly enter a
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reversible growth arrest at Gi- S of the cell cycle, but can also arrest at S or at G2-
M phases in a p53 dependent manner (Agarwal et al, 1995 and Petrocelli et al,
1996). It is generally accepted that p53 dependent growth arrest is achieved
almost exclusively via the transcriptional transactivation of a number of specific
downstream genes, among which of particular physiological relevance is the
cyclin-dependent-kinase (cdk) inhibitor, p21 (WAF1/CIP1).
The expression of p21 is induced in a p53 dependent manner following DNA
damage (el-Diery et al, 1993). P21 is a potent inhibitor of the family of proteins
responsible for increasing the phosphorylation state of pRb, the cyclin dependent
kinases (Harper et al, 1993). Direct interaction between p21 and a number of
cyclin/cdk complexes results in their functional suppression, one result of which
being an inhibition of cdk-mediated phosphorylation of pRb.
Hypophosphorylated pRb in turn remains associated with the E2F transcription
factor complex, an interaction that inhibits initiation of S-phase and results in the
cell being held in a reversible Gl arrest (Sanchez and Elledge, 1995).
Initiation of p53 dependent cell cycle arrest also appears to create a cellular
environment in which damaged DNA may be repaired with greater efficiency.
P21 has also been demonstrated to interact with PCNA (Proliferating Cell Nuclear
Antigen), a protein that facilitates DNA synthesis (Flores-Rozas et al, 1994 and
Waga et al, 1994). PCNA is also involved in NER (Nucleotide Excision Repair),
but interaction with p21 has been demonstrated to block DNA replication
selectively without affecting PCNA dependent NER (Li et al, 1994). The
relationship between p53 and p21 and mediation of the Gi-S cell checkpoint is not
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exclusive however, as fibroblasts derived from mice deficient in p21 are still
partially able to arrest at Gi-S following DNA damage (Deng et al, 1995).
Expression of GADD45 has also been shown to be upregulated in a p53
dependent fashion following exposure to ionising radiation in a wide variety of
cell types (Kastan et al, 1992). This gene directly interacts with PCNA in
response to DNA damage, in such a manner as to enhance DNA repair whilst
inhibiting DNA replication. This interaction has also been associated with the
induction of a growth arrest at Gi-S (Hall et al, 1995).
In addition to inducing the expression of genes shown to affect the efficiency of
DNA repair, p53 itself has been directly implicated in participating with the repair
of damaged DNA template. In addition to possessing 3' to 5' exonuclease activity
and the ability to bind recognise and bind damaged DNA template (see section
l.ii.2c), p53 can also directly bind to both the single-strand DNA binding protein
RP-A and the DNA strand repair factor CsB (Dutta et al, 1993 and Wang et al,
1995). Further, the C- terminal domain of p53 is known to be able to directly
interact with two helicase components of the TFIIH repair complex, XPD and
XPB (Wang et al, 1995). The in vivo significance of these interactions has yet to
be established however the in vivo consequences regarding p53 status and DNA
mutation rate are presented and discussed in section 1 .ii.6.
Recently published evidence has suggested a role for p53 mediated growth arrest
in the suppression of cell transformation following attenuation of p53 independent
apoptotic pathways in the cell.
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The expression of a dominant negative FADD (Fas Associated Death Domain)
transgene in T cells has shown that although still able to initiate apoptosis in
response to UV light and dexamethasone, these cells are no longer responsive to
Fas induced apoptosis (Zornig et al, 1998).
FADD has been demonstrated to directly mediate apoptotic signals generated in
response to ligand interaction with the TNF (Tumour Necrosis Factor) receptor
family to the effector molecules of apoptosis, the caspases (Boldin et al, 1996).
Fas induced apoptosis signals through one such receptor (CD95) and is
physiologically relevant with regard to mediating T cell cytotoxicity and in
removing surplus numbers ofmature B and T cell lymphocytes in the aftermath of
infection, a process termed AICD (Activation-Induced Cell Death; Ekert and
Vaux, 1997). One could predict therefore, that animals possessing T cells
resistant to Fas induced apoptosis may be more likely to develop T cell lymphoma
in comparison to wild-type animals. Rather than gaining selective growth
advantage however, T cells expressing this mutant version of FADD exhibited
growth arrest, which further experimentation proved to be p53 dependent (Zornig
et al, 1998).
(l.ii.5b) Apoptosis
P53 status has been shown to be critical for the induction of a rapid apoptotic
response in many tissue and cell types in response to the majority of stimuli listed
in section l.ii.3 (for review see Bellamy, 1997). Indeed, it is highly likely (but not
directly proven) that the attenuated apoptotic responses exhibited by p53 deficient
cells contribute to an overall increase in the probability of their malignant
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conversion (see section l.ii.7). As means of illustration, wild-type thymocytes
commit to apoptosis in a p53 dependent manner following y-irradiation, whilst
p53 -/- thymocytes do not. P53 deficient thymocytes still retain p53 independent
apoptotic responses (e.g. in response to glucocorticoid exposure), yet p53
deficient animals are highly prone to the development of T- cell lymphomas early
in life (Clarke et al, 1993 and Purdie et al, 1994).
P53 can induce apoptosis in response to DNA damage through both
transactivation dependent and independent mechanisms. Experimental evidence
exists to demonstrate that p53 can induce apoptosis in cells cultured in the
presence of both actinomycin D and cyclohexamide (inhibitors of RNA and
protein synthesis respectively) in response to DNA damage or c-myc
overexpression (Caelles et al, 1994 and Wagner et al, 1994). Further, a C-
terminal deficient and consequently transactivation deficient p53 molecule was
shown to retain the ability to induce HeLa cell apoptosis in response to
inappropriate oncogene expression (Haupt et al, 1995). An apoptotic domain,
putatively essential for p53 mediated cell death has recently been mapped to
amino acids 43-63 (Zhu et al, 1998).
The mechanisms underlying p53 dependent apoptosis in the absence of
downstream gene transactivation remain to be elucidated, however direct
interaction between p53's C- terminal domain and both XPB and XPD helicases
seems to be essential in certain cellular contexts (Wang et al, 1996). Further, a
recent publication has described the ability of activated p53 to directly mediate
translocation of the Fas receptor from Golgi apparatus to cell surface. Activated
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p53 also induced interaction between FADD and the Fas receptor and so can
transiently sensitise cells to Fas-induced apoptosis (Bennett et al, 1998).
Examples also exist in the literature demonstrating an absolute requirement for
p53 mediated transactivation or repression of downstream targets to induce
apoptosis (Sabbatini et al, 1995 and Yonish-Rouach et al, 1995). The identity of
several of these transactivated and repressed loci would theoretically appear to
increase the likelihood of an apoptotic cellular outcome in response to cellular
stress.
Activated p53 has been shown to both transactivate the expression of Bax in
response to y-irradiation and to repress the transcription of Bcl-2 (Miyashita and
Reed, 1995 and Miyashita et al, 1994). Overexpression of Bcl-2 has been
demonstrated to block p53-dependent apoptosis (Chiou et al, 1994), however cells
become predisposed to apoptose when the relative levels of Bax predominate over
the levels of Bcl-2 within the cell. In this respect, p53 influences the expression
of both target genes to promote apoptosis. Indeed, a recently published study
demonstrated that p53 dependent induction of Bax was essential in slowing the
rate of neural tumour growth and progression in vivo (Yin et al, 1997).
P53 can also induce the expression of IGF-BP3 (insulin-like growth factor
binding protein 3), a protein that appears to block mitogenic signalling resulting
from stimulation of the IGF receptor (Buckbinder et al, 1995). P53 has been
further implicated as a direct regulator of cellular IGF receptor levels (Neuberg et
al, 1997) and so in this manner, p53 may either retard cellular proliferation rate or
induce apoptosis through deprivation of growth signals.
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In an attempt to further elucidate the mechanisms underlying p53 transactivation
mediated apoptosis, the group of Bert Vogelstein analysed the number of gene
transcripts influenced by activated p53 in a human colorectal cancer cell line prior
to apoptosis (Polyak et al, 1997). Using SAGE (serial analysis of gene
expression) they identified 14 transcripts (0.19%) that appeared to be induced
greater than 10-fold and 20 transcripts (0.28%) repressed greater than 10-fold in a
p53-dependent manner. Further analysis of the induced transcripts identified them
as being either capable of generating, or responding to oxidative stress within the
cell. Accordingly, they have proposed that p53 transactivation mediated apoptosis
is initiated by induction of redox-related genes, which in turn results in the
formation of reactive oxygen species, which in turn leads to mitochondrial
degradation and cell death.
Interestingly however, this study reported no observable p53 dependent difference
in the expression levels of Bax. Therefore, whilst Bax expression appears to be
relevant regarding the suppression of tumours of neural origin, less reliance (if
any) appears to be placed upon this apoptotic pathway regarding the suppression
of colorectal tumours.
In summary then, this data would suggest that p53 can induce apoptosis through
several pathways, but apoptotic outcome as yet is not predictable and appears to
be highly dependent upon context in vivo.
From the evidence presented in each of the preceding sections, it is possible to
make several predictions about the effects of p53 deficiency upon both mutation
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rate and tumourigenesis. The availability of strains of p53 deficient mice has
permitted a wide-range of experiments addressing both of these endpoints.
(l.ii.6) P53 and Mutation Frequency
Abrogation of wild-type p53 function is predicted to lead to an increase in the
number of cells bearing DNA damage, as a result of altered apoptotic and DNA
repair profiles. Experiments designed to test this prediction suggest that p53
dependent differences may only become apparent following exogenous damage.
Two different groups have used a transgene target to monitor spontaneous
mutation frequency, but in both cases no p53 dependent differences were
observed (Sands et al, 1995 and Nishino et al, 1995). By contrast, experiments
using either short pre-B cell cultures (Griffiths et al, 1997) or a transfected
fibroblast line (Yuan et al, 1995) have now provided data in support of a p53
dependent decrease in the number of mutation bearing cells in response to
genotoxic stress. In vivo experiments using the Dlb-1 locus as a marker for
mutation, have also shown a p53 dependent decrease in mutation frequency in the
murine small intestine (Clarke et al, 1997), although this was only observed at
high levels of DNA damage. Taken together, these different experiments do
support a role for p53 in preventing the acquisition of mutation, but it is clear that
it is not the sole mechanism, particularly at low levels ofDNA damage.
A further difficulty exists in interpreting the relevance of p53 dependent apoptosis
because of the diversity of roles played by p53. However, evidence does exist to
show that, at least in certain cell systems, the induction of apoptosis is the critical
response to DNA damage. Thus, where mutation frequency and clonogenic
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survival have been scored independently (Griffiths et al, 1997), it can be shown
that mutation frequencies amongst surviving clones are largely unaffected by p53
status, but that the effect of p53 deficiency is to increase the number of mutation
bearing progeny by virtue of increased cell survival. That is, the failure to initiate
p53 dependent apoptosis in response to DNA damage is perhaps more relevant to
the increase in DNA damage bearing cells than an actual DNA repair deficit.
(l.ii.7) P53 and Tumourigenesis
The majority of p53 -/- mice develop normally to birth, but then rapidly succumb
to tumourigenesis, predominantly of the thymic lineages. P53 +/- mice develop
both lymphomas and sarcomas at an approximately equal rate, but +/- mice
develop a broader spectrum of tumours at low incidence in comparison to -/- mice
and also exhibit a longer latency period before tumour appearance (Purdie et al,
1994 and Jacks et al, 1994).
Transgenic experiments using a dominant negative p53 transgene in combination
with the p53 heterozygous and null animals (Harvey et al, 1995) have strongly
supported the idea that mutation of p53 predisposes to tumourigenesis by blocking
wild type p53 function. In vivo analysis of these strains has been used to address
the relevance of p53 gene status at different stages of tumourigenesis.
A critical role for wild-type p53 in the suppression of radiation-induced
malignancy was identified following exposure of mice mutant for p53 to y-
irradiation. Treated p53 +/- and -/- mice developed tumours with an identical
spectrum to non-irradiated counterparts, but exhibited a comparatively much
reduced latency period (Kemp et al, 1994). Similarly, transgenic mice expressing
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a dominant negative mutant p53 allele, treated in a similar fashion, displayed a
higher incidence rate of sarcoma and lymphoma occurrence, and also
demonstrated an increase in the incidence of double strand chromosomal breaks,
and therefore exhibited increased genomic instability (Lee et al, 1994). Analysis
of the tumours derived from irradiated +/- mice revealed loss of the remaining
wild type p53 allele in 96% of all cases, a significantly higher level of loss than in
the mock irradiated +/- mice.
Loss of p53 function therefore confers a strong selective growth advantage during
the processes of y-irradiation induced tumourigenesis, however p53 status is not
the sole rate determinant. If this were the case, one would predict p53 -/- mice to
develop large numbers of primary tumours simultaneously following irradiation.
The protective role of p53 is not limited to the prevention of y-irradiation induced
tumourigenesis. For example, treatment of p53 +/- animals with the carcinogen
dimethylnitrosamine leads to a reduction in latency (in comparison with wild
type) of tumour development within the liver (Harvey et al, 1993).
P53 status has also been shown to influence both initiation and progression ofUV
induced skin cancer (Zeigler et al, 1994). In addition to demonstrating that the
majority of actinic keratoses (first clinically apparent lesion in skin cancer
development) have at least one mutated p53 allele, p53 +/- and -/- cells possess a
selective survival advantage over p53 +/+ cells following repeated re-exposure to
sunlight.
Following the exposure of mice +/+, +/- and -/- for p53 to UV B irradiation, +/+
mice exhibited extensive sunburn, characterised by high levels of apoptosis,
within 24 hours. Significantly, -/- skin tissue presented far fewer sunburn cells
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and correspondingly less apoptosis and +/- skin tissue exhibited an intermediate
phenotype.
The ability to become sunburn cells and enter apoptosis is clearly p53 gene dose
dependent. DNA damaged cells surviving UV irradiation by virtue of
compromised p53 activity would subsequently select for lesions positively
influencing growth or negatively affecting death-promoting genes, and thus be
predisposed to malignant conversion.
Skin swabbed with the carcinogen DMBA initiates tumourigenesis in the mouse.
Promotion of tumourigenesis can be achieved by exposing the initiated skin to
TPA, the result of which is the appearance of multiple papillomas (benign
hyperplastic regions). Within two months, a small proportion of these papillomas
become carcinomas, which vary in their state of differentiation and invasiveness.
Kemp et al, utilised this well characterised model of chemically induced multi¬
stage tumourigenesis to determine the effects of p53 status upon these different
stages (Kemp et al, 1993).
In the absence of DMBA treatment, no papillomas arose on the skin of p53 -/-
mice swabbed with the tumour promoter TPA, demonstrating that loss of p53
function is insufficient for tumour initiation. Indeed, this experiment
demonstrated that a p53 null phenotype is refractory to papilloma formation.
The effect of p53 status on the latency of papilloma development was also
investigated and no difference was observed between mice +/+, +/- and -/- for
p53, again implying a role for other genetic lesions at this stage of tumour
development.
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The conversion rate from benign papillomas to malignant carcinomas was,
however, shown to be highly dependent upon p53 status. In p53 null mice,
conversion occurred at higher penetrance and significantly faster than in +/+
animals.
These somewhat confusing results are supported by experiments using transgenes
epidermally targeted to express v-rasHa, v-fos and human growth factor a. These
transgenic strains are predisposed to papilloma development, but this process is
again blocked following breeding onto a p53 null background (Greenhalgh et al,
1996).
Taken together, these experiments argue that failure to initiate p53-dependent
pathways leads to increased genomic instability and therefore increased rate of
malignant progression, but only beyond the point of papilloma development.
Prior to this point it is possible that cells possessing functional p53 can tolerate a
higher level of DNA damage by virtue of attempted repair by p53 dependent
pathways, whereas damaged p53 null cells are deleted by p53 independent
apoptotic mechanisms. These experiments highlight the potential difficulty in
over-interpreting the role of apoptosis in the prevention of tumourigenesis, as in
this system failure to invoke p53 dependent pathways actually confers protection,
at least against the benign lesion.
P53 deficiency clearly plays an important role in malignant development, yet as
has been shown above, it is not the sole determinant of this process. The nature of
the complex inter-relationship between p53 and other tumour-related genes has
been investigated through a range of transgenic intercrosses. These experiments
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have produced results which, while strongly supporting a tumour suppressor role
for p53, clearly underline the cell specific nature of this function. For example,
mice transgenic for an MMTV-driven c-Myc transgene predominantly develop
mammary carcinoma, yet crossing onto a p53 null background reveals synergy in
tumour development within the haematopoietic system, with no effect upon
mammary tumourigenesis (Elson et al, 1995). Further evidence is available for
synergy between p53 and c-Myc within the lymphoid system, as mice null for p53
and transgenic for a CD2 driven c-Myc construct show accelerated lymphoma
development (Blyth et al, 1995).
Intercrossing p53 null mice with animals heterozygous for the APC tumour
suppressor gene has yielded similarly contradictory results. Mice heterozygous
for APC normally develop adenomas of the small and large bowel. When crossed
onto a p53 null background, no difference in tumour formation or progression was
observed even though loss of wild-type p53 function is strongly implicated in
intestinal neoplasia (Clarke et al, 1995). Synergy between these mutations was
however observed within the pancreatic tissues in the intercrossed animals, with
almost 100% of doubly mutant mice developing neoplasia.
In summary, the experiments discussed above argue strongly for complex reliance
upon p53-dependent pathways, largely determined by cell type. However, this
may again be too simplistic a view of p53 function, as even within a given tissue
type, deficiency of p53 can lead to different endpoints. For example, as stated
above, p53 fails to synergise with c-Myc in mammary carcinoma development,
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yet it does accelerate mammary adenocarcinoma formation in conjunction with a
Wnt-1 transgene (Donehower et al, 1995).
These differences presumably arise as a consequence of other genes modulating
apoptosis. For example, data from intercrosses of Bcl-2 transgenic animals and
p53 null mice strongly argue that p53 deficiency may be substituted by Bcl-2 gene
deregulation (Marin et al, 1994).
One alternative explanation for the variable reliance upon p53 derives from the
multiple functions of this gene. If one presupposes that tissue types vary in their
reliance upon apoptosis or DNA repair to eliminate mutation, it is inevitable that
there will be a tissue specific pattern of reliance upon p53 and indeed, any other
genes that regulate these processes.
Finally, it should again be stressed that although it is possible to detect a p53-
dependent apoptotic phenotype within many of the systems discussed above, it is
currently not possible to determine if this process is the sole mediator of
phenotype. The future analysis of p53 point mutants may enable the dissection
and analysis of specific p53 dysfunction and their phenotypic consequences. It
seems more likely however, that it is the lack of a combination of p53 functions
which ultimately determines predisposition to malignancy.
(l.ii.8) P53 and Angiogenesis
P53 has also been implicated in exerting influence over the process of neo-
vascularisation of tumours in vivo. Hypoxic conditions, at the centre of poorly
vascularised solid tumours, have been demonstrated to induce p53 dependent
apoptosis in vivo (Graeber et al, 1996). P53 can be induced to bind sequence
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specific DNA in response to the generation of reactive oxygen species (ROS)
within the cell. These highly reactive molecules have been implicated in the
physical damage ofDNA but as such, remain to be established as being sufficient
to stabilise p53 in the absence of further associated damage.
Certain cell lines have been demonstrated to secrete increased amounts of the
antiangiogenesis factor, thrombospondin, in a p53 dependent fashion in vitro
(Dameron et al, 1994), but again it remains to be determined whether this
observation is of physiological relevance regarding in vivo tumour suppression
(for review see Bouck, 1996).
(l.ii.9) Requirement of p53 Expression during Embryogenesis
P53 expression does not appear to be essential for normal murine embryogenesis
(Donehower et al, 1992). However, a small proportion of p53 -/- male animals are
affected with defects in spermatogenesis (Rotter et al, 1993), and a small subset of
p53 -/- female embryos are affected by exencephaly (defect in neural tube closure)
(Sah et al, 1995). These developmental phenotypes seem to be dependent upon
the genetic background of the experimental mouse, as they were not observed in
the initial knockout animals (Donehower et al, 1992).
P53 dependent gene transactivation is mostly detectable in the developing nervous
system of developing embryo's and newborn animals (Komarova et al, 1997). It is
therefore tempting to speculate that the observed overgrowth of neural tissue
observed in female exencephalics result from the failed induction of a p53
dependent, embryonal stage specific, wave of apoptosis.
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Whole body y-irradiation of pregnant mice has shown a p53 dependent
hypersensitivity to DNA damage in the early embryo (between days 8-13),
characterised by high levels of apoptosis in virtually all developing tissue
(Komarova et al, 1997).
P53 has also been demonstrated to remove mutant cells from developing embryos
in response to low levels of y-irradiation, thus reducing numbers of resultant
teratogenic offspring (Norimura et al, 1996). At high levels of damage however,
the opposite phenomenon occurs and a p53 dependent increase in teratogenic
offspring is observed (Wubah et al, 1996). It is proposed that the high rates of
p53 dependent apoptosis within developing tissue in response to extensive DNA
damage cannot be compensated for by the proliferation rate of cycling non-
damaged cells.
Inappropriate expression of wild-type p53 during murine embryogenesis has been
shown to give rise to malformations of the developing kidney, resulting in
progressive kidney disease and failure (Godley et al, 1996), and in the absence of
accompanying mdm-2 expression, to be lethal (Montes de Oca Luna et al, 1995),
(Jones et al, 1995).
(l.ii.10) P53 and Gene Therapy
In summary, the p53 tumour suppressor gene has been demonstrated to preserve
genomic integrity by being a critical regulator of both cell cycle and apoptosis in
response to stress. Further, loss of wild-type p53 gene expression is one of the
most common events to arise during the development and progression of many
human and murine malignancies.
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Upon this basis and observations made through extensive in vitro overexpression
experimentation (e.g. Baker et al, 1990; Yonish-Rouach et al, 1991), it is
proposed that the reintroduction of p53 expression into p53 deficient and
malignant cells in vivo may restore p53 dependent cellular pathways and thus
confer positive therapeutic effect. Indeed, the cytotoxicity conferred by many
conventional chemotherapeutic drug treatments is potentiated in tumour cells
retaining some functional wild-type p53 expression (Lowe et al, 1993). Therefore
even if the re-introduction of wild-type p53 gene expression into mutant tumour
cells proved insufficient to revert tumourigenic state, then at the least one could
expect an enhanced anti-tumour response to conventional chemotherapeutic
treatment.
Several research groups have taken this initiative and have started human gene
therapy trials testing both adeno- and retroviral p53 gene replacement vectors as a
means of correcting otherwise untreatable malignancies (Clayman et al, 1996 and
Roth et al, 1996). The current failing of conventional gene replacement style
therapy however is the inability to deliver stable gene expression at high
efficiency to the desired target cells (Blau, 1997). These problems are especially
pertinent with regard to the application of replacement gene therapy in the
treatment of malignant disease. If one considers the manner in which
tumourigenic cells clonally evolve to progressively more aggressive and invasive
phenotypes, then theoretically near 100% efficiency in gene delivery will be
required before significant therapeutic benefit is conferred to the patient. Indeed,
these predications regarding the success of replacement gene therapy in the
treatment of cancer are being made without formal proof that re-introduction of
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tumour suppressor gene function is capable of significantly modulating tumour
phenotype in vivo.
The advent of inducible promoter technology and the comparative ease at which it
is now possible to generate precisely modified mice on controlled genetic
backgrounds has provided an opportunity to produce model systems with which to




The aim of this chapter was to apply currently available inducible promoter
technology to develop a tumour cell-line based system in which it would be
possible to examine the phenotypic consequences resulting from the introduction
of p53 expression within an otherwise p53 deficient genetic background.
(2.i) Inducible Transgene Approach
The application of current inducible promoter technology to studies aimed at
evaluating transgene-dependent effects upon the cell offers considerable
advantages over both conventional transient or stable transfection approaches and
viral transduction approaches (see sections l.i.2 and l.i.8).
Transient transfection efficiencies using plasmid DNA and current DNA transfer
technology can vary largely between different cell types and between
experiments, making accurate phenotypic comparison difficult. Transient
approaches do however offer immediacy which studies of stable transgene
expression do not offer. The selection of clones possessing stably integrated
transgenic DNA requires at least a 10-day latency period before meaningful
observations can be recorded and so often results in the analysis of transgene
expression within a sub-clonal population of cells distinct from the parental non-
transfected cell line.
The main advantage of an inducible transgene approach over conventional
constitutively expressing transgenic approaches is that stably transfected clones
can be established in the absence of transgene expression. This is particularly
advantageous when the constitutive expression of a desired transgene is predicted
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to confer a strong selective disadvantage upon the host cell (e.g. a tumour
suppressor gene).
Following the selection of clones stably transfected with a constitutively
expressing and growth limiting transgene, cells that exhibit low levels of
transgene expression (as a result of position effect) will possess a selective
advantage over cells that exhibit high levels of transgene expression. The likely
consequence of this selective pressure will be that during the course of antibiotic
selection for stably transfected clones, cells weakly expressing the transgene will
become the predominant population within the culture system, as cells strongly
expressing the transgene will be inhibited or removed. Such an eventuality could
potentially result in the analysis of cells clonally distinct from the parental non-
transfected cell, where it may not be possible to observe the full spectrum of
transgene-mediated phenotypic effects as a result of weak expression.
Through the application of inducible expression technology however, stably
transfected clones can be established in the absence of selective pressure
conferred by transgene expression. Further, these clones possess the ability to
rapidly and uniformly induce transgene expression, thus potentially enabling
reproducible observation of a wider range of transgene-mediated effects within
cells more likely to be representative of the original non-transfected parental cell
type.
The development of recombinant adenoviral and retroviral expression vectors now
permits both a rapid and highly efficient means of introducing transgene
expression into cells in vitro. Variation of virus titre and extent of viral exposure
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can result in the rapid transduction of virtually 100% of cells growing in culture.
As discussed in section l.i.2 however, the ability to use viral vectors as a means of
introducing stable transgene expression into cells growing in vivo can be of highly
variable efficiency and thus difficult to reproduce. In these respects and with
regard to the aims of this project (section l.ii.10), inducible promoter technology
is superior to both conventional transfection and viral transduction technology in
permitting the examination of transgene mediated effects within mammalian cells
in vivo.
Once tumour cells have been transfected with an inducible tumour suppressor
transgene and fully characterised for transgene expression levels and phenotypic
effects in vitro, these cells can be potentially returned to the mouse to grow in vivo
in the absence of transgene expression (see chapter 3). In this manner it may be
possible to examine how fully in vitro characterised levels of transgene expression
affect tumour cell growth in vivo and so permit a means of better evaluating the
potential application of replacement tumour suppressor gene therapy in the
treatment of cancer.
(2.i.l) Choice of Inducible Expression System
In order to best achieve the experimental aims described in the opening section of
this chapter, an inducible expression system was required that would permit both
a low level of "leaky" transgene expression when in the non-induced state, yet
also produce a high level of transgene expression when induced.
As summarised in section l.i.8, there are presently a wide variety of inducible
gene expression systems currently available. For this study however, two
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inducible promoter systems were chosen to regulate the expression of a p53
transgene: the human 6-16 promoter system (interferon a/[3 inducible) and the
tetracycline inducible expression system.
The tetracycline inducible promoter system (described in section l.i.8c) was
selected because it affords very tight regulation of transgene expression; i.e. very
low basal transgene expression in the non-induced state and a high level of
transgene expression in the induced state. This system is also desirable because
two forms of Tet repressor molecule exist which permit the researcher to either
repress or induce transgene expression following administration of tetracycline (or
tetracycline derivative). Other inducible gene expression systems do not offer
such a degree of flexibility.
Further, the Tet system can efficiently induce or repress transgene expression in
mammalian cells at very low concentrations (O.ljig ml"1) of inducer. This
effective concentration of tetracycline does not exert any other gross pleiotropic
effects upon mammalian cells, thus this system permits the examination of
transgene mediated effect on cell phenotype without further complication arising
in the form of effects mediated by transgene inducer.
The one slight disadvantage regarding the use of this system to regulate transgene
expression is that a greater length of time is often required to optimise
experimental conditions before it is possible to successfully achieve induction of
transgene expression. Two plasmid components must be stably introduced into
the host cell and sequentially optimised before transgene expression can be
manipulated precisely.
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Further, the cytotoxic effects associated with high levels of tetR expression often
necessitates screening a greater number of clones than is otherwise required in the
other 'two-component' inducible systems (listed in table 1 .i.a of chapter 1) before
inducible clones are identified. The advantages associated with the application of
this system however far outweigh the disadvantages.
The interferon inducible expression system was also selected to achieve these
experimental goals, as this system is also capable of tightly regulating transgene
expression. The effective inducing concentration of interferon a/(3 does however
exert several pleiotropic effects upon a wide variety of mammalian cells (see
section l.i.8b).
Whilst the cellular effects elicited by interferon a/(3 may preclude the choice of
this conditional expression system for the routine analysis of effects conferred by
transgene expression, the application of this conditional expression system to
regulate the expression of tumour suppressor genes does open some interesting
possibilities with regard to observing tumour cell phenotype. In addition to
enabling the investigation of the experimental goals outlined at the beginning of
this chapter, the application of this inducible expression system also permits the
investigation of possible adjuvant anti-tumour effects resulting from the
introduction of p53 gene expression simultaneously in the presence of interferon
a/(3.
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(2.i.2) Cloning Strategy of Inducible p53 Expression Constructs
The p53 cDNA cassette used in the following experiments detailed in this chapter
was derived from a previously cloned and characterised version, (from
pBKOP53wt, Roger Malcomson (Malcomson, 1996), by a double EcoRI and
Mlul restriction digest. The resultant 1.9Kb DNA fragment, which includes full-
length p53 cDNA sequence, a small intron and SV40 polyA sequence, was then
blunt ended with Klenow fragment and cloned into a cut and de-phosphorylated
EcoRV site within the polylinker of pBluescript to generate pBSP53.
The p53 cDNA cassette was then orientated relative to the other restriction sites
within the pBS polylinker, to determine an appropriate position in which to
directionally clone promoter sequence, such that the expression of p53 would be
rendered inducible.
N.B. all plasmids referred to within sections 2.i.2, 2a and 2b are mapped and
included separately within the appendix.
(2.i.2a) Cloning Strategy of Interferon a/(3 Inducible p53 Constructs
The human 6-16 interferon a/(3 inducible promoter exists in both a long and a
short format (see sectionl.i.8a). These will be referred to as the 6-16l and 6-16s
promoter sequences respectively for the remainder of this thesis.
Both 6-16l and 6-16s promoter sequences were removed from plCX and p3CX
respectively (both plasmids kindly provided by Austin Smith) by a Bgllll/Hindlll
double restriction digest. The resultant 1.1Kb and 0.6Kb fragments were then
blunt ended with Klenow fragment and cloned into pBSP53 polylinker sequence
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at a cut and Klenow fragment blunted Hindlll site to generate p6-16lp53 and p6-
16sp53 respectively.
To enable the selection and derivation of stably transfected tumour and ES cell
clones with these constructs, a PGK promoter driven Hygromycin resistance
cassette was cloned into both p6-16lp53 and p6-16sp53 at Klenow fragment
blunted Xbal and Spel sites respectively to generate p6-16lp53-HYG and p6-
16sp53-HYG. Bacterial cultures transformed by the latter construct grew very
poorly and yielded very low amounts of DNA, therefore only fully constructed
p6-16Lp53-HYG is depicted in figure 2.1 below.
Fig 2.1
(i) (ii)
Fig2.1 Shows two gel photographs depicting both p6-16Lp53 (i) and p6-16Lp53-HYG (ii)
constructs. Correctly constructed p6-16Lp53 will produce a 3.9Kb, 1.6Kb, 1.0Kb, 0.5Kb and
0.48Kb banding pattern following PstI digestion [lanes 3 and 5 of (i)]. Correctly constructed p6-
16Lp53-HYG will produce a 5.9Kb, 1.2Kb and 0.75Kb banding pattern following digestion with
EcoRI [lane 1 of (ii)] and a 3.9Kb, 1.6Kb, 1.0Kb, 0.8Kb and 0.48Kb banding pattern following
digestion with PstI [lane 2 of (ii)].
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(2.i.2b) Cloning Strategy of Tetracycline Inducible p53 Construct
As detailed within the appendix, constructs were also generated to render the
expression of transgenic p53 inducible to tetracycline within the cell. Although
these constructs were stably transfected into p53 deficient sarcoma cell lines (see
section 2.i.3) no further analyses were conducted and the remaining portion of this
chapter will detail only experimental work undertaken with the interferon a/(3
inducible p53 construct, p6-16lp53-HYG.
(2.i.3) Derivation of p53 Deficient Sarcoma Cell Lines
Tumour cells that have always lacked p53 gene expression (i.e. tumour cells
arising from targeted p53 deficient mice) will theoretically respond better to p53
replacement gene therapy than other tumour cell types that have lost p53 gene
function at a later stage of tumourigenesis. In theory, little further selective
advantage can be gained from the additional loss of gene function in an already
inherited dysfunctional p53 dependent pathway. Thus, re-introduction of p53
gene expression in these cells will more likely restore p53 dependent pathways in
comparison to other tumour cells that have lost p53 gene function at a later stage
of tumourigenesis.
As such, eight sarcoma cell lines were derived from tumours arising from outbred
p53 -/- mice (see section MM4.2 for procedure). These cultures were incubated at
37°C in 5% CO2, and were grown up over the course of several weeks to establish
multiple freezes of primary tumour cell lines.
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Two of the eight primary lines, SL1 and SL5, possessed near uniform morphology
and grew efficiently past passage 3. These two lines were selected for subsequent
transfection with p6-16tp53-HYG.
(2.i.4) Derivation of p6-16lp53-HYG Stably Transfected Clones
Both Sarcoma Line 1 (SL1) and Sarcoma Line 5 (SL5) were plated at a density of
5 x 106 cells/lOcm dish and were transfected with construct p6-16Lp53-HYG by
lipofectin reagent (see section MM4.2).
Following a 12-day period of hygromycin selection (80(Xg/ml), 60 SL1 and 20
SL5 hygr (hygromycin resistant) clones were picked and grown further to enable
characterisation of transgene expression (again see section MM4.2). All clones
were cultured continuously in the presence of hygromycin following transfection.
(2.ii) CHARACTERISATION OF STABLY TRANSFECTED CLONES
The aim of these experiments was to identify SL sub-clones, stably transfected
with the p6-16lP53-HYG construct, which exhibited high levels of induced
transgene expression following administration of interferon a/(3 to cell culture
media, but which also exhibited very low amounts of transgene expression in the
absence of inducer.
(2.ii.l) Optimisation of rtPCR Assay
The transgene expression levels of all 80 stably transfected clones were initially
analysed by rtPCR, as this assay is both highly sensitive and can be further refined
to provide comparative quantitation of transgene expression between samples.
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To detect gene expression by rtPCR, total mRNA is extracted from either cultured
cells or fresh tissue and is used as template for the production of cDNA by the
enzyme reverse transcriptase (see materials and methods sections MM2.1 and
MM2.4).
Subsequent PCR cycling of this total cDNA, with sequence specific primers, will
result in the amplification of template originating from a specific transcriptional
product.
To enable the screening of p53 transgene expression levels by rtPCR, primers
prP53cDNA and prPA.SEN (see table 2.1), were optimised to amplify transgene
specific sequence at the 3' end of the p53 cDNA cassette (see fig 2.2).
Theoretically, correctly spliced p53 transgene transcript no longer possesses
intronic sequence but retains both primer annealing sites. Application of these
primers to screen transgene expression can therefore permit differentiation of PCR
product origin via agarose gel electrophoresis, as the predicted size of amplified
product originating from genomic template is 520bp whilst amplified product
originating from correctly spliced mRNA is 350bp.
Table 2.1
prP53cDNA 5'ATG CTA CAG AGG AGT CTG GA j Located from 1172 to
1191 bp on cDNA seq.
prPA.SEN 5'GAT CAT GAA CAG ACT GTG AG J Located from 693 to
712bp on pBKCMV seq.
p(3-act.A
5' CAT GAA GTG TGA GGT TGA CAJ Located at 924bp of (3-
actin cDNA sequence
p|3-act.B
5' CAG AAG CAA TGC TGT CAC CTJ Located at 1650bp of (3-
actin cDNA sequence
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To standardise quantified amplification product originating from transgenic
mRNA and thus control for template loading error and variability in PCR reaction
efficiency between samples (see section 2.ii.3 for discussion), primers were also
designed and optimised to amplify a 740bp portion of the constitutively expressed
P-actin gene (see table 2.1).
On the evening prior to transgene induction, stably transfected cells were seeded
in triplicate, at a density of 2 x 105 cells per 10cm2 (single well of a 6 well plate).
The following morning, media was aspirated from cells and replaced with
medium containing 0, 500 or 1000 I.R.U (International Reference Units), of
interferon a/p (SIGMA) per ml. All clones were grown for a further 48 hours in
the presence of (or absence of) interferon a/p, at which time cells were lysed




(2.ii.2) p6-16Lp53-HYG Transgene is Inducible, but does not Splice
Following reverse transcription of mRNA derived from these induced clones,
there are a number of possible transgene specific PCR amplification products that
can theoretically arise through the application of primers prP53cDNA and
prPA.SEN (see fig.2.2).
Amplification product can originate from correctly spliced transgenic cDNA,
from unspliced transgenic cDNA and from contaminating genomic DNA carried
over during the preparation of mRNA. It is not possible to differentiate the
amplification products arising via the latter two origins by agarose gel
electrophoresis.
Although reaction conditions were readily optimised to efficiently amplify the
background 550bp cDNA/DNA template, conditions could not be optimised to
detect the 350bp amplification product, predicted to correspond to correctly
spliced transgenic transcript, in any of the stably transfected and induced samples.
There are a number of possible scenarios that could explain this result. Firstly,
failure to detect correctly spliced transgene cDNA template could simply be the
result of poorly optimised PCR reaction conditions. This explanation is unlikely
however as the amplification of the related background transgene specific
template, using the same pair of primers, is possible through a wide-range of
reaction conditions.
Another explanation could be that none of the stably transfected clones possess
the ability to induce transgene expression in the presence of interferon a/p. This
eventuality could arise from either mutation of the p6-16Lp53-HYG construct or
from an intrinsic inability of the SL cell lines to respond to interferon a/|3 (i.e.
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through mutation or constitutive down-regulation of the cell-surface interferon
a/(3 receptor or other down-stream signalling molecules).
Failure of induced mRNA to correctly splice at the 3'end would also result in the
amplification of cDNA template indistinguishable by agarose gel electrophoresis
from contaminating genomic DNA. Genomic DNA can be easily removed from
mRNA samples, and thus subsequent cDNA samples, by DNase I treatment of the
sample prior to reverse transcription. Following rtPCR, this enzymatic step will
only permit the production of amplification products originating from either
spliced or unspliced transgenic mRNA.
Fig2.3 shows the amplification products produced from cDNA originating from
clone 49 (SL1) following DNase I treatment prior to reverse transcription.
Sample lanes (2) to (4) demonstrate that transgene expression originating from p6-
16Lp53-FIYG is inducible to interferon oc/(3 and that transgene expression in the
uninduced state is very low. Sample lanes (5) to (7) show that following DNase I
treatment of these mRNA samples prior to reverse transcription, all traces of
contaminating genomic DNA have been removed from each sample. Taken
together, these results imply that the induced mRNA transcript never exists in a
spliced form, thus explaining the failure to detect cDNA template corresponding
to correctly spliced mRNA.
The inclusion of splice acceptor and splice donor sequences within transgene
expression constructs, such that they effectively enable the splicing of transgenic
mRNA, is believed to enhance translation efficiency and thus the expression of
transgenes in mammalian cells (Sambrook et al, 1989). As shown in fig.2.2, the
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failure of transcript originating from p6-16Lp53-HYG to splice does not alter or
affect final transgene translation product, although it must be considered that
efficiency of transcript translation may be compromised. To demonstrate the
usefulness of these stably transfected clones in achieving the experimental goals
detailed at the start of this chapter, further analysis and characterisation of p53
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Fig 2.3 From left to right, gel lanes (2) to (4) show amplification product originating from
uninduced, 500 I.R.U. and 1000 I.R.U. interferon a/(3 treated samples respectively, following
DNase I treatment prior to reverse transcription. Gel lanes (5) to (7) show the amplification
products produced from uninduced, 500 I.R.U. and 1000 I.R.U. interferon a/(3 treated samples
respectively, treated with DNase I and not reverse transcribed. Gel lanes (8) to (10) show
uninduced, 500 I.R.U. and 1000 I.R.U. interferon a/(3 treated samples respectively, treated with
DNase I prior to reverse transcription but amplified using a set of P-Actin specific primers
(sequence not shown).
Following DNase I treatment of all mRNA samples, rtPCR experimentation
identified 9, from the total of 80 clones, exhibiting good inducible transgene
expression when cultured in the presence of interferon a/p. The remaining clones
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were discarded as either no transgene expression was detectable or the basal, non-
induced level of transgene expression was high.
5 of the 9 inducible SL clones lost their capacity to proliferate within several
passages of identification and so could not be expanded in culture to enable
further experimentation. However, of the remaining four expandable clones, three
(ID, 16 and 44) were derived from SL1 and one (5A) was derived from SL5.
N.B. Time restraints limited much of the experimentation detailed in the
remainder of this chapter to the characterisation and investigation of inducible
clone ID only.
(2.ii.3) Optimisation of Quantitative rtPCR Assay
Maria Wallace primarily undertook the practical work detailed in this section
under the supervision ofboth Dr Alan Clarke and myself as part requirementfor
her B.Sc. (Med. Sci.) Hons degree.
Following the success of the non-quantitative rtPCR approach employed as a
means to identify inducible transgene expressing clones, quantitative rtPCR
analysis was the method of choice to further analyse the transcriptional kinetics of
transgene induction.
Quantitative rtPCR is currently the most sensitive means of detecting levels of
specific gene expression when amounts of analytical starting material are limiting.
The main advantage of such an approach for these specific experiments therefore,
was that it enables the analysis of inducible gene expression kinetics on a
relatively small scale, thus reducing consumption of inducing reagent. In
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addition, there was no further requirement to design and optimise the use of novel
PCR reagents, as this approach uses reagents identical to those employed
previously in the non-quantitative rtPCR assay.
To enable the quantitation of initial template copy number via this approach, total
mRNA is extracted from samples, reverse transcribed and amplified as detailed in
the previous section. The final concentration of transgene-specific amplification
product is then quantitated and is used as a measure to determine the relative
amounts of initial cDNA template (thus the relative levels of gene expression)
present in each of the samples prior to amplification.
To ensure reproducibility in the final concentration of amplification product for a
given sample, and to ensure that any observed differences between samples are
genuine, several important considerations must be borne in mind when designing
and optimising quantitative rtPCR reaction conditions.
Firstly, the amplification of DNA template by PCR does not indefinitely increase
exponentially at every cycle and eventually reaches a maximum level of DNA
concentration, termed the plateau phase. Both the progressive consumption and
saturation of reagents with increasing cycle number and the progressive decrease
in Taq DNA polymerase activity following repeat exposure to high temperature
are believed to be the underlying reasons responsible for this phenomenon (Reidy
et al, 1995).
In order for any difference between final PCR amplification product
concentrations to be meaningful therefore, it is essential that the concentration of
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final rtPCR product be quantitated during the exponential, or log, phase of the
reaction, i.e. before the reaction reaches plateau phase.
Due to the extreme sensitivity afforded by the PCR technique, it is also essential
that any difference arising in final amplification product concentrations between
samples are not the result of variation in the amount of extract loaded or from
variation in PCR reaction efficiency between samples. The amplification of
another gene, typically that of a constitutively expressed or "housekeeping" gene,
in the same reaction tube as the gene of interest, can control for these variables if
both the amplification reactions are terminated in their respective log phases.
Constitutively expressed genes, typically (3-actin or G3PDH, are effectively
expressed at a consistent level across a diverse range of tissue and cell-types. By
standardising the final concentration of amplification product resulting from the
gene of interest against the concentration of amplified product originating from a
housekeeping gene, it is possible to control for both template loading error and
variability in PCR reaction efficiency between samples.
Finally, the presence of trace amounts of contaminating genomic DNA in the
mRNA preparation will also theoretically give rise to amplification product. To
facilitate the discrimination of amplification product origin from between these
two possible sources, gene specific PCR primers should be designed to anneal to
exonic sequence separated by a small portion of intronic sequence. In this way,
amplification product originating from mRNA will be shorter than amplification
product originating from genomic DNA, and hence amplification product
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originating from transcriptional product can be readily discriminated from
background product by agarose gel electrophoresis.
To determine the log phases for both transgene specific and p-actin specific
amplification reactions, PCR reactions were set-up and terminated in triplicate
following 26, 29, 32 and 35 completed cycles, using both primer pairs
independently and cDNA template derived from clone ID. 10% of each reaction
was then run on a 0.8% agarose gel, and the specific PCR product was quantitated
using the Herolab E.A.S.Y. enhanced analysis system. As shown in fig.2.4, both
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(2.ii.4) Further Analysis of Transgene Induction
The aim of this experiment was to apply the quantitative rtPCR assay optimised in
the previous section, to further characterise transgene induction by examining the
transcriptional kinetics of transgene mRNA production following the exposure of
inducible SL cells to interferon a/(3.
On the evening prior to transgene induction, inducible clone ID was seeded in
triplicate for each time-point, at a density of 2x105 cells per 10cm2. The following
morning, media was aspirated from all cells and replaced with media containing
1000 I.R.U of interferon a/(3 per ml. All clones remained in the presence of
interferon a/p before being lysed with TRIZOL at either 0, 6, 12, 24, 36, 48 or 72
hours post-induction, at which time RNA was extracted to enable analysis by
quantitative rtPCR.
The results of this experiment are presented in the form of a graph in fig.2.5
This data demonstrates that the induction of transgenic mRNA by interferon a/p
is rapid, reaching maximal levels within the cell following 6 hours continuous
exposure to inducer.
Perhaps the most interesting feature of this data however is that despite the
continuous presence of inducer for the duration of the experiment, the
transcriptional kinetics of transgene expression varies extensively over time.
After rapidly reaching maximal levels of transgene expression at 6 hours, the
relative amount of transgenic mRNA drops to near uninduced levels in the cell by
24 hours, before proceeding to rise again to near maximal levels by 48 hours. At
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this time, the amount of transgene mRNA falls before reaching relatively low
levels in the cell again by 72 hours.
Fig 2.5
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Fig2.5 The above graph shows the relative amounts of transgenic mRNA expressed over time
following exposure of cells from clone ID to 1000 I.R.U. of interferon a/p. The final
concentration of transgene specific PCR product was standardised against the final concentration
of P-actin PCR product from each sample at every time-point.
This data would suggest that the response of SL1 cells to interferon cx/(3 is rapid,
but following continuous stimulation of these cells, the response becomes
modulated and by 24 hours SL1 cells are held in a transitory non-responsive state.
The data depicted in figure 2.5 should be considered as semi-quantitative
however, as opposed to precisely quantitative, as although the general pattern of
observed mRNA induction was reproducible utilising both clone ID and 5A, the
relative standardised band intensities varied considerably between identical
induction experiments. As the observed pattern of transgene induction was
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reproducible between clones and induction experiments, it is likely that the
observed modulation of induced transgenic mRNA levels relative to constitutively
expressed mRNA are not artifactual. Indeed, the results described within section
2.ii.6 demonstrate that the percentage of p53 protein expressing cells over time
follows a comparatively similar pattern to the kinetics of p53 mRNA induction.
This would further suggest that the observed kinetics of p53 mRNA induction is
genuine.
It should also be noted however that this pattern of interferon induced transgene
expression, mediated through the human 6-16 promoter, has not been previously
described. Indeed, previous application of this system in ES cells reported both
rapid and stable induction of reporter transgene expression following 50 hours of
continuous stimulation with interferon a/(3 (Whyatt et al, 1993).
The levels of transgenic mRNA were not investigated in the Whyatt study, so it
may be possible that the nature of this observed difference in the kinetics of
transgene induction is the result of cell-type specific responses to interferon a/(3.
Hypothetically, a transitory induction of IRF-2 expression within SL but not ES
cells may be able to influence interferon cx/(3 mediated gene transactivation
sufficiently to produce these observed cell-type specific differences in transgene
expression level (see section l.i.8a). A further hypothesis could be that SL cells
become somehow 'de-sensitised' following continuous signalling from the
interferon a/p receptor, whilst ES cells do not.
It could further be postulated that these observed differences in transgene
induction kinetics are simply the result of differences in induced protein stability.
It is possible that the translated reporter gene product observed in the Whyatt
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study is stable in ES cells, whilst p53 protein is known to be unstable and rapidly
turned-over in many unchallenged cell-types (see section l.ii.3).
(2.ii.5) Characterisation of Transgene Induction at the Protein Level
The aim of this experiment was to prove by immuno-staining of induced cells
grown in vitro, that the translation product corresponding to previously detected
transgenic mRNA was p53.
On the evening prior to transgene induction, inducible clone ID was seeded onto
chamber-slides at a density of 3xl04cells per chamber well (see MM3.2). Each
chamber-slide contains two chamber wells, therefore on the morning following
plating, media was aspirated from both wells of every slide and replaced with
media containing either 0 or 1000 I.R.U. of interferon a/p per ml.
Wild-type p53 protein is known to stabilise following DNA damage, so all cells
were exposed to 10 J/m2 UV C irradiation 6 hours following induction (time-point
corresponding to maximal levels of transgenic mRNA, section 2.ii.4) in an
attempt to enhance the detection of p53 protein by this approach. Following
irradiation, all cells were returned to media conditions identical to those prior to
genotoxic insult.
Media was aspirated at every time-point and the cells were washed once in PBS
before being fixed in 50% methanol: 50% acetone for 10 minutes at room
temperature. Following fixation, the cells were air-dried and stored at -80°C prior





Fig2.6 - shows the results of immunochemistry performed on populations of both uninduced (U; 0
I.R.U. interferon a/P) and induced (I; 1000 I.R.U. interferon a/P) ID cells. Staining was achieved
using the anti-p53 monoclonal antibody, Pab421. N.B. The times used to head each photograph
are times following genotoxic insult. (Magnification 500X).
in*
The immunochemistry performed on these samples used the monoclonal antibody
Pab421 (see section MM.3.2 for protocol) and the results of are shown in Fig.2.6.
No p53 expression can be detected within non-induced ID cells growing in vitro 6
hours after exposure to DNA damage, however strong p53 expression is detected
within induced cultures of ID cells at a corresponding timepoint. At later
timepoints (24 hours after DNA damage), again p53 expression can barely be
detected within cultures of non-induced ID cells, whilst p53 expression is again
readily detected within induced 1D cells at a corresponding timepoint.
The results of this experiment conclude that following stable transfection of
construct p6-16Lp53-HYG, it is possible to induce p53 expression in response to
interferon a/(3.
(2.ii.6) Kinetics of Transgene Translation
The results described in section 2.ii.5 confirm that p53 protein can be detected at
all times following administration of interferon oc/(3. The aim of this experiment
was to measure the proportion of p53-positive cells over time, via the application
of an immuno-flow cytometry method (see section MM.3.4 of materials and
methods).
On the evening prior to transgene induction, inducible clone 1D was seeded at a
• 5 2 ....
density of 2x10 cells per 10cm . The following morning, media was aspirated
from all cells and replaced with media containing 1000 I.R.U. of interferon a/(3
per ml. At each time-point, cells were trypsinised and frozen at -20°C. The time-
points analysed were 0, 6, 12, 24, 36, 48 and 72 hours post-induction.
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Following completion of the experimental time-course, all samples were de¬
frosted and labelled with an anti-p53 1° anti-body (Ab-1)/ FITC conjugated 2°,
before being run on a gated flow cytometer to determine the percentage of
fluorescent cells in each sample. Untransfected SL1 (p53 deficient) cells were
also labelled and included in this experiment to control for the effects of cellular
auto-fluorescence within samples. Non-specific FITC background staining was
controlled as specified at point seven of protocol MM3.4 within the materials and
methods section.
The results of this experiment are shown in fig.2.7. The percentage of cells
expressing detectable levels of transgene is maximal at 6 hours post-induction
(approx. 37%), however this figure falls between 6 hours to 36 hours, where only
5% of all cells express p53. Expression levels rise again between 36 and 48
hours, before falling once more at 72 hours.
The kinetics of transgene translation, as determined by this flow cytometry
technique, are similar to the kinetics of transgene transcription. This would
suggest that rapidly following translation of transgenic mRNA, the protein
product is rapidly degraded within SL1 cells.
However, despite the success of this immuno-flow cytometry technique to detect
and discriminate between both transgene expressing and non-expressing cells, the
ability of this technique to exactly quantitate the percentage of transgene
expressing cells appears to be inconsistent. Upon subsequent repetition of this
experiment, the exact percentage value of expressing cells was variable, despite
high consistency of the overall observed kinetics of transgene expression. One
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must conclude therefore, that this technique is only suitable for the approximate
quantitation of p53 expressing cells, thus permitting the observation of trends in
transgene expression.
Fig.2.7
(2.iii) The Effect of p53 Expression upon Tumour Cell Cycle In Vitro
The aim of this experiment was to investigate the possible effects upon tumour
cell cycle in vitro, resulting from the induction of p53 gene expression, in both the
presence and absence ofUV-C mediated DNA damage through time.
On the evening prior to transgene induction, cells from clone ID were plated in
triplicate for each time-point, at a density of 2x105 cells per 10cm2. The following
morning, media was aspirated from the cells and replaced with media containing
either 0 or 1000 I.R.U. of interferon a/(3 per ml.
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Four experimental conditions were investigated; ID cells uninduced without
damage; ID cells induced without damage; ID cells uninduced with damage and
ID cells induced with damage.
To investigate the effects of p53 induction plus DNA damage upon tumour cell
cycle, the media from all populations of cells intended for damage was aspirated 6
• 2hours following induction and exposed to 10 J/m UV C irradiation. These cells
were then returned to media conditions identical to those prior to damage. The
time-points analysed were 0, 6, 12, 24, 36, 48 and 72 hours post-induction (where
6 hours post-induction is equivalent to 0 hours post-damage).
Flow cytometry and Vindalov-type analysis (see section MM4.3) was
subsequently performed to determine the proportion of cells in each compartment
of the cell cycle (i.e. G1/G0, S or G2/M) and thus to determine the extent of
transgene mediated effect upon tumour cell cycle.
To control for any possible phenotypic effects conferred by interferon a/(3 upon
tumour cell cycle, it was essential that transgene"ve SL1 cells be examined under
conditions identical to those as detailed for clone ID. Only in this manner is it
possible to dissect transgene-mediated effects from effects conferred by transgene
inducer upon tumour cell cycle.
Flow analysis of the parental, non-transfected SL1 cells demonstrated the
presence of multiple, large aneuploid populations of cells within the total cell
population. These cells were therefore unsuitable to act as the control population
in this experiment, as the presence of multiple aneuploid populations of cells
"confuses" the cell cycle analysis software package (XL, Coulter) which in turn
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Fig.2.8
Fig.2.8 depicts a typical cell cycle profile of tumour cell ID following Vindalov-type and flow
cytometric analysis (see section MM4.3). The proportion of cells in G1/G0 of the cell cycle
corresponds directly to the percentage of events scored at peak A. Similarly, the proportion of
cells in G2 of the cell cycle corresponds to the percentage of events scored at peak B. The
proportion of cells in S phase can be calculated by scoring the number of events arising between
both the G1/G0 (A) and G2 (B) peaks. The proportion of cells undergoing apoptosis can also be
ascertained from this histogram by scoring the number of sub-Gl events. In practical terms this
can be achieved by scoring the number of events arising within zone Z
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results in aberrant and inaccurate placing of cells into the various cell cycle
compartments. To facilitate meaningful analysis of the cell cycle by this flow
cytometry method therefore, it is essential that the analysed population of cells
possess a near uniform chromatin content.
Two p53-transgene"ve sub-clones, M25 and M48, were derived from the parental
SL1 line following lipofection of a puromycin resistance cassette and the selection
of puror0S (lpg/ml puromycin), stably transfected clones. These two lines were
shown to possess uniform chromatin content by flow cytometry and thus were
suitable to act as the p53-transgene"ve control cell populations in this experiment.
(2-iii.l) p53 Induction and the Cell Cycle
The effects of transgene induction upon tumour cell cycle, in the absence ofDNA
damage, are shown in figure 2.9 (N.B. — Only one control data set (M48) is
shown in comparison to the experimental inducible clone ID in Fig.2.9). The data
set generated from the other transgene"ve control line, M25, supports the trends
exhibited by clone M48 in all experimental conditions, therefore there was little
need to additionally reproduce this control data in the following figures [fig2.9,
and fig 2.10]).
At the beginning of the time course, uninduced ID cells appear to possess a large
proportion of cells in S-phase of the cell cycle, indicating very rapid cellular
proliferation. At later time-points however (post-48hours) the proportion of cells
in S-phase drops and begin to accumulate in Gl/GO-phase. This shift in the
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percentage of proliferating cells to non-proliferating cells is coincident with ID
cells reaching confluence on the tissue culture plate.
Similarly to the population of uninduced ID cells, induced ID cells initially
possess a high proportion of cells in S-phase of the cell cycle, indicative of rapid
cellular proliferation. Overall however, this data would suggest that induced ID
cells proliferate slower than uninduced ID cells.
Within the population of induced cells, the proportion of cells in S-phase only
reach levels greater than 40% 24 hours post-induction. Uninduced cells in
comparison possess this proportion of cells in S-phase by 12 hours. Further,
induced 1D cells only reach confluence and begin to drop out of S-phase into
G1/G0 at 72 hours post-induction, thus reaching confluence a full 24 hours later
than uninduced cells.
To determine whether this effect on the proliferation rate of ID cells is transgene
or inducer mediated, it is necessary to examine the cell cycle profile ofM48 cells
cultured in both the presence and absence of interferon a/(3.
Uninduced M48 cells initially possess a very high proportion of cells in S-phase,
however between 6 and 36 hours, the proportion of cells in S-phase progressively
stabilises to approximately 30% of all cells. By 48 hours, the proportion of cells
in S-phase begins to fall and to accumulate in G1/G0, coincident with M48 cells
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Fig2.9 - shows the percentage of ID and M48 cells in each compartment of the cell cycle when
cultured in either the absence or presence of interferon a/p (values are expressed as the mean ±
SD). The figures written on the Y-axis correspond to percentage of cells from total cell
population.
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Induced M48 cells however only possess greater than 30% of cells in S-phase by
24 hours, a level that is stable through to 48 hours. The 72 hour time-point is
missing from this data, but it is clear that by 48 hours uninduced M48 cells drop
out of S-phase into G1/G0, whilst induced M48 cells do not.
It must be concluded that this observed slowing in proliferation rate of SL1
tumour cells is interferon a/(3 mediated as both transgene positive and transgene
negative SL1 cells respond in essentially an identical manner.
Further, as induced experimental samples are exposed to inducer at all times of
this experiment, one must also conclude that the proliferation rate of SL1 cells is
only initially inhibited by interferon a/(3. This inhibition can only be temporary,
as induced SL1 cells are able to resume a proliferative rate approximate to that of
uninduced cells, as well as possessing the ability to reach confluence, within
approximately 24 hours of non-treated cells.
(2.iii.2) Effects of p53 Induction and DNA Damage upon Tumour Cell Cycle
The effects of transgene induction upon tumour cell cycle, in the presence of
DNA damage, are shown in figure 2.10
(N.B .- the time-scale depicted on the X-axes of the graphs displayed in fig.2.10
are not equivalent to the times depicted in fig.2.9. Zero hours, as depicted in
fig.2.10 is equivalent to zero hours genotoxic insult (exposure to 10 J/m2 UV-C
irradiation) or to 6 hours post-induction as depicted in fig.2.9.
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At the time of genotoxic insult, uninduced ID cells appear to predominantly
reside in G1/G0 of the cell cycle. Immediately following damage however, cells
exit G1/G0 and accumulate progressively into S-phase of the cell cycle reaching
peak levels (approx. 55% of all cells) by 24 hours.
The number of cells in G2/M remains relatively constant between 0 and 24 hours
suggesting that the accumulation of cells in S-phase is the result of an increase in
the rate of cellular proliferation and not the result of a block in the cell cycle
between S and G2/M phases. At later stages of the time-course (between 24 and
72 hours), the proportion of cells in G2/M rises, most likely as a consequence of
the high proportion of cells in S-phase at 24 hours progressing through the cell
cycle.
Induced cells also appear to reside predominantly in the G1/G0 portion of the cell
cycle at the time of genotoxic insult. The main difference between the cell cycle
profiles of induced and uninduced ID cells however, is that throughout the
duration of the time-course, cells treated with interferon a/(3 exhibit only a slight
increase in the rate of proliferation, reaching maximal levels (approx. 45% of all
cells) by 6 hours. No proliferative burst is observed at 24 hours and this rate of
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Fig2.10 - shows the percentage of ID and M48 cells in each compartment of the cell cycle when
cultured either in the presence or absence of interferon a/p and in the presence of UV-C induced
DNA damage (values are expressed as the mean ± SD). The figures written on the Y-axis
correspond to percentage of cells from total cell population.
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To determine whether this observed tumour cell phenotype is transgene or inducer
mediated, it is necessary to examine the cell cycle profile of DNA damaged M48
cells, cultured in both the presence and absence of interferon a/(3.
Uninduced M48 cells exhibit a similar cell cycle profile following DNA damage
to that observed for uninduced ID cells. At the time of genotoxic insult
uninduced M48 cells predominantly reside in the G1/G0 phase of the cell cycle.
Immediately following DNA damage however, these cells exit G1/G0 and
accumulate in S-phase, reaching peak levels (52% of all cells) by 24 hours.
Again, the number of cells in G2/M remains relatively constant throughout the
course of the experiment, suggesting that the accumulated cells in S-phase are the
result of an increase in proliferation rate and not of a block in the cell cycle
between S and G2/M.
M48 cells treated with interferon a/(3 also appear to exhibit a similar cell cycle
profile following DNA damage to that observed for induced ID cells. At the time
ofDNA damage, treated M48 cells reside predominantly in the G1/G0 portion of
the cell cycle. This cell cycle profile is essentially maintained throughout the
duration of the experiment, although there is a slight observed increase in the
proportion of cells in S-phase, exiting from G1/G0, reaching maximum levels
(32%) by 24 hours.
It must be concluded therefore that inhibition of SL1 cell proliferation following
DNA damage is interferon a/(3 mediated as both transgene positive and transgene
negative SL1 cells respond in essentially an identical manner.
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(2.iii.3) Conclusions from Section (2.iii)
Interferon oc/|3 temporarily inhibits the proliferation of SL1 tumour cells in the
absence of damage, and also inhibits the rapid increase of SL1 tumour cell
proliferation following DNA damage.
The introduction of p53 expression appears to have no effect upon SL1 tumour
cell cycle in either the presence or absence ofDNA damage. The existence of any
transgene mediated phenotypic effects must therefore be slight, as they are not
detectable by flow cytometric analysis.
(2.iv) The Effect of p53 Expression upon the Rate of Apoptosis In Vitro
The aim of this experiment was to investigate the rate of SL1 tumour cell
apoptosis following induction of p53 expression, in both the presence and absence
ofDNA damage.
On the evening prior to transgene induction, cells from clone 1D were plated in
5 2
triplicate for each time-point, at a density of 2 x 10 cells per 10cm . The
following morning, media was aspirated from the cells and replaced with media
containing either 0 or 1000 I.R.U of interferon a/p per ml.
Four experimental conditions were investigated; ID cells uninduced without
damage; ID cells induced without damage; ID cells uninduced with damage and
ID cells induced with damage.
To investigate the effects of p53 induction plus DNA damage upon the rate of
tumour cell apoptosis, the media from all populations of cells intended for damage
was aspirated 6 hours after induction and exposed to 10 J/m2 UV-C irradiation.
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These cells were then returned to media conditions identical to those prior to
damage. The time-points analysed were 0, 6, 12, 24, 36, 48 and 72 hours post-
induction (where 6 hours post-induction is equivalent to 0 hours post-damage).
At each time point, the medium from each sample was aspirated and reserved
prior to trypsinisation. Following trypsinisation of adherent cells, the reserved
medium was subsequently used to neutralise trypsin activity for every
corresponding sample. The rate of tumour cell apoptosis was determined as the
percentage of cells sub-Gl/GO, following Vindalov-type analysis and flow
cytometry (see section MM4.3). The data generated by this method was
confirmed to reflect apoptosis following staining of samples with Acridine Orange
and manual counting of apoptotic bodies by fluorescence microscopy.
(2.iv.l) Effects of p53 Induction upon the Rate of Tumour Cell Apoptosis
As shown in figure 2.11, the induction of p53 expression in the absence of DNA
damage had no measurable effect upon the rate of apoptosis of SL1 cells in
culture. The percentages of apoptosis shown in this diagram are equivalent to the
levels of apoptosis in untreated samples, therefore it is also possible to conclude
that the transgene inducer, interferon a/[3, exerts no measurable effect upon the
rate of apoptosis in vitro.
Following DNA damage of SL1 tumour cells, a transgene dependent apoptotic
phenotype is observed in cell line ID (see fig.2.12). All untreated SL1 cell lines





Fig.2.11 shows the percentage apoptosis of SL1 cell lines M25, M48 and ID following
administration of 1000 I.R.U. interferon «/p at time-point 0 hours, in the absence ofDNA damage.
(Values are expressed as the mean + SD).
By 24 hours, the levels of apoptosis have risen above the level of background
observed in non-DNA damaged cultures. The percentage of apoptosis in
experimental line ID is also marginally elevated above the levels of both control
lines M25 and M48, however the rate of increase between all cell lines is
comparable. The reason for this elevation in the apoptotic rate of ID cells could
be either the result of "leaky" transgene expression in the uninduced state, or
simply because of an intrinsic difference in the properties of cell lines derived
from the parental SL1 line.
By 48 and 72 hours, levels of apoptosis are maximal (approximately 4%), with no
significant difference recorded between the rates of experimental line ID and both
control lines.
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DNA damaged and interferon a/(3 treated SL1 cells again show little difference
from the level of background apoptosis observed in non-DNA damaged cultures at
early time-points. By 12 hours however, the percentage of apoptosis of induced
1D cells begins to increase above the level of apoptosis detected in both control
lines. By 24 hours the rate of apoptosis in induced ID cells has reached maximal
levels (approx. 8%), which is approximately 24 hours faster and at nearly double
the rate of uninduced ID cells. The level of apoptosis in the ID samples remains
high through 36 hours, from which time the level of apoptosis becomes no longer
significantly different from the control lines.
The apoptosis levels of both treated control lines are essentially identical to those
observed in the non-treated control lines following DNA damage. This result
further confirms that interferon a/(3 exerts no measurable effect upon the rate of
apoptosis of SL1 cells in vitro.
(2.iv.2) Conclusions from Section (2.iv)
Interferon a/(3 exhibits no measurable effect upon the rate of SL1 cell apoptosis in
either the absence or presence of DNA damage. The introduction of p53
expression also appears to have no effect upon the rate of SL1 cell apoptosis in the
absence ofDNA damage.
In the presence ofDNA damage however, populations of induced 1D cells reach
maximal levels of apoptosis by 24 hours. This time-point is 24 hours faster than
non-induced and damaged ID cells. Further, the maximal level of apoptosis
reached by induced and damaged 1D cells is approximately double that reached
by non-induced and damaged ID cells. These results clearly demonstrate the
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existence of both p53 dependent and independent waves of apoptosis elicited by
the cell following DNA damage.
Fig.2.12
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Fig.2.11 shows the percentage apoptosis of SL1 cell lines M25, M48 and ID following
administration of 1000 I.R.U. interferon a/p at timepoint 0 hours, in the absence ofDNA damage.
(Values are expressed as the mean + SD).
(2.v) The Long Term Consequences of Transgene Dependent Effects In Vitro
The aim of this experiment was to determine the long-term consequences of
transgene mediated apoptosis upon tumour cell viability by means of a clonogenic
survival assay.
The immediate consequences of transgene dependent apoptosis are illustrated in
Figure 2.13. These photographs of ID cells were taken at a time-point equivalent
to 36 hours after DNA damage and clearly demonstrate that the short-term
viability of ID tumour cells, when cultured in both the presence of interferon a/(3
and DNA damage, are severely compromised (Magnification 500X).
To determine the long-term consequences of transgene dependent apoptosis, both
M25 and 1D cells were plated out at a density of 5 x 106 cells per 1 Ocm petri dish
on the evening prior to transgene induction. The following morning, all cells were
re-fed in media containing either 0 or 1000 I.R.U. interferon a/(3. At 6 hours post-
induction, the media from all cells were again aspirated and were either exposed
to 10 J/m2 UV C irradiation and re-fed in media containing 0 I.R.U. interferon
a/p, or were re-fed immediately in 0 I.R.U. interferon oc/p media in the absence of
DNA damage. Two hours after DNA damage, all cells were trypsinised and
plated out in triplicate at serially diluted concentrations ranging from 1 x 106 cells
to 1 x 102 cells per 10cm petri dish. Long-term surviving clones were counted




Fig. 2.13 shows the consequences of transgene induction, in both the presence and absence of UV
mediated DNA damage, on ID cells growing in vitro. Cells were photographed 36 hours after
induction. U = uninduced; I = induced (1000 I.R.U. interferon a/(3 ml"1); UV-C indicates
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Table 2.2 on the previous page shows the number of surviving M25 (transgene"ve)
and ID clones following treatment with both 0 and 1000 l.R.U. interferon a/p, in
both the presence and absence of DNA damage and serial dilution. Plates grown
to confluence or with very large numbers of clones are denoted as a dash sign (-).
The results of this assay demonstrate that there is no gross difference in the long-
term clonogenic survival of transgene positive or negative cells following
treatment with interferon a/p in either the presence or absence ofDNA damage.
(2.vi) Further Research
The observation that growth arrest of tumour cell cycle did not accompany the
induction of p53 gene expression in the presence of DNA damage was not
predicted as this is a well characterised p53-dependent phenotypic response in
many cell types, including a wide variety of tumour cell lines transfected with
wild-type p53 transgenic DNA.
As discussed in section l.ii.5, functional p53 can induce growth arrest or
apoptosis in response to DNA damage, but the means through which these
biological end-points are achieved are almost certainly different. Indeed, much
experimental evidence has been recorded to demonstrate that lesions affecting
either the central core domain or the N- terminal domain of p53 can prevent the
initiation of p53-dependent growth arrest in response to cellular challenge. In
addition to mutation of the p53 transgene, the genetic background of SL tumour
cells could also result in this observed deficiency of cell cycle arrest. As p53
requires the specific downstream activation of gene expression to induce growth
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arrest, it is possible that the inability of SL cells to initiate a p53-dependent arrest
could be the result of lesions affecting the wild-type expression of these genes.
The p53 cDNA cassette used in the experiments detailed within chapter 2 had
previously been sequenced and determined to encode wild-type p53 protein prior
to the construction of p6-16lp53-HYG (Malcomson, 1996). Therefore, it is most
likely that any mutational event arising within the p53 coding region of this
construct would have had to have occurred during the in vitro clonal expansion of
stably transfected and non-induced ID cells (see section 6.ii for discussion). To
examine whether the p53 protein encoded by p6-16Lp53-HYG was wild type, both
a functional reporter assay and Western analyses were attempted.
(2.iv.l) RGC-LacZ Reporter Assay
A functional reporter assay (RGC-LacZ reporter assay (Frebourg et al, 1992),
(Bargonetti et al, 1992)) was attempted to determine whether the induced p53
protein encoded from p6-16Lp53-HYG possessed the ability to transactivate the
expression of downstream genes.
Induced ID cells staining positive for LacZ following the transient transfection of
the RGC-LacZ reporter construct would indicate that the p53 protein encoded by
p6-16Lp53-HYG was indeed capable of transactivating the expression of
downstream genes. Suitable transient transfection conditions for SL1 cells could
not be optimised within the time left available to me however, so unfortunately no
conclusions could be drawn from this experiment.
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(2.vi.2) Western Analysis of p6-16tp53-HYG Translation Product
Induced p53 mRNA encoded from p6-16lp53-HYG was shown not to splice
appropriately at its 3' UTR region (see section 2.ii.2). Theoretically, the failure of
the p53 transgene to splice should not alter the final translated transgene product,
however if the unspliced sequence were translated, the presence of an additional
C- terminal peptide 'tag' could hypothetically compromise the ability of
transgenic p53 protein to tetramerise. A likely consequence of this would be less
efficient sequence-specific DNA binding and correspondingly, lessened p53-
dependent influence on the expression of downstream genes. Western analysis of
induced p53 protein from p6-16Lp53-HYG in ID cells permits the comparison of
transgene translation product size relative to that of wild-type p53 protein.
To optimise the detection of p53 protein on a western blot, total protein was
extracted from UV-C irradiated wild-type ES cells and p53 protein was detected
using the anti-p53 sheep polyclonal antibody BMG-1 (see section MM3.1).
BMG-1 can recognise multiple epitopes of both wild-type and mutant p53, at both
N- and C- terminal domains (Boehringer Mannheim). The results of this
optimisation experiment are shown in figure 2.14.
Fig 2.14
Fig 2.14 shows the result of a western blot containing total protein extract derived from UV-C
irradiated (10 J/m2) WT ES cells and the sheep poly-clonal antibody BMG-1. Reading from left to
right, lane one contains protein markers (both the 44Kd and 67Kd bands are visible). Lanes 2 to 5
were loaded with 5gg, lOpg, 15gg and 20gg of total ES cell protein extract respectively and shows
detected p53 protein using BMG-lat a concentration of lgg/ml. Lanes 6 to 9 were loaded with
5gg, 10pg, 15gg and 20|ig of total ES cell protein extract respectively and shows detected p53
protein using BMG-1 at a concentration of2gg/ml.
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The result of this experiment would suggest that it is possible to specifically
detect stabilised p53 protein on a western blot using only small amounts of total
cell extract and low concentrations of the anti-p53 sheep polyclonal antibody
BMG-1.
For the main experiment, cells from clone ID were plated at a density of 2 x 105
cells per 10cm2 on the evening prior to transgene induction. The following
morning, media was aspirated from the cells and replaced with media containing
either 0 or 1000 I.R.U of interferon a/(3 per ml. To stabilise p53 protein, all
9 ...
induced samples were exposed to 10 J/m of UV-C irradiation 6 hours after
induction. Cells were lysed at 0, 6, 12, 24, 36, 48 and 72 hours following DNA
damage and protein samples were stored at -20°C prior to western analysis (see
section MM3.1).
Fig 2.15 shows the western analysis results of induced and irradiated ID cell
extracts run beside the WT ES cell extract, used in the previous experiment to
optimise p53 detection conditions.
Fig. 2.15
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Fig 2.15 shows the result of a western blot containing total protein extract derived from both
uninduced and induced + DNA damaged ID cell extracts run beside the WT ES cell extract used
previously in figure 2.14. P53 protein was detected using the sheep polyclonal antibody BMG-1,
at a concentration of lpg/ml. Reading from left to right, lane 1 contains 20)ug of total cell extract
derived from uninduced ID cells. Lanes 2 to 7 contain 20pg of total cell extract derived from
induced and DNA damaged ID cells lysed at 6, 12, 24, 36, 48, 72 hours respectively, following
damage. Lane 8 contains 10pg of DNA damaged WT ES cell lysate, as used previously to derive
figure 2.14.
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The result of this western analysis shows little specific recognition p53 protein in
ID cell lysate samples until approximately 36 hours after DNA damage, at which
time the signal intensity increases, reaching maximum intensity at 72 hours.
There is however an apparent discrepancy in the sizes of p53 protein recognised in
ID cell lysate samples compared to that recognised in wild-type ES cell lysate.
Recognised p53 protein in the former sample set appears to be at least several Kd
larger than the specific product recognised in the latter.
It is currently not possible to conclude, in the absence of further experimental
data, whether the protein detected in induced ID cell lysates corresponds to p6-
16lp53-HYG translation product or to non-specific background.
Although the protein recognised by BMG-1 appears to be specific in ID cell
lysate samples, previous analysis of within this chapter would suggest that
maximal levels of p53 transgene expression are achieved rapidly and become
diminished by 72 hours.
If however this recognised protein was shown to correspond to the translation
product of p6-16lp53-HYG, then although this protein must possess p53
epitope(s) to be recognised by BMG-1, it is not the same size as wild-type p53
protein. These results would then implicate the existence of peptide 'tag' at either
the N- or C- terminal domains of the transgenic p53 protein, thus perhaps
explaining the inability of this protein to induce cell cycle arrest in response to
DNA damage.
In the absence of time constraints, it would be ideal to repeat this blot and use cell
lysate derived from the transgene"vc cell line M25 as a negative control. Absence
of BMG-1 recognition within this sample and reproducible detection of protein
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product within ID cell lysates (as shown in figure 2.14) would strongly suggest




The aim of this chapter was to use the sarcoma derived p53 inducible cell line ID,
as a means of evaluating possible therapeutic benefit arising from the introduction
of p53 gene expression in otherwise p53 deficient tumour cells in vivo.
(3.i) The In Vivo Experimental System
Retention of SL1 cell tumorigenic potential, following their establishment as a
cell line in vitro, was determined by injecting an aliquot of untransfected SL1
cells sub-cutaneously into the flanks of SCID (Severe Combined Immuno-
Deficient) mice and observing the time required before tumours arose at the site of
injection. Host immuno-deficient animals were essential in this experiment as
SL1 cells originate from an outbred genetic background and so would likely be
rejected if injected sub-cutaneously into an inbred immune competent animal.
6 SCID mice were initially injected with 1 x 107 untransfected SL1 cells into each
flank and tumours became visible at all sites of injection approximately 2 weeks
after injection (see section MM5.1). Within the following 2 weeks, all mice had
to be sacrificed as a result of rapid tumour growth.
This same experiment was subsequently repeated using ID cells, following their
preliminary characterisation. These cells were derived as a tumour sub-clone
from SL1 cells and were shown to induce the expression of a p53 transgene when
cultured in the presence of interferon a/(3 (see chapter 2). Sub-cutaneous injection
of 1 x 107 ID cells into the flanks of SCID mice also resulted in the appearance of
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rapidly growing tumours at the site of injection within approximately 2 weeks.
The demonstration that injected ID cells give rise to tumours as rapidly as
untransfected SL1 cells in the absence of interferon a/p, would suggest that in the
absence of transgene expression, ID cells possess an essentially equivalent
tumourigenic potential as p53 deficient SL1 cells.
It is possible to stimulate endogenous levels of interferon a/p in the mouse by
injecting micro-gram amounts of a synthetic double stranded RNA, polycytidylie:
polyinosinic acid (pI:pC), into the peritoneal cavity (see sections l.i.8b and
MM5.2). Indeed, a previously published report has detailed the induction of ere
protein in vivo, encoded by a transgene regulated by the murine and interferon a/p
responsive Mxl promoter, via exactly such an approach (Kuhn et al, 1995).
As p53 transgene expression can be induced in vitro by culturing ID cells in the
presence of interferon a/p, it was reasoned that it may be possible to stimulate the
expression of p53 within ID cells growing in vivo by following a similar pI:pC
dose regime as detailed by Kuhn et al. In this way, it may be possible to better
evaluate the potential therapeutic benefits conferred by the introduction of p53
gene expression in the treatment of p53 deficient tumours in vivo.
Perhaps the most serious potential drawback concerning the application of an
interferon a/p inducible expression system in vivo, is that sufficient amounts of
endogenous interferon a/p can be produced to induce the gene expression of loci
containing ISRJE promoter elements following viral or microbial infection (see
chapter 1, section l.i.8b). It is therefore highly likely that mice held in standard,
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non-barrier mouse house conditions will be exposed a number of pathogens
sufficient to induce transgene expression at inappropriate and undesirable times.
The necessitive use of SCID animals in the prevention of SL cell rejection for
these experiments however, may possibly be advantageous with respect to
reducing the constitutive background levels of systemic interferon a/p. SCID
animals must be maintained in barrier conditions to minimise both microbial and
viral infection and thus to retain viability. Barrier conditions should therefore
provide an environment for the mouse in which the normal physiological inducers
of interferon cx/(3 are absent and so consequently should minimise the likelihood
of uncontrolled transgene induction.
The relevance of background systemic levels of interferon a/p with respect to
induction of transgene expression does appear to be questionable however. The
results published by Kuhn et al showed that non-induced levels of cre-mediated
recombination between loxP sites was very low (~1%) in essentially all organs
except the spleen of non-barrier maintained mice possessing an Mxl-cre
transgene. These mice were immune-competent and so it was not essential to
keep these animals under barrier conditions to retain viability.
Upon administration of three 250jlg doses of pI:pC over a six-day period, the
percentage of cre-mediated recombination in certain tissues rose to nearly 100%,
perhaps suggesting that supra-physiological levels of endogenous interferon a/p
are required in the host animal before the expression ofMxl -regulated transgenes
are induced efficiently.
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(3.ii) Optimisation of In Vivo Transgene Induction
The initial experiments of this chapter were intended to define a pI:pC treatment
regime that would efficiently induce p53 transgene expression within ID cells
growing in vivo.
Accordingly, a cohort of 12 SCID mice were injected sub-cutaneously in both
flanks with an aliquot of ID cells as prepared previously. Due to the observed
efficiency and rapidity of tumour appearance following the injection of ID cells in
section 3.i, only half the previous amount of ID cells (i.e. 5 x 106 ID cells per
flank) were injected into these animals. Tumours arose at all sites of injection
approximately 3-4 weeks after injection and so thus enabled a reduction in the
already considerable consumption of cell culture resources required to set up
experiments with these numbers of animals.
In keeping with the protocol described by Kuhn et al, it was intended that once
tumours became visible, 4 animals would be injected intra-peritoneally (IP) with
one 250|lg dose of pkpC, 4 animals would be injected IP with two separate 250[ig
doses of pI:pC two days apart, and 4 animals would be injected with three
separate 250p.g doses of pI:pC each two days apart. Tumours would then be
collected the day following the last administered dose of pI:pC and analysed by
light-microscopy for any gross phenotypic effects and for p53 transgene
expression by immuno-histochemical analysis on micro-sections and by western
analysis.
All SCID animals were closely monitored following the first IP administered dose
of pI:pC for any signs of adverse effect. Although no animals appeared to become
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significantly distressed by pI:pC treatment, it was noted that all animals showed
altered coat condition within approximately 6 to 12 hours of injection.
The majority of injected SCID mice appeared to have fully recovered their coat
condition within 24 hours of injection however surprisingly several animals were
found dead in their cages.
This pattern of rapid sickness and recovery or death of the SCID animals
following IP injection of 250|lg pI:pC continued at all subsequent stages of this
experiment. Indeed, over the course of all attempts at inducing p53 transgene
expression in vivo, this SCID response to pI:pC accounted for the deaths of
approximately 20% of all injected animals. The nature of this phenomenon is
discussed in greater detail in chapter 4.
Subsequent histological examination of all tumours recovered from surviving
SCID animals treated with pI:pC, from all of the induction regimes detailed
above, did not reveal any gross phenotypic effect of transgene or inducer upon
either the number of mitotic figures or on the rate of apoptosis relative to non-
treated ID tumours (see fig.3.1). It should be noted that it is very difficult to
detect subtle histological changes of this kind within tumour samples, as the rate
of both mitosis and apoptosis are already very high.
Further however, immuno-histochemical analysis of pfipC treated tumour samples
did not detect any p53 transgene expression (see fig.3.2). Western analysis of p53
expression within these tumour samples was also attempted, but no p53 protein
could be detected using the partially optimised assay conditions described in
section 2.vi.2 of chapter 2 and so these results are not presented.
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Fig.3.1 on the next page shows two H+E stained and fixed sections of tumours
resulting from the sub-cutaneous injection of ID cells. Photo A shows the
histology of a non-pI:pC treated tumour, whilst the photo B shows the histology
of a pI:pC treated tumour. No grossly apparent difference in the number of
mitotic or apoptotic bodies exists between tumour sections (magnification 500X).
Fig.3.2 on the page following next shows the results of immuno-staining fixed
and paraffin embedded tissue sections with anti p53 CM5 antibody as detailed in
section MM3.3. Photo A shows positive staining for p53 in the nuclei of wild-
type epithelia cells derived from the intestinal crypt following exposure to 5 Grays
whole body y-irradiation. Photo B shows that ID tumour cells grown in vivo do






The fact that no obvious transgene mediated effects were detected upon the rate of
tumour cell proliferation and cell death following the stimulation of endogenous
interferon a/(3 was not entirely surprising. The in vitro data presented in chapter 2
also showed no observable transgene mediated effects upon either of these two
biological processes following transgene induction in the absence of DNA
damage.
The fact that IP injection of pI:pC, the most potent inducer of endogenous murine
interferon a/(3, did not result in the induction of transgene expression in vivo was
not predicted however. In the study published by Kuhn et al, a single IP injection
of 250(lg plrpC was sufficient to induce cre-mediated recombination between
loxP sites within 97% of liver cells. The observed failure of this regime to induce
6-16 regulated transgene expression must either be the result of inefficient
induction of transgenic p53 protein, which rapidly becomes degraded in vivo in
the absence of relevant cellular challenge, or the result of a transcriptional
'silencing' of p53 transgene expression within ID cells growing in vivo. To test
both of these hypotheses, a further cohort of SCID animals were injected sub-
cutaneously with ID cells to generate additional tumours.
In an attempt to enhance the immuno-histochemical detection of possibly weak in
vivo p53 transgene induction, it was reasoned that damaging the DNA of ID cells
growing in vivo, in addition to the pI:pC dose regime detailed above, may stabilise
any low levels of induced transgene expression sufficiently to facilitate detection.
Further, as a transgene-dependent apoptotic phenotype was detected in ID cells
growing in vitro (see chapter 2, section 2.iv), it was reasoned that the addition of
141
DNA damage to pI:pC treatment of ID tumours may result in a transgene-
dependent histological phenotype discernible from non-treated and treated but
non-DNA damaged ID tumours.
Accordingly, 12 SCID mice were injected sub-cutaneously with 5 x 106 ID cells
into each flank and upon the appearance of tumours, in addition to the previously
applied pI:pC dose regime, these animals were also exposed to 5 Grays whole
body y-irradiation on the day following the last administered dose of pI:pC. All
tumours were removed for analysis 48 hours after y-irradiation.
Fig. 3.3 on the next page shows two micro-sections of a ID-cell tumour at 500X
magnification following treatment with pI:pC and 5 Grays whole body y-
irradiation. Photo A shows an H+E stained tissue section and demonstrates that
no gross difference in the numbers of mitotic or apoptotic figures was observed
within tumours treated with both pI:pC and y-irradiation relative to non-pI:pC
treated or pfipC treated and non-DNA damaged tumours (see figure 3.1).
Photo B shows a tissue section derived from the same tumour following immuno-
histochemistry with anti p53 CM5. Whilst the vast proportion of this tumour did
not appear to express p53 protein, small pockets of ID cells grown in vivo




These results would suggest that ID cells modulate or lose their capacity to induce
p53 transgene expression when grown in vivo. To further investigate the
underlying causes of such a scenario, ID-cell tumours were removed from two
animals and re-established in culture as cell lines ID.EX.1 and ID.EX.2 (as
detailed within section MM4.2).
These cell lines were initially demonstrated to have retained resistance to
hygromycin in culture. This would suggest that the lack of observed in vivo
transgene induction was not directly the result of p53 transgene loss through either
gross chromosomal deletion or loss, as both hygromycin resistance cassette and 6-
16 regulated p53 transgene sequences are tightly linked.
To enable a comparison of the ability of ID.EX clonal lines to induce transgene
expression relative to the non-injected and in vitro characterised ID cells (see
chapter 2), both explanted cell lines were further expanded in culture.
Cells from ID.EX.1 and EX.2 were plated on chamber-slides at a density of 3 x
104 cells per well on the evening prior to transgene induction (see section
MM3.2). Each chamber-slide contains two chamber wells, therefore on the
morning following plating, medium was aspirated from both wells of every slide
and replaced with medium containing either 0 or 1000 I.R.U of interferon a/(3 per
ml. To enhance the detection of p53 transgene expression, all media was
aspirated and all cells were exposed to 10 J/m2 UV-C irradiation 6 hours after
induction. Following irradiation, all cells were returned to media conditions
identical to those prior to genotoxic insult. ID cells were also plated and treated
as described to act as a positive control for transgene induction in this experiment.
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Medium was aspirated at each time-point from all appropriate cells, which were
then washed once in PBS prior to fixation and storage at -70°C. The time-points
analysed were 0, 6, 12, 24, 48 and 72 hours after genotoxic insult.
Immunochemistry was performed on these samples using the monoclonal
antibody Pab421 and the results of this experiment are shown at 6 hours after
DNA damage on the following page as Fig.3.4 (see section MM.3.2 for protocol).
Photographs A and B of figure 3.4 show that in the absence of interferon oc/|3,
virtually no p53 expression can be detected in the nuclei of non-injected ID cells
(A), whilst p53 expression can be readily observed within the nuclei of the same
cells following treatment with interferon a/fi (B). Photographs C and D also show
an equivalent level of p53 induction (D) following the treatment of ID.EX.2 cells
with interferon a/(3, whilst photographs E and F demonstrate that ID.EX.1 cells
have lost the ability to induce p53 transgene expression (F).










The results of this immuno-assay would appear to suggest that ID cells grown in
vivo can rapidly evolve and lose their ability to induce p53 transgene expression in
response to interferon a/(3. It is not possible to determine the overall frequency of
presenting ID-cell tumours that lose transgene inducibility from the data
presented as only two tumours were re-established as cell lines and analysed in
vitro. However, upon the basis of the immuno-histochemistry performed upon
pI:pC treated and DNA-damaged tumours, it could be predicted that loss of
transgene expression would be frequently observed.
Non-induced levels of transgene expression in vivo must therefore confer
considerable selective growth advantage, as ID cells can lose inducible transgene
expression within three to four weeks of injection.
This observation could be considered surprising as non-induced amounts of
expressed p53 transgene appear to be very low in ID cells grown in vitro as
determined by rtPCR and immuno-analysis (see chapter 2). Further, no transgene-
mediated effects were observed upon either the rates of tumour cell proliferation
or apoptosis following the induction of transgene expression in the absence of
additional DNA damage.
As mentioned in section 3.i, the presence of endogenous amounts of interferon
a/p within host SCID animals may account for higher levels of non-induced
transgene expression in vivo than that previously characterised in vitro. Even
upon that basis, the data contained within chapter 2 would suggest that ID cells
exhibiting background "leaky" expression of transgene expression should possess
no short-term differences in their ability to proliferate, or in their disposition to
commit to apoptosis, relative to non-transgene expressing ID cells.
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As detailed within chapter 1 however, the expression of wild-type p53 can be
stabilised and activated by many more stimuli other than DNA damage. It is
therefore highly likely that the selective pressures exerted on ID cells growing in
vivo are different from the pressures on cells growing in vitro. Thus, the data
presented within this chapter would suggest that the amounts of non-induced p53
transgene are sufficient to confer a selective disadvantage to ID cells growing in
vivo.
The implications of these in vivo observations with regard to p53 replacement
gene therapy are discussed in greater depth in chapter 6.
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CHAPTER 4
As discussed in chapter 3, attempts to stimulate the production of interferon a/(3 in
SCID animals possessing tumours comprised of ID cells were made by injecting
250pg of synthetic double stranded RNA (pI:pC) intra-peritoneally (IP).
Within 6 to 12 hours after IP injection of pI:pC however, all SCID mice appeared
to show altered coat condition. The majority of injected SCID mice made a full
recovery 24 hours after injection, however approximately 20% of all SCID
animals injected with pI:pC died within an equivalent timeframe. This
phenomenon has not been previously reported and so the aim of this chapter was
to investigate the underlying biology responsible.
(4.i) SCID Phenotype following Injection of pI:pC
The main reasons for using pI:pC to induce transgene expression in vivo were that
this reagent is much more affordable than purified preparations of interferon a/(3
and a previously published report detailed a complete protocol for the use of this
reagent in achieving the induction of transgene expression, regulated by an
interferon a/(3 responsive promoter, in vivo (Kuhn et al, 1995).
The results ofKuhn et al did not report any phenotypic side-effects resulting from
the administration of250pg pI:pC IP and so this was the dose we initially chose to
inject into SCID mice whilst attempting to induce the expression of p53 from p6-
16lp53-HYG within ID cells growing in vivo. The observed response of SCID
mice to this administered dose of pI:pC, as detailed within the opening paragraphs
149
of this chapter and within section 3.ii of chapter 3, was therefore highly
surprising.
Initially it was suspected that the concentration of supplied pI:pC was higher than
that stated by the manufacturer, therefore we injected a total of 8 further SCID
mice with a range of lower doses of pI:pC to observe whether these animals were
equally affected as those injected with 250pg IP. Two animals each were injected
with 50|O,g, lOOjig, 150|ig and 200jag amounts of pI:pC IP.
All animals rapidly lost coat condition following the injection of pI:pC as
described previously and again none of the animals appeared to be suffering
unduly. The following day however, one of the animals injected with 50|J.g, one
of the animals injected with 150|ig and both of the animals injected with 200|ag of
pI:pC were found dead in their cages. The surviving animals appeared to have
regained coat condition and appeared normal, thus the observed SCID response to
pI:pC administered IP does not appear to be dependent upon the amounts of pI:pC
injected within this range.
The next concern was that the SCID response to pI:pC was the result of impurities
present within the manufacturers preparation of this reagent as no potentially toxic
chemicals are added to prepare pI:pC prior to injection. Poly(I):poly(C) reagent is
supplied as a sterile, lyophilised potassium salt, which is resuspended in PBS,
heated to 50°C to aid solubilization and gradually cooled to room temperature to
ensure efficient annealing of complementary RNA strands, as specified by the
manufacturer, prior to use.
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To test the hypothesis of pI:pC batch contamination, small quantities of pI:pC
were ordered from other leading manufacturers, prepared as specified and then
injected IP as a single 250jag dose as previously described into duplicate SCID
animals. The pI:pC supplied by ICN, SIGMA and Pharmacia (as used in the
original IP injections) all resulted in the observed SCID response.
The transgenic mice used by Kuhn et al, that showed no apparent pI:pC-mediated
effects following IP injection, were all on a C57BL/6 x CBA genetic background.
To test the hypothesis that the observed SCID response was mouse-strain specific,
3 SCID and 3 Balb/C mice were injected with 250jag IP. All animals were
sacrificed 12 hours after injection and kidneys, liver, heart, lungs and pancreas
were removed from all animals and fixed in formalin. The small intestine was
removed and fixed (as detailed in section MM5.3) from one SCID and one Balb/C
animal only.
Subsequent microscopic analysis of these organs did not reveal any abnormal
histology apart from the SCID small intestine, which exhibited an increased
number of apoptotic bodies within the crypt compartments of the intestinal
epithelium (see figure 4.1).
This experiment was repeated with additional animals to determine the time-
points after IP injection of pI:pC that SCID mice exhibit elevated levels of
apoptosis within this compartment of the small intestine relative to Balb/C mice.
3 SCID mice and 3 Balb/C mice were sacrificed at each of the 3, 6, 12, 24, 48 and
72 hour time-points following the IP injection of pI:pC. At every timepoint, the
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small intestine was removed from each animal and prepared for histological
analysis as detailed in section MM5.3. The results of this experiment are detailed
in figure 4.2, which shows an immediate and SCID-specific apoptotic response in
the crypt compartments of the intestinal epithelium. Further however, both
animals appear to show elevated levels of apoptosis within this region of the
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Fig.4.1 shows fixed and H + E stained small intestine samples derived from both Balb/C and SCID
mice (from left to right respectively) 12 hours after IP injection of 250pg pI:pC. Note the
increased numbers of apoptotic bodies present within the crypt compartments of the small intestine
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Fig.4.2 shows the number of apoptotic bodies present per 50 intestinal crypts of pI:pC treated
SCID and Balb/C mice. The intestines from three animals were analysed per data point and the
data is expressed as the average ± SD.
(4.ii) Interferon a/p and Morphology of the SCID Intestine
The observed SCID response to pI:pC has not been previously described although
a paper published by Garside et alexamined the effects of interferon a/p upon the
induction of intestinal pathology in CBA x Balb/C mice (Garside 1991).
The results of this study suggested that either the administration of lOOpg of
pI:pC or purified interferon a/p resulted in significant villus atrophy and crypt
hypertrophy by 24 and up to 72 hours after their respective administrations.
Further, these effects were abolished following NK cell depletion with anti-asialo
GM1 antibody prior to the induction or administration of interferon a/p.
The data presented by Garside et al did not examine levels of apoptosis within the
intestine and our data would suggest that the increased degree of intestinal
disruption observed in SCID animals relative to Balb/C animals following
1S1
induction of interferon a/(3 is predominantly the result of a rapidly induced wave
of apoptosis affecting intestinal crypt epithelial cells. Indeed, it could be
hypothesised that the villus atrophy and crypt hypertrophy recorded by Garside et
al at later timepoints could result from increased levels of crypt cell apoptosis at
earlier timepoints, immediately following administration of interferon a/(3.
Interferon a/|3 has previously been described as being a potent stimulator ofNK
cell activity (Perussia, 1991) and in addition to heightened cytotoxic activity,
activated NK cells produce large amounts of the inflammatory cytokine TNFa
(tumour necrosis factor a; Degliantoni et al, 1985). Elevated levels of TNFa
have been implicated as being partly responsible for mediating an enteropathic
side effect that occurs during the course of graft versus host disorder (GVHD;
Garside and Mowat, 1993). The expression of many cytokines are implicated in
mediating the side effects of GVHD however, which is a complex, common and
serious side effect of allogenic bone transplantation (Ferrara et al, 1997). Our
data would suggest however that mice deficient in both T and B cells are more
susceptible to the enteropathic side effects conferred by elevated levels of
interferon a/(3 relative to immune competent strains ofmice.
A speculative hypothesis that would explain this data could be that cytokines
produced by either T or B cells can partially inhibit NK cell activation or modify
stimulated NK cell activity. Indeed, the secretion of IL-10 from CD4+ T cells has
been shown to strongly inhibit the ability of IL-2 activated NK cells to secrete
interferon y (Hsu et al, 1992). SCID mice are essentially deficient in both T and B
cells and therefore would perhaps be more susceptible to the effects elicited by
NK cell activity relative to immune competent mice.
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Preliminary experiments have accordingly been attempted to deplete NK cells
within SCID animals prior to pI:pC treatment to investigate whether the
heightened levels of pI:pC-mediated apoptosis observed within the intestine of
SCID mice is NK cell dependent. Initial observations would suggest this is
indeed the case, however more extensive experimentation is required before these
observations can be considered definitive.
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CHAPTER 5
The aim of this chapter was to render the expression of p53 inducible in the
mouse by replacing the host p53 promoter sequence of murine ES cells with that
of an inducible promoter sequence via double replacement targeting.
(5.i) Targeting Approach
Double replacement targeting involves the sequential use of two independent
targeting vectors. Despite the increased length of time and effort involved in the
selection of two homologous recombination events, the application of gene
targeting technology in rendering the expression of a gene inducible confers a
number of advantages and refinements over the inducible transgenic approach
detailed in chapters two and three.
As described in section l.i.7c (chapter 1), the first targeting vector is used to
delete and replace host cell promoter sequence with a positive/negative selection
marker {e.g. for the introduction an HPRT selectable marker cassette into
otherwise HPRT deficient ES cells; see fig 5.a). Multiple second round vectors
can subsequently be generated, utilising the same regions of homologous
sequence as the first vector, to retarget this original locus and replace marker
sequence with any desired DNA sequence.
This is of strong advantage regarding the aim of this chapter, as within recent
years rapid and significant improvements have been made within the field of
inducible promoter technology. This strategy therefore provides a high degree of
flexibility and enables the generation of multiple, targeted ES cell lines with
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inducible gene expression influenced by a variety of different promoter
sequences. This could be viewed as useful in the comparison of inducible
promoter systems, as well as providing an opportunity to keep pace with all
technological inducible promoter advances.
A further advantage arising from this application of gene targeting is that the
expression of a gene can be rendered inducible whilst leaving downstream gene
organisation and structure virtually unaltered. All exon/intron boundaries can be
left intact, which should result in the normal post-transcriptional processing of
induced mRNA and the optimal translation of gene product. Further, as the
genetically modified locus is known and highly specific, the expression of all
other loci in the cell will remain unaffected following HR and the stable
integration of foreign DNA.
The level of inducible gene expression between targeted clones should also be
highly consistent. Inducible cells will no longer be prone to the transgene
associated problems of position effect or with variance of construct copy number.
For those reasons, this type of approach would be useful in the comparison of
transcriptional activity resulting from different constitutive or inducible promoter
systems.
The region spanning from approximately 250 base pairs upstream of the
published transcriptional initiation site of p53, plus the entire length of non-
coding exon 1 contain all the transcriptional regulatory sequence elements
previously demonstrated to influence p53 expression (see chapter 1, section
157
l.ii.4a). This region will be referred to as the promoter region of p53 for the
remainder of this chapter.
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(5.ii) Targeting Vector Construction
(S.ii.l) Vector Homology Requirements
The construction of a targeting vector that will knock-out and replace the
promoter region of p53 without altering p53 coding sequence requires the
derivation of homologous sequence, flanking both immediately upstream and




Schematic diagram illustrating gene organisation at the 5' region of p53 locus in mouse. Orange
sequence corresponds to candidate sequence that could be cloned as regions of homology in final
targeting constructs.
The p53 locus in mouse has been previously characterised with respect to gene
organisation and all exons and introns have been fully sequenced. Briefly, the
first exon of p53 is wholly composed of non-coding sequence and is separated
from the coding sequence of exon 2 by a 6.2kb intron.
The presence of such a large region of non-coding DNA immediately
downstream of the region to be replaced is a useful feature of p53 gene
Fig.5b







organisation and provides obvious candidate sequence to comprise the
downstream "arm" of homology in the final targeting vector. Once cloned as
such, all homologous recombination between host and vector sequence will occur
within non-coding DNA thus reducing the risk of mutation to, or rearrangement
of, p53 coding sequence during the process of HR. As the full sequence of intron
1 is known, it was possible to devise a conventional long PCR strategy to
facilitate the rapid cloning of this region (see section 5.ii.3).
The region of DNA located immediately upstream of p53's first exon was
previously uncharacterised with the exception of a small region of approximately
250bp which had been cloned, sequenced and analysed for its ability to influence
the expression of reporter gene constructs. In order to clone a portion of DNA
rapidly from this region, an inverse PCR strategy was employed (see section
5.ii.2). N.B. The restriction maps relating to all plasmids constructed within this
chapter are included within the appendix.
(5.ii.2) Derivation of the Upstream Arm of Homology
It is not possible to amplify and clone novel sequence via conventional PCR
approaches because prior sequence knowledge of the DNA template is essential
to design both upstream and downstream primers. However, if one sequence
specific primer can be designed, inverse PCR strategies have been developed that
enable the amplification of novel DNA sequences.
The vectorette tag system is such a PCR based approach, which employs the use
of small synthetic DNA tags composed of double stranded DNA with an internal
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mismatch region (see fig. 5c). These tags are ligated onto the free ends of total
genomic DNA fragments resulting from the treatment of the DNA with various
six-cutter restriction enzymes (see MM1.7).
Using the mix of "tagged" genomic DNA as PCR template, the PCR reaction
proceeds in the presence of the sequence specific primer and a synthetic primer.
The synthetic primer is a 25mer comprising of sequence identical to that of the
leading strand at the mismatch region of the vectorette tag, thus initially, this
primer has no complementary sequence to anneal to.
Strand extension can only occur from the sequence specific primer during the first
round of PCR amplification. The complementary strand to the leading strand at
the mismatch region is synthesised at this stage, thus producing complementary
sequence for the synthetic primer to anneal to in subsequent amplification rounds.
The PCR reaction proceeds normally from the second amplification round
onwards, exponentially synthesising increasing copy numbers of the DNA
sequence located between the sequence specific and synthetic primer.
Using this Vectorette tag approach, I constructed tagged genomic libraries from
EcoRI, Hindlll, BamHI, Bglll, Bell and XhoII digests. I then designed two
nested primers (see table 5.1), complementary to the leading strand and orientated
to extend away from the p53 locus into the previously uncharacterised upstream
sequence. The location of the primer, expressed as 'bp' in the third column of
table 5.1, corresponds to the location of the primer relative to the number of
nucleotides upstream of the main transcriptional initiation site of p53 (+lbp).
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Fig. 5c - Schematic Illustrating Vectorette 'Tag' Strategy
1. Digest Genomic DNA with vectorette tag








2. Ligate Vectorette tag to fragments of genomic DNA.
KNOWN SEQUENCE
3. At the first round ofPCR amplification, strand extension can only proceed from the
sequence specific primer. The first round extension product is now tagged at the
3' end with sequence complementary to that of the synthetic vectorette primer,









5 GAC TCC TGC CTC TGT GTC AAG TA 3' Located -185
to -152bp
Initial amplification attempts from the tagged libraries were cycled at the
conditions listed below in table 5.2, but resulted in the amplification of a smear of






Cycled for 40 cycles
The problems of high background with this approach are reportedly not
uncommon, and are predominantly the result of unligated vectorette tags and
genomic fragments present in the PCR template mix of tagged genomic
fragments. This problem, termed end-repair priming, can lead to significant
amounts of non-specific background PCR amplification products.
Recently, vectorette technology has been superseded by splinkerette technology,
which employs the use of a highly stable internal stem loop structure instead of
the region of internal mismatch. The modified splinkerette tag is reportedly free
from the problems of end-repair priming (Devon et al, 1995).
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Following modification of PCR programme cycle and reaction volumes, I
produced a band from the XhoII tagged library using primer PI and the
conditions listed below in table 5.3.
Table 5.3
94°C 1 1/2 minutes
68°C 1 minute
72°C 2 1/2 minutes
Cycled for 40 cycles
Fig. 5d
1 M
Fig 5.d shows specific 1.3Kb PCR product in lane 1, resulting from the amplification of the XhoII
tagged vectorette library with primer P2.
This band sized at approximately 1.3Kb (see fig 5.d) was the predominant PCR
amplification product over a small amount of non-specific background and was
cloned using a TA cloning vector (Invitrogen; see MM1.6). This fragment will
be referred to as FX for the remainder of the chapter (Fragment from XhoII
library).
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To rapidly prove that FX was the desired sequence immediately upstream of the
p53 promoter and not non-specific artefact, I developed a diagnostic PCR assay.
This screen used primer P2 and another existing primer, designed previously to
anneal at the very limit of previously characterised sequence, termed Sou 1 (see
table 5.4). The screen was optimised (see table 5.5) to amplify a 117bp fragment
from genomic DNA template. If genuine, the 1.3Kb band FX should contain both
primer annealing sites to enable amplification of this product.
Table 5.4
5 GAT GGC TAT GAC TAT CTA GCT GG 3Sou 1 Located -280 to -258bp





Cycled for 32 cycles
Fig. 5e
1 2 3
Fig 5e shows results of diagnostic PCR using primers P2 and Sou 1. From left to right, lane 1 is
1Kb DNA ladder, lane 2 is +ve control (wild-type ES cell DNA as template), lane 3 is
amplification product from FX.
165
As shown in fig. 5e, FX was positive for the 117bp diagnostic band.
Subsequent sequencing proved conclusively that the PCR derived sequence ofFX
was immediately upstream of the p53 promoter (see section MM1.9). This
limited amount of sequence data also permitted the design of another primer, PIN
1 (see table 5.6) to work in conjunction with primer PI, and enabled the re-
derivation of FX using high-fidelity Taq DNA polymerase and genomic DNA as
template (see table 5.7). The re-derived, hi-fidelity version of FX was cloned into
pCRII (Invitrogen) as pCRII.FX, then sub-cloned and fully sequenced (see fig. 5f
and 5g).
Table 5.6
PIN 1 5 GAG GCA CCG GTT CAA AGT CTG
TAT3'
Located from 59bp to

















Fig 5f shows the successful cloning of Hi-fidelity amplified FX (at 1.3Kb) into pCRII plasmid
backbone (4Kb) in all lanes to generate pCRII.FX. DNA marker is 1Kb ladder.
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Fig. 5g FX - COMPLETE SEQUENCE
1
TCGCTGTCCT CTCCTTCGAT CTGTGGCTAG CTGGGGTTGG TCATCACCAC
51
CGCATGGCGA GGCACCGGTT CAAAGTCTGT ATTTTTCCTC CGCCTGGGGA
PinAI PIN 1 ->
101
ACCTTGGGGT ACCGGAGCTG GGGCCAGGTC AGGAGGGAGG CTATCCGGAG
Kpnl
151
CTAAGAGTCG CTCCTCCGAC GTCTTCATTC TGTAGAGTAA GCCCCCGGAA
201
GGCAGAGGTC GGGCAAGTCT CGCTGAGCCG GCTACCAGCT GCCGAGGCTA
PvuII
251
GAGTGCATTA CCGTTCCCAG GGATGCTCAG AGACCGGAGT CCGCTTTCCT
501
CTTCCGGAAA ATGTAAGCCG AACCTAAAGC AATCACCAGG GAACGAGTGT
351
CCAAAGCCAA GCGCCTAGGG TCGCTAGGCG CCGCCAGGGC TTCTTGCTCT
401
CGCGGGAGTC GGGCCACCTT CCGATAGGCT CTCCGCATCC TCCTCCGATT
IflS
451
CCGAGCGGGA AGGCGGGAAG GAGCGACTTT GCCTACACCT CAAGCGCTGG
501
AGAATTCCTA GAGGTTTCTG GAAGTTGTAG TCTGAACTCT GGCCTTGGCG
Eco RI
551
AAAACTACAC GAGCGCCCCC TACCGTCCCC TGGGGGTAAT TCTTAAAGCG
601
CCTATCCTCC CTGGCCTGCA GAGGGCGCAT AATTTCTACA GTTTTTGCCC
651
CTCTTGACTA TCTTGTTTTG AATCCCGTAA CCTCAGGTTT CCTTTCTCCC
701
CATCTCTCCC CCCTTCTTGT TCCTCTCTTT CCCTTTCTCC CCCGCCCTCC
751
CTTCATTCAT TCGACATTTA TTGTCAAGTT CTTACTGCCT AACCCAGGAC
801
TATACAAGGC ATTGGGAAAA AAATAGCAAT GTTTTCTAGT TCTTAATCTC
851
CATAAAGTTT TCGTTGCTGT GCAATTAAAG GCTGTGAAAA CAGTCTTTAC
160
901
A6A6A6T6AT AAGGACTGTA CAGGAAATTA AACACGGTGG TGCGATACCA
951
AGTATCTCGG AGAACACGTT AGATTGAGAT ACTATGAAAA GCCTTTCTAA
1001
AGTGACATTT TAGCTAATGA GGGGAAAAAG AACTTAGGGG CCCGTGTTGG
1051
TTCATCCCTG TACTTGGAAG GCCTAAAGCA GGAAGACGGC CGCGAATTCC
Eco RI
1101
AGGCCAGCCT TGGCTACAAA GACTCTATCT TAAAAATCCA AAAAGATGGC
1151
IATGACTAIC TAGCTGGATA GGAAAGAGCA CAGAGCTCAG AACAGTGGCG
<-Pl
1201




Red text = Primer Sequences
Green text = Restriction Sites used in mapping fragment
Blue text = Previously characterised sequence
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(5.ii.3) Derivation of the Downstream Vector Arm
The successful amplification of DNA template by PCR is generally limited to
product sizes of no greater than 5kb using conventional Taq DNA polymerase.
This size limitation is thought to result from the inability of Taq DNA polymerase
to proof-read and correct nucleotide misincorporations and this consequently
affects the ability of Taq to continue primer extension (Barnes, 1994). Different
formulations of DNA polymerase are now commercially available that combine
both the thermostable properties of Taq DNA polymerase with DNA polymerases
originating from other species of micro-organism, which possess proof-reading
activity (e.g. Pwo DNA polymerase). Using such a mix of DNA polymerase,
amplification of DNA templates up to 40Kb in length have been reported,
however, it should be noted that high quality template DNA is essential when
attempting to amplify fragments larger than 12Kb in size. All PCR reactions
subsequently listed in section 5.ii.3 have been conducted using the Expand Long
Template PCR system from Boehringer Mannheim (see section MM1.8 and
accompanying literature provided by supplier with kit).
The complete 6.2Kb sequence of p53's intron 1 has previously been published
(GENBANK; accession U10088) and primer pairs were designed to anneal and
amplify DNA template from this region. The initial primer pair FL3.1 and FL3.2
(see fig 5h and table 5.8), were designed to anneal to sequence within exon 1 and
the 3' end of intron 1. Theoretically this should result in the amplification of the
entire region immediately downstream of the p53 promoter. Subsequent
restriction enzyme modification and cloning of this amplification product would
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entire region immediately downstream of the p53 promoter. Subsequent
restriction enzyme modification and cloning of this amplification product would
















Fig. 5h illustrates approximate primer annealing sites and resultant amplification product size
relative to both exons 1 and 2 at the 5' end of the p53 locus. See table 5.8 for primer data.
Table 5.8
FL3.1 5' CTG TAG GTA GCG ACT ACA GTT AGG3' Located. +125 to
+149bp within
exonl
FL3.2 5 TGT AGA GAG AAG AGA TTG TGT ACT G 3 Located 6156bp
to 6180bp at 3'
end of intron t
LPE.l 5'CTC CGA ATT CTG GGT AAG TAA TTG ATG
AGC GTG3'
Located +204 to
20bp at 3' end of
exon 1
LPX.1 5 AGT CTA GAA TAA AAA GAA GGT GGG ACA
TCC AGT 3'
Located 6059bp
to 6091bp at 3'
end of intron 1
P3KE 5 GCA CAG TTC TCT TGC AAT CAG CTA GA3' Located 4746bp
to 4771bp of
intron 1




Following extensive modification of PCR reaction component concentrations and
PCR cycling conditions, primers FL3.1 and FL3.2 could not be optimised to
produce the desired 6.3Kb product.
A further primer pair, LPE. 1 and LPX. 1, was designed to anneal to sequence at
both the 5' and 3' ends of intron 1. These primers were designed to amplify a
6.1Kb template which, with respect to its moderately shorter length, would
perhaps be amplified more efficiently than the previously desired 6.3Kb product.
Again, following extensive attempts at reaction optimisation, this primer pair also
proved to be unsuccessful at producing the specific amplification product.
Further reaction optimisation attempts were made using alternative primer pair
combinations from the 2 primer pair sets, but this approach was also
unsuccessful.
Further decreasing the length of DNA template, a third primer set, P3KE and
P3KX was designed to amplify a 3.2Kb fragment. This primer pair combination
was optimised to amplify the desired template (see fig. 5i) using the cycle
conditions detailed in table 5.9.
This 3.2Kb amplification product, termed F3K for the remainder of this chapter
(Fragment of 3 Kb), was subsequently cloned into pCRII (Invitrogen), to form
pCRII.F3K (see figures 5.ia and 5.ib). This plasmid was then extensively
restriction mapped and approximately 200bp, at both the 5' and 3' ends of F3K,















Fig. 5i.a Fig. 5i.b
Fig 5i .a shows the successful amplification of F3K.
Fig.5.i.b shows pCRII.F3K, following digestion with BamHI, Hindlll, uncut, SacI, Kpnl and
Xhol respectively (looking at gel lanes from left to right). Resultant fragment sizes are as
predicted (see pCRII.F3K plasmid map in appendix).
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Despite the possibility that F3K may have been cloned with occasional point
mutations arising from the process of PCR amplification, F3K was directly
cloned into the final targeting construct without prior sequencing. The reasons
for this are essentially two-fold.
Firstly, F3K is wholly comprised of non-coding sequence, therefore following
homologous recombination, the introduction of any point mutation into this
region of the host ES cell will not affect resultant wild type gene expression.
Further, it is not essential for homologous targeting vector sequence to be entirely
composed of isogenic DNA. Although isogenic targeting constructs reportedly
possess enhanced homologous recombination frequencies, the presence of
occasional Taq DNA polymerase mediated nucleotide misincorporations within
F3K does not preclude against its use as an arm of homology in the final
replacement targeting vector. It should be noted however that F3K was amplified
from isogenic 129/OLA genomic DNA template with high fidelity Taq DNA
polymerase in an attempt to derive sequence with the highest possible degree of
homology to that of the host cell locus. DNA template amplified by both Taq and
Pwo DNA polymerase, reportedly exhibit a nucleotide misincorporation rate
approximately 10 fold lower than template amplified with Taq DNA polymerase
alone (ref. technical data sheet, Boehringer Mannheim).
(5.ii.4) Selection Marker Strategy and Construction of Targeting Vector
A successful double replacement targeting strategy must enable both the positive
selection of the deletion event and the negative selection of the marker
replacement event at both the first and second rounds of HR respectively (see fig
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5a). This can be achieved by either replacing host cell sequence with both
positive and negative selectable marker sequences (e.g. neo and tk), or by
replacing with a single selectable marker cassette that will permit both positive
and negative selection (e.g. HPRT selectable marker cassette in otherwise HPRT
deficient cells). There is no significant advantage to be gained from either
approach and so the HPRT approach was chosen as it simplified subsequent
targeting vector construction.
The basis of positive and negative HPRT selection in mammalian cells arises
from the ability of normal cells to utilise both HPRT mediated salvage and de
novo purine synthesis pathways to synthesise inosinic acid; a prerequisite for
nucleic acid synthesis.
In HPRT deficient mammalian cells, only the de novo purine synthesis pathway
exists and gain of HPRT function can be positively selected when these cells are
cultured in the presence of HAT (hypoxanthine, aminopterin and thymidine)
containing media (see section MM4.1). Aminopterin blocks de novo purine
synthesis, thus HPRT deficient cells become completely dependent upon the gain
ofHPRT function for their survival when cultured in the presence ofHAT. Media
containing Aminopterin must also be supplemented with hypoxanthine and
thymidine to enable the positive selection of HPRT expression however, as the
former is a required substrate of HPRT and the latter because aminopterin also
inhibits the synthesis of this nucleoside (Syzbalski, 1992).
It is also possible to select for cells that lack HPRT gene expression by culturing
cells in the presence of 6-Thioguanine (6-TG). 6-TG is metabolised by HPRT to
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a toxic nucleotide, therefore HPRT deficiency confers cellular resistance to this
molecule (Stutts and Brockman, 1963).
Both F3K and a modified version of FX were positionally cloned to flank an
HPRT mini-gene (kindly provided by David Melton).
F3K was removed from pCRII.F3K following EcoRI digestion and was ligated
into the EcoRI site of the HPRT mini-gene containing plasmid, pPolylll/PGK-
HPRT(RV) V.17. Hindlll digestion was subsequently performed on recombinant
clones to orientate F3K relative to the HPRT mini-gene. This new construct was
termed pHPRT-F3K.
To enable subsequent PCR screening of HAT resistant ES cells (see section
5.iii.l) the plasmid pCRII.FX was digested with Kpnl to remove ~80bp from the
5' end of FX prior to targeting vector construction. Re-ligation ofKpnl digested
pCRII.FX generated the plasmid pCRII.FXAK.
An essential requirement for the application of a PCR screen to identify targeted
clones is that one of the primers used must anneal within a region of sequence
external to sequences involved in the targeting event. As the sequence upstream
of FX is not known, this enzymatic step enabled the previously designed primer
PIN1 (see table 5.6) to be used in conjunction with a primer specific to targeting
vector sequence for the screening of targeted ES cell clones.
FXAK was removed from pCRII.FXAK following digestion with Xbal and
Hindlll and was cloned into a Klenow fragment blunted Xbal site of pHPRT-F3K
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following blunt-ending with Klenow fragment. FXAK was then orientated with
respect to HPRT and F3K sequences by PvuII restriction digest (see Fig. 5.j).
Fig. 5.j
Fig.5.j illustrates the completed construction of the 1st round targeting vector pFXAK-HPRT-F3K.
Lane 2 shows the correct orientation of FXAK sequence relative to HPRT-F3K sequences by
producing a 4.2Kb, 3.1KB, 1.1Kb and 0.4Kb band following digestion with PvuII. Lane 4 shows
FXAK sequence in the other orientation relative to F1PRT-F3K, producing 3.2Kb, 3.1KB, 1.1Kb,
1.0Kb and 0.4Kb bands following PvuII digestion.
The replacement of host cell sequence located between FXAK and F3K will
remove sequences previously demonstrated to influence both the transcriptional
and post-transcriptional regulation of p53 gene expression. Following FIR, all
known transcription factor binding sites will be removed from one allele of p53.
The deletion of this region also disrupts the putative region of dyad symmetry
located at the 5' end of the p53 locus. This DNA sequence has been implicated in
the post-transcriptional regulation of p53 expression by coding to form a stable
stem loop structure in resultant mRNA (see chapter 1, section l.ii.4b). In theory
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therefore, the replacement of this region with inducible promoter sequence will
produce cells with the ability to conditionally express p53.
(5.iii) Targeting Event Screening Strategies.
Both PCR and southern strategies were devised to screen HAT resistant ES cell
clones to demonstrate the successful replacement of the p53 promoter region with
HPRT mini-gene sequence via HR.
(5.iii.l) Development of PCR Screen to Detect HR at 5' Vector Arm
A PCR based screening approach can confirm HR between vector and host locus
sequences providing that the amplification product is of reasonable size (see
comments made in section 5.ii.3), that one primer anneals to sequence external of
recombining sequences and that the other primer is vector specific. The
application of such an approach can greatly facilitate the rapid analysis of
potentially targeted ES cells.
Primer PIN1 (see table 5.6) was used in conjunction with primer Pr.T.V.,
designed to anneal to the 3' end of the HPRT mini-gene (see table 5.10), to
confirm HR between the upstream vector arm FXAK and host locus sequence.
Only targeted cells possess both primer annealing sites and therefore only these
cells can amplify the diagnostic 1.3Kb product from genomic template (see fig
5m).
Table 5.10
Pr.T.V CTG AAG CTC TCG ATT TCC
TAT CAG 3'
Located at 1054bp to 1077bp of
HPRT sequence (Melton '85).
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As no PCR product can be amplified from wild-type cells, a plasmid, pFX.HPRT,
was constructed to mimic the correctly targeted locus and enable optimisation of
PCR reaction conditions. Full-length FX sequence was cloned adjacent to HPRT
mini-gene sequence, thus positioning both primer annealing sites adjacent relative
to one another and enabling amplification of the appropriate 1.3Kb template.
PCR reaction conditions were optimised in the presence of wild-type ES cell
DNA to ensure that the amplification of plasmid template occurred within a
complex DNA template background. For this approach to be successful when
applied to the screening of targeted ES cell DNA, the PCR reaction must be
sufficiently sensitive to detect and amplify one single gene copy per copy of the
genome. Upon the assumption that there are approximately 3 x 109 bp per murine
genome and that there are approximately 7 x 103 bp per copy of pFX.ElPRT, the
number of plasmid copies per 0.7pg of DNA is equal to the number of genome
copies per of 300ng DNA.
To determine the absolute boundaries of reaction sensitivity using primers PIN1
and Pr.T.V and the cycling conditions detailed in table 5.11, lpl from each of a
series of '/io serially diluted plasmid DNA samples was used as PCR template in
reactions containing a consistent background amount of 300ng wild-type genomic
DNA.
The initial experiment demonstrated that the PCR reaction was highly sensitive,
as the 1.3Kb amplification product was readily visible following 1CT7 dilution of
1 pg plasmid DNA, approximately equivalent to one single gene copy per copy of
the genome. The experiment was repeated with two further serial dilutions and
still the 1.3Kb amplification product was detectable following 10~9 dilution (see
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fig. 5.k). The amplification of the desired product following dilution to 10"9,
approximates to the detection of lfg plasmid DNA per 300ng of genomic DNA,
or to one single gene copy per hundred genome copies. These results would
suggest that primers PIN1 and Pr.T.V are sufficiently sensitive to detect HR
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Fig 5.k is a gel photograph demonstrating PCR results following the amplification of serially
diluted concentrations of pFX-HPRT DNA plus 300ng genomic DNA. The lanes read from left to
right as, 1Kb DNA marker, 10 dilution, 10~2 dilution, 10'3 dilution, 10"4 dilution, 10~5 dilution,
NT6 dilution, NT7 dilution, 10"9 dilution, 10"8 dilution, negative control and positive control
consisting of primers PIN1 and PI, with wild-type genomic DNA template alone. This positive
control demonstrates that the quality of genomic DNA used as complex background in all other
samples is of sufficient quality to enable PCR amplification. 10gl from a total of 1 OOjul final PCR
reaction was loaded per lane.
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Despite producing convincing data to demonstrate that the PCR screening assay is
sufficiently sensitive to detect a single targeted locus from within the genome,
failure to amplify the 1.3Kb targeted locus specific PCR product can result for
three reasons.
Firstly, if the p53 locus is not targeted, PIN1 and Pr.T.V primer annealing sites
never become adjacently positioned relative to one another and therefore are
unable to amplify the diagnostic amplification product from genomic template.
An additional reason is that the genomic DNA preparation may be of insufficient
quality to enable template amplification. This eventuality can be roughly
controlled by using primers PIN1 and PI to amplify 1.2Kb of wild-type and
overlapping genomic DNA template, in addition to using primers PIN1 and
Pr.T.V to screen samples.
Finally, it should be noted that the PCR assay was optimised from simple template
within a complex genomic background and not from targeted genomic and
therefore complex DNA template. In theory, this should make little difference to
the optimisation of successful PCR reaction conditions, as the presence of any
problematic secondary structure within the complex genomic template should be
removed at every PCR cycle following heat denaturation at 94°C. However, any
difference in optimal reaction conditions between these two template types could
potentially result in the inability to detect HR events in correctly targeted cells via
this approach.
Although PCR based screening approaches can greatly facilitate the rapid analysis
of potentially targeted ES cells, rather than risk discarding correctly targeted ES
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cell clones solely upon the basis of the absence of a diagnostic amplification
product, all clones were further screened by Southern analysis.
(5.iii.2) Development of Screen to Detect HR at 3' Targeting Arm
To enable the detection of HR between F3K and host locus sequences, a probe
was generated by PCR to anneal to sequence external of the targeting event and
immediately downstream from F3K. The probe was produced using two primers,
Pro3A and Pro3B (see table 5.12) and was amplified from wild-type ES cell DNA
using cycle conditions detailed in table 5.13. The resultant 224bp probe was fully
sequenced and was shown to be 99.8% identical relative to the sequence of intron
1 stored in Genbank.
Table 5.12
Pro 3A 5 AGC CTG TGA CGC ACT AGA TT J' Located from 4777bp
to 4796bp of intron 1
Pro 3B 5'CAG CAA AGG CAA GCA TTT C j Located from 4983bp
to 5 001 bp of intron 1
N.B. Primer Pro 3B forms an internal stable secondary structure and so must be heat denatured










Following the successful replacement of p53 sequence with HPRT mini-gene
sequence, it is predicted that both a Bell restriction site will be introduced and a
BstXI site removed from the host locus (see fig 5m). Southern analysis of Bell
and BstXI digested wild-type ES cell DNA, with the 3' probe described above,
results in the hybridisation and detection of 13Kb and 4.5Kb bands respectively
(see fig.5m). Although it is not possible to predict the exact size and mobility
shift of hybridised bands following the digestion of a successfully targeted locus,
it can be predicted that the size of targeted hybridisation products will be readily
discernible from wild-type hybridisation products. Following successful HR, the
additionally hybridised band resulting from Bell digestion must be between
approximately 10Kb and 4Kb in length, whilst the additionally hybridised band
resulting from BstXI digestion must be greater than 7.5Kb.
Fig 5L
Fig 5L. shows an autoradiograph of Bell digested wild-type ES cell DNA, hybridised to P32
labelled 3' probe. The detected band runs at approximately 13Kb.
184









Bst XI Approx. 4.5Kb Bst XI
mpm
P53 locus following 1st round of targeting
Between 10Kb and 4Kb
>7.5 Kb Bst XI
>1
■ mm i ■M
Bst XI Approx. 4Kb Bst XI




Homologous Targeting Vector Sequence PESfl PCR primer Sequence
™ HPRT mini-gene Sequence «<- HPRT mini-gene Specific Primer
Sequence
1SK
(5.iv) Targeting Results using pFXAK-HPRT-F3K
Initial attempts to target the p53 locus with pFXAK-HPRT-F3K were problematic
as large numbers of false-positive ES cell clones proved resistant to, and survived
HAT selection following electroporation and plating at a density of 8 x 105 cells
per 10cm2 dish. The underlying cause of this phenomenon is well understood, in
that cells that stably integrate and express the HPRT mini-gene can rescue non-
HPRT expressing clones within close proximity during HAT selection (Hooper
and Subak-Sharpe, 1981). Repeat electroporation and plating at a reduced density
of 5 x 105 cells per 10cm2 dish produced far fewer, but true HAT resistant ES cell
clones (on average 5 HAT resistant clones per dish).
Southern analysis on 128 of these true HAT resistant clones concluded that none
had been successfully targeted. All clones produced only the wild-type 13Kb
band following Bell digestion and hybridisation with the 3' screening probe.
Subsequent PCR analysis on these clones also concluded that no clones had been
targeted as all clones failed to amplify the diagnostic 1.3Kb product. To ensure
that this was genuinely the result of a zero percentage targeting efficiency and not
the result of poor quality genomic DNA preparation, primers PIN1 and PI were
used to amplify 1.2Kb of overlapping genomic template. 121/128 of clones
amplified this 1.2Kb template.
Southern analysis ofBstXI digested DNA with the 3' probe was not performed on
these samples.
It is well known that the frequency of successful HR can vary extensively during
the course of targeting experimentation at different gene loci, and that reported
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targeting efficiencies of less than 1/200 are not uncommon. Thus, despite the fact
that 0/128 clones proved to be successfully targeted via this approach, it would be
wrong to abandon this targeting strategy before more HAT resistant ES cell clones
were analysed.
Accordingly a further 420 HAT resistant clones were grown in 24 well plates
following electroporation with pFXAK-HPRT-F3K. 380/420 clones grew
sufficiently to enable analysis.
Southern analysis of Bell digested DNA demonstrated that 1/380 clones possessed
a second detectable band following hybridisation with P32 labelled 3' probe (see
MM1.4 and MM1.5). Sample 272, as shown in fig.5n, possesses both the wild-
type band at 13Kb as well as an additional hybridising band at approximately
4.5Kb. This mobility shift is within the size range predicted to result following
the successful replacement ofp53 sequence with HPRT mini-gene sequence.
Fig.5n
Fig.5n shows the results of a southern analysis conducted on the genomic DNA derived from
multiple ES cell clones following targeting with pFXAK-HPRT-F3K and HAT selection. Note
that the sample furthest on the left (clone 272) possesses two hybridising bands at approximately
13KB and 4.5Kb.
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To confirm that the recombinant p53 allele of clone 272 is the desired targeting
event and not the product of illegitimate recombination, attempts were made to
analyse this DNA further by PCR screen to confirm HR between FXAK and host
locus sequences.
Using the reaction conditions optimised in section 5.iii.2, it was not possible to
amplify the diagnostic 1.3Kb product from clone 272. However, the amplification
of this diagnostic template also failed in all positive control samples, i.e.
amplification failed in the serially diluted pFX-HPRT template plus wild-type
genomic DNA background. Further alteration ofPCR reaction conditions was not
permitted in the time left available, but all individual PCR reagents were renewed
in an attempt to re-establish this screen. Unfortunately, technical difficulties
persisted with this assay and as a result it was not possible to confirm the
successful HR between FXAK and host locus sequences in clone 272.
Attempts, by Southern type analysis, to additionally confirm that clone 272 had
undergone the desired HR event between F3K and host locus sequences, were
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made by hybridisation of P labelled 3' probe to BstXI digested genomic DNA.
In similar circumstances to the PCR targeting screen mentioned above, time was
the limiting factor with this experiment, and again technical problems prevented
the direct confirmation or otherwise, regarding the nature of the re-arrangement
present at the p53 locus of clone 272.
(5.v) Conclusions
The results clearly show that these attempts to target and delete the 5' promoter
region of p53 are highly inefficient with this construct. Despite the possibility
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that this approach may have been successful in producing one clone from five
hundred and eight analysed, time constraints do not permit the complete
characterisation of this ES cell clone, neither do they permit the second round of
targeting to render expression from the p53 locus inducible.
Given more time, there are several modifications that could be made to this
targeting strategy that would possibly enhance the frequency of successful
homologous recombinant clones.
The most obvious would be to increase the overall length of targeting vector
homology by increasing the length of the downstream vector arm F3K.
Potentially this could be achieved rapidly by further attempting to optimise
amplification conditions for new PCR primer sets. Alternatively, considering the
difficulties already faced whilst attempting to amplify DNA template from this
region of the genome, the existing arms of vector homology could be radio-
labelled and used as probes to screen a A phage genomic library. If successful,
this approach would likely produce clones spanning between 10 to 16kb in
length, encompassing the p53 locus.
Increasing the length of FXAK, the upstream targeting vector arm, would also be
a means of increasing the overall length of targeting vector homology, but this
would require further inverse PCR or A phage cloning and characterisation of
novel sequence. Significant extension in the length of FXAK would also make it
increasingly difficult to develop a sufficiently robust PCR assay to reliably screen
for the successful HR of the upstream targeting arm in ES cell clones surviving
selection. Failure to develop a suitable PCR assay of this type would necessitate
further cloning and characterisation of novel sequence upstream of FXAK, to
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enable the generation of probes and the derivation of a southern assay to confirm
the successful HR of this vector arm into the target locus.
Cloning a negative selection marker (e.g. a tk cassette) outwith the two arms of
vector homology is another approach that could be employed to increase the ratio
of correctly targeted to randomly integrated surviving ES cell clones (see chapter
1, section l.i.7b for discussion).
Following HR between both targeting vector arms and the desired host locus, tk
expression will be lost. Non targeted clones resistant to HAT by virtue of the
random integration of the HPRT mini-gene, will also likely retain the expression
of tk. Therefore, culturing HAT resistant ES cell clones in media containing
gancyclovir will theoretically enrich for the desired targeting event.
Although it is not possible to simultaneously select for loss of tk expression and
gain of HPRT expression (the thymidine in HAT protects against the kill by
gancyclovir), it would be possible to select for and against the expression of these
markers sequentially.
A further means of improving targeting efficiency would be to alter
electroporation conditions. A recent publication by Templeton et al describes an
alternative ES cell transfection procedure utilising a modified electroporation and
plating procedure which considerably reduces the amount of cell death associated
with other well established electroporation procedures. Templeton claims that
these protocol modifications are sufficient to raise the absolute efficiency of gene
targeting from 10° to approximately 10"' cells. This targeting frequency is
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sufficiently high to enable the isolation of targeted ES cell clones in the absence
of selection.
An alternative vector design and targeting strategy, utilising cre/loxP technology,
is proposed in fig.5o, which enables both the replacement of p53 promoter
sequence with inducible promoter and splice donor sequence within only one
round of homologous recombination.
Transient expression of ere recombinase in successfully targeted cells will cause
recombination to occur specifically between loxP sequences, resulting in the
deletion of both selectable marker cassettes.
Thus, following one round of HR, targeted cells that successfully undergo cre-
mediated recombination will be able to conditionally express p53, in the absence
of potential transcriptional interference resulting from the presence of residual
selectable marker cassettes at the host locus.
The implications for further research concerning clone 272 and these alternative
targeting approaches are discussed in chapter 6.
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(6.i) A Brief Summary of Aims and Experimental Approaches
The main aim of the experimental work described within this thesis was to render
the expression of p53 inducible in murine cells and thus generate animal models
with which to better evaluate the therapeutic benefits conferred by p53
replacement gene therapy in the treatment of cancer.
As discussed within chapter 1, multiple human gene therapy trials are currently
being undertaken whereby tumours are treated with recombinant viral vectors that
constitutively express the tumour suppressor gene p53. These trials were initiated
primarily upon the basis of observations made from extensive in vitro
experimentation suggesting that the re-introduction of p53 expression, within an
otherwise p53 deficient tumour cell background, can induce the growth arrest or
apoptosis of tumour cells. Indeed, preliminary observations from these gene
therapy trials would appear to suggest that in certain instances tumour size can be
stabilised or even regression induced via such a therapeutic approach (Roth et al,
1996).
The major limitation of all human gene therapy trials is the current inability of
vectors to efficiently deliver and maintain stable gene expression within cells
growing in vivo (Blau, 1997). It is therefore highly unlikely that these current p53
replacement gene therapy trials will form an effective and permanent anti-tumour
treatment.
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To formally test the hypothesis that the introduction of p53 gene expression into
tumour cells growing in vivo can form the basis of an effective anti-tumour
treatment, animal models are required whereby the expression of wild-type p53
can be precisely manipulated. Many p53 deficient cell types are known to be
predisposed to tumourigenesis, therefore the ability to efficiently upregulate p53
expression within these cells growing in vivo would essentially mimic highly
efficient vector-mediated gene delivery and thus would permit an opportunity to
better evaluate subsequent therapeutic effects.
To achieve these aims both an inducible transgene approach (chapters 2 and 3)
and a double replacement targeting approach (chapter 5) were attempted to
effectively render the expression of all p53 protein within the cell inducible. As
described within the opening section of these respective chapters, both approaches
have associated advantages and disadvantages relative to one another. In brief,
the inducible transgene approach is rapid to establish compared with the targeting
approach, however the targeting approach is not affected by 'position effect' and
so potentially offers greater reproducibility in modelling the effects of highly
efficient vector gene delivery between different tumour types.
Clearly the efficacy of both approaches in achieving the experimental aims stated
is also dependent upon maintaining the transcriptional silence of desired gene
expression in the absence of inducer. Significant non-induced levels of transgene
expression may be sufficient to confer phenotypic effects upon the cell, therefore
to truly model and evaluate the consequences of replacement gene therapy by
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these approaches, the expression of the desired gene must be silent or at least at
very low levels within the cell in the absence of inducer.
With regard to these considerations, the inducible expression systems initially
intended to be applied to these studies were the tetracycline inducible and the
human 6-16 (interferon a/|3) inducible promoter systems. The plasmid constructs
required to render the expression of a p53 transgene inducible to both these
stimuli were constructed as detailed within section 2.i.2, however lack of time
precluded further experimental work utilising the tetracycline system.
To render the expression of p53 from the genomic locus inducible to various
stimuli, a replacement targeting vector was constructed to delete endogenous p53
promoter sequence and enable the subsequent introduction of inducible promoter
sequence (chapter 5). The resultant targeting efficiency was very low, but one
clone appeared to possess a re-arrangement at the 3' end of targeting homology.
The results and implications from both studies are discussed in the following
section.
(6.ii) Discussion of Experimental Data
The experimental data described within chapter 2 was generated following the
stable transfection of an interferon a/(3 inducible p53 transgene (p6-16lp53-HYG)
into a novel sarcoma derived cell line termed SL1 (Sarcoma-Line 1). SL1 tumour
cell sub-clones were subsequently derived, which demonstrated very low levels of
p53 transgene expression when in the non-induced state, but the ability to induce
p53 transgene expression when cultured in the presence of interferon a/(3.
Transgene dependent effects upon tumour cell cycle and the rate of apoptosis
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were measured in both the presence and absence of UV-C induced DNA damage
by flow cytometric analysis.
In brief, proliferation of SL1 tumour cells was shown to be rapidly, but
temporarily reduced when cultured in the presence of interferon a/p, irrespective
of additional genotoxic insult. No further significant cell cycle effect was
observed within SL1 cell cultures following the induction of p53 transgene
expression.
Conversely, interferon a/p appeared to exert no effect upon the induction of
apoptosis in transgene"ve SL1 cells in either the presence or absence of DNA
damage, whilst a clear 'early' p53-dependent wave of apoptosis was detected
within cultures of transgene+ve SL1 cells following treatment with interferon a/p
and exposure to UV-C irradiation.
Transgene"ve cells retained the ability to enter apoptosis in response to an
equivalent dose of DNA damage, but this p53-independent apoptotic response
was initiated and reached maximal levels approximately 12 and 24 hours
respectively after the p53-dependent apoptosis observed in transgene+ve cells. The
initiation of p53-dependent apoptosis did not however appear to significantly
affect the long-term clonogenic survival of transgene+ve SL1 cells relative to
transgene"ve cells.
As described within section l.i.8b, interferon a/p has been used as an anti-tumour
treatment for several human malignancies, therefore the observation that this
reagent can temporarily inhibit SL1 tumour cell cycle should not be considered
surprising. Indeed, in addition to tightly regulating transgene expression, this
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inducible expression system potentially enables observation of synergistic or
adjuvant anti-tumour effects elicited by the introduction of p53 gene expression in
the presence of interferon a/p.
The lack of observed p53-dependent growth arrest, especially in the presence of
DNA damage was not predicted. The ability of p53 to cause cell cycle arrest at
multiple checkpoints is well characterised in a wide variety of wild-type and
transformed cells possessing either damaged DNA template or elevated levels of
oncogene expression.
Perhaps the most obvious hypothesis to explain this observation is that the p53
protein expressed from p6-16Lp53-HYG is not wild-type p53 protein. P53-
mediated growth arrest appears to be dependent upon the ability of p53 to
transactivate or repress the expression of specific downstream loci. As discussed
in section l.ii.2a and 2b, mutant p53 proteins have previously been identified that
are unable to transactivate gene expression as a result of point-mutations affecting
the coding of amino acid residues within their N- terminal and core domains.
Mutations affecting the N- terminal domain of p53 appear to prevent appropriate
interaction between p53 and other protein components of the basal transcriptional
machinery, whereas mutations within the core domain of p53 can affect wild-type
protein conformation or the ability of p53 to bind to its cognate sequence.
The RGC-reporter assay, mentioned within section 2.vi, was intended to directly
test the ability of transgenic p53 protein to transactivate the expression of
downstream genes. Time constraints however limited the opportunity to define
optimal and reproducible transient transfection conditions and thus the results of
this experiment could not be concluded.
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A further scenario that could explain the observed lack of transgene-mediated cell
cycle arrest of ID cells is that additional sequence may be translated from p6-
16lp53-HYG and 'tagged' to the C- terminal domain of transgenic p53.
Messenger RNA transcribed from p6-16Lp53-HYG was shown not splice
appropriately at the 3' end (see section 2.ii.2), although theoretically this should
not alter the final p53 translation product.
As p53 tetramerizes within this protein domain however, it may be possible that
the presence of an additional C- terminal peptide 'tag' could inhibit or de-stabilise
the multimerisation of transgenic p53 protein and thus alter the ability of p53 to
modify the expression level of specific downstream loci.
To examine and compare the size of transgenic p53 protein relative to wild-type
p53, whole cell extracts from interferon a/(3 treated ID cells were subjected to
western analysis using the anti p53 polyclonal antibody BMG-1 (section 2.vi).
Specific p53 epitope(s) appeared to be most abundant at 72 hours after DNA
damage on a protein several kilodaltons larger than wild-type p53. Although this
recognised protein would appear to be specific, all previous data examining
transgene expression levels at times following transgene induction and DNA
damage suggest that transgene expression is maximal within 6 hours of exposure
to interferon oc/(3. No specific protein was recognised on the western blot at this
time, therefore it is not possible to conclude in the absence of further
experimentation whether the protein recognised on this blot is genuinely
expressed from p6-16Lp53-HYG or is non-specific background.
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The p53 cDNA cassette used in these studies was fully sequenced prior to vector
construction and was shown to encode wild-type p53 protein accordingly
(Malcomson, 1996). Presumably therefore, the underlying nature of both of these
hypotheses must be a mutational event affecting the coding region of transgenic
p53 that occurred after the transfection of p6-16Lp53-HYG into SL1 cells.
Non-induced levels of transgenic p53 protein appear to be very low in ID cells,
but this level of protein may still have been sufficient to confer a selective
disadvantage to these cells growing in vitro. Indeed, an observation that was not
at first deemed of relevance was that from the total of 9 clones initially shown to
exhibit good-fold induction of p53 expression, 5 lost their proliferative capacity
within a few passages in culture. It is therefore feasible that the 4 remaining
clones either expressed non-physiologically relevant amounts of non-induced
wild-type p53 protein or had gained selective advantage through the mutation of
p53 coding sequence enabling escape from this 'crisis' in culture. Further
circumstantial evidence to support the latter notion is that following the induction
of p53 transgene expression, no transgene-dependent effects were observed upon
either the cell cycle or rate of apoptosis of ID cells when cultured in normal
conditions (i.e. in the absence of additional DNA damage).
To formally prove such a theory, both the comparison of p53 transgene-mediated
effects and direct scrutiny of the sequence comprising the coding region of stably
integrated transgenic DNA would be required between multiple SL1 derived cell
lines.
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Interferon a/p and p53 appear to inhibit tumour progression through different
molecular pathways, therefore one could predict that the appropriate use of both
reagents in conjunction would at least confer an additive anti-tumour effect. A
further speculative hypothesis to explain the lack of observed p53 transgene-
dependent growth arrest however, may be that interferon a/(3 is indirectly
responsible for editing p53 mRNA.
Interferon a/p is known to stimulate the expression of the enzyme dsRAD in
response to double stranded RNA (see section l.i.8b). The expression of dsRAD
has also been shown to be physiologically relevant regarding the generation of
isoform diversity amongst glutamate and serotonin 2C receptors within the brain
(Seeburg, 1996 and Burns et al, 1997).
The expression of dsRAD can effectively mutagenise coding sequences residing
within dsRNA as this enzyme binds to dsRNA and catalyses the conversion of
adenosine to inosine. tRNA recognises rITP as rGTP, thus dsRAD-mediated
editing of dsRNA is equivalent to an adenosine to guanosine conversion.
The 5' portion of p53 mRNA encodes for the N- Terminal (transactivation)
domain of p53 protein and possesses extensive dyad symmetry that potentially
forms a stable dsRNA stem loop structure (see section 1 .ii.4b).
In addition to interferon a/p inducing the expression of p53 from p6-16Lp53-HYG
therefore, interferon a/p mediated induction of dsRAD may be able to alter the
coding sequence of transgenic p53 mRNA molecules sufficiently to impair p53-
dependent transactivation (and consequently growth arrest) within the cell.
Although all of the above theories concerning the lack of p53-dependent growth
arrest relate to mutation or modification of transgenic p53 coding sequence, it
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could also be reasoned that this observation might result from lesions affecting the
expression of p53-dependent genes.
An examination of the expression levels of known downstream components of the
p53-dependent growth arrest pathway (e.g. p21, GADD45 etc.) may enable the
investigation of such a scenario. However, as not all the components or
requirements regarding the initiation and maintenance of this pathway are yet
known, the detection of p53-dependent p21 gene expression would not necessarily
confirm that all the molecules through which p53-dependent growth arrest can be
achieved are present within the cell and are functional.
Transient transfection studies utilising the original p6-16lP53-HYG construct and
SL1 cells cultured in the presence of interferon oc/(3 may be able to demonstrate
the ability of transgene expression to arrest cell growth. Indeed, such experiments
could provide further insight regarding whether the lack of observed transgene
dependent cell cycle arrest in response to DNA damage is cell line or transgene
dependent.
One of the major limitations of current human gene therapy trials is the inability
to introduce and maintain the expression of genes in cells growing in vivo. The
results detailing attempts to induce transgene expression in vivo, following sub¬
cutaneous injection of ID cells (see chapter 3), also appear to highlight this
problem as a potentially major limitation of utilising genes that restrain cell
growth as candidates for replacement gene therapy.
Following sub-cutaneous injection of ID cells, tumours appeared rapidly at the
site of injection (within 3 weeks), yet transgene expression could barely be
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detected following stimulation of endogenous interferon a/(3 and whole body y-
irradiation.
Following the explantation of two ID-cell tumours back into culture, the cells
from one tumour retained the ability to induce similar levels of p53 transgene
expression as cultured ID cells, whilst the cells from the other tumour cell line
had lost the ability to induce p53 expression. This suggests that during the
establishment of tumours derived from ID cells in vivo, selective advantage could
be gained from loss of non-induced transgene expression. Although the in vitro
characterisation of ID cells demonstrated low levels of non-induced p53 protein,
it is possible that levels of non-induced transgene expression are significantly
higher (and physiologically relevant) within ID cells growing in vivo as a result of
exposure to systemic levels of interferon a/(3 within the mouse.
The observed loss of inducible transgene expression could have occurred through
multiple mechanisms including chromosomal loss or gross deletion, point- or
frame-shift mutation of transgene coding sequence or through modulation of the
host cell interferon cx/[) signalling pathway.
Both explanted cell lines retained resistance to a concentration of hygromycin
comparable to that of non-injected ID cells suggesting that transgene expression
was not lost as a result of chromosomal loss or by large chromosomal deletion.
An experiment that could potentially discriminate between loss of transgene
expression by mutation of p53 transgene coding sequence or modulation of host
cell interferon a/p signalling involves the sequential stable transfection of both
p6-16Lp53-HYG and a 6-16 regulated luciferase reporter construct into SL1 cells.
These cells could be injected sub-cutaneously into SCID animals as detailed
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previously and following the appearance of tumours, would be explanted back
into culture prior to treatment with interferon a/(3.
Low luciferase expression levels from the cells passaged in vivo relative to the
cells maintained in vitro would suggest that host cell interferon a/|3 signalling had
been modified. Such a situation could account for the inability of these cells to
induce p53 transgene expression.
An approximately equivalent level of luciferase expression within the cells
passaged in vivo and cells maintained in vitro would suggest that any observed
loss of inducible transgene expression had resulted from genetic lesions directly
affecting p53 coding sequence.
Theoretically a single mutational event conferring less efficient interferon a/p
signalling within ID cells would modify or even ablate the anti-tumour effects
conferred by both interferon a/(3 and transgenic p53. A single mutation arising
within p53 transgene coding sequence however, would impart less selective
advantage as ID cells would still be susceptible to the anti-proliferative effects
conferred through exposure to interferon a/(L It would therefore be interesting to
conduct the experiment as detailed above and to observe whether the frequency of
functional inactivation of interferon a/(3 signalling pathway relative to p53
transgene product reflects these predictions.
The inability to efficiently induce transgene expression in vivo effectively
precluded any evaluation of therapeutic transgene-mediated effects upon tumours
comprised of ID cells. An experiment that could potentially examine the ability
of injected ID cells to establish tumours in vivo would be to sequentially treat ID
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cells growing in vitro with interferon a/(3 and DNA damage immediately prior to
sub-cutaneous injection. This experiment represents an ex vivo equivalent to the
long-term clonogenic survival assay described within section 2.v. Recording the
mean time taken for tumours to present, following all combinations of transgene
induction and exposure to DNA damage, would potentially enable some insight
regarding the transgene-mediated effects within ID cells growing in vivo before
transgene inducibility is selectively modified or lost.
One of the major limitations of the inducible transgene study described within
chapters 2 and 3 is that the effects of p53 expression cannot be analysed in p53
deficient tumours arising de novo. Time constraints precluded against the
generation of p53 inducible mice, although the construct p6-16Lp53-HYG was
transfected into ES cells and stable recombinant clones were selected.
The intrinsic polygenic nature of cancer means that any conclusions drawn upon
the basis of observations within ID cell culture or tumours, regarding the potential
efficacy of p53 replacement gene therapy in the treatment of malignant disease,
would have to be qualified. The genetic background of ID cells is unlikely to be
generally representative of all tumour cell types, therefore the ability (or
otherwise) to treat ID-cell tumours by this approach cannot directly be
extrapolated as being of relevance to the treatment of malignant disease in
general.
The double replacement targeting approach described within chapter 5 would
theoretically permit an examination of induced wild-type p53 gene expression
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within tumours arising de novo. Indeed, the effects of p53 replacement gene
therapy could also potentially be modelled within tumours originating from an
outbred genetic background following successful replacement targeting and a
conventional breeding programme. Such animals would provide the most
accurate means of assessing the ability of p53 to treat a wide spectrum of
malignancies.
If ES cell clone 272 proves to be correctly targeted, then it will be possible to re¬
target and replace the HPRT marker sequence of these cells with that of an
inducible promoter by using the same regions of homology as the first targeting
vector. Multiple second round targeting vectors could potentially be constructed
rendering the expression of the p53 locus inducible to a wide variety of stimuli,
however following the experience gained through experimentation with the 6-16
promoter, the targeted introduction of Tet-0 sequences would be the favoured
option.
Animals targeted with 6-16 promoter sequence would not possess the SCID
mutation and so would likely not be negatively affected by attempts to stimulate
endogenous levels of interferon a/(3 following administration of pI:pC. Use of the
tetracycline inducible system however, would have the advantage of being
effective at concentrations that do not elicit pleiotropic effects in vivo, and so
would permit a clearer examination of transgene mediated effects upon the
treatment of tumours.
An alternative 1-step targeting strategy utilising Cre/loxP technology has also
been proposed within section 5.v of chapter 5, which would rapidly render the
expression of p53 inducible from its genomic locus.
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(6.iii) Future Perspectives and Concluding Remarks
Current DNA vector technology is unable to efficiently deliver stable gene
expression to cells growing in vivo, thus it is presently not possible to accurately
evaluate the therapeutic benefits conferred by replacement gene therapy in the
treatment of genetic disease.
The value of modeling replacement gene therapy within animals utilising
inducible promoter technology is therefore likely to remain high until significant
improvements are made in the field of DNA vector technology, sufficient as to
enable a direct measure of therapeutic effects conferred by replacement gene
therapy treatment regimes in vivo.
Inducible promoter technology is both relatively new and improving, but is also
widely available and so will undoubtedly prove to be of great utility in efforts to
understand the basis of genetic disease. It is now known that certain inducible
expression systems are better than others for precisely regulating gene expression
and enabling clear examination of transgene-mediated effects within the cell.
Thus it is likely that increasing amounts of experimental data will be generated in
the short-term utilising both the choice tetracycline and ecdysone based inducible
expression systems. Indeed, the results of such a research effort will certainly
prove highly informative regarding both the evaluation of prospective replacement
gene therapy treatment regimes, as well as providing further insight into the
underlying molecular basis of genetic disease.
Recent technical improvements have been reported within the field of inducible
promoter technology that should further enable these experimental goals to be
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reached rapidly. In an attempt to reduce background levels of transgene
expression within non-induced cells, tet repressor molecules have been engineered
to possess altered dimerisation domains (Rossi et al, 1998). The system,
designated Retro-Tet-ART, possesses repressor molecules that can bind to tet-0
sequences and inhibit transgene expression in the absence of tetracycline, as well
as activator molecules that bind to tet-0 sequences in the presence of tetracycline
and transactivate transgene expression. In this manner, background levels of
transgene expression are reportedly further reduced, thus this system would
appear to be the current inducible expression system of choice for analysing the
effects of potentially toxic or growth-limiting transgene expression within the cell
and for modelling replacement gene therapy.
Even in the light of improved inducible expression systems and correspondingly
in the ability to generate improved and accurate animal models, the ultimate goal
to effectively cure human genetic disease remains.
In this respect, a recently developed recombinant lentiviral (HIV-derived) vector
has been described as being able to deliver stable reporter gene expression to cells
within the brain, muscle and liver at higher efficiency relative to existing adeno-
and retroviral vectors (Naldini et al, 1996 and Kafri et al, 1997). Lentiviral
vectors are reportedly superior to both adenoviral and retroviral vectors as they
can efficiently transduce non-dividing cells and because they are pseudotyped
with YSVG (Vesicular Stomatitis Virus G) glycoprotein, they can potentially
transduce a wide variety of cell types in vivo with a high degree of efficiency.
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The application of recombinant lentivirus as means of introducing stable gene
expression in vivo has yet to be extensively tested and fully optimised however,
therefore their true potential as a means of efficiently transducing cells growing in
vivo, sufficient to enable direct evaluation of gene replacement therapeutic effect,
cannot presently be estimated.
Disruption of p53-mediated tumour suppression pathways appears to be a near
unifying feature of human tumourigenesis and therefore is an obvious candidate
gene to base the development of future anti-cancer treatments. Before
replacement gene therapy can be considered a viable alternative to conventional
chemotherapeutic and drug-based cancer treatments however, significant technical
improvement in the ability to deliver stable therapeutic gene expression to target
cells growing in vivo currently appears to be an absolute requirement.
Considering the inherent genetic instability of tumour cells, the task of attempting
to improve the means through which gene expression is introduced and
maintained, such that replacement gene therapy can become an effective means of




Section 1 - DNA Techniques
MM1.1
Heat-Shock Transformation of CaCL Competent E. Coli with Plasmid DNA
1. Add either 50ng of supercoiled plasmid DNA, or 10% volume of a plasmid
DNA ligation mixture to a freshly thawed 100|il aliquot of CaCh Competent
XL-1 blue E. Coli (Stratagene) on ice.
2. Gently mix samples by stirring with a p200 pipette tip and keep on ice for a
further 30 minutes.
3. Heat-shock sample tubes at 42°C for 45 seconds, before replacing back on ice
for 2 minutes.
4. Add 250|ll of LB broth to each sample tube and incubate at 37°C with shaking
(approx. 225 rpm) for 1 hour.
5. For routine transformation of supercoiled plasmid DNA, plate l/5th sample
volume, and for DNA ligation experiments, plate entire sample volume, onto
appropriate antibiotic containing LB-agar plate and incubate inverted at 37°C
overnight.
MM1.2
Preparation of Plasmid DNA from E. Coli
Mini-Prep
The preparation of plasmid DNA by this method should be sufficient to produce
between 20-50|lg DNA. This method was routinely used to provide sample DNA
for the analysis of cloning steps involved during the construction of all vectors
detailed within this thesis.
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1. Using a white-capped universal tube (Griener), inoculate 5mls of LB media
(supplemented with appropriate antibiotic) with a single bacterial colony
previously grown on a LB-agar plate (see section MM1.1).
2. Incubate sample at 37°C overnight with vigorous shaking (~225rpm).
N.B. - To promote efficient growth of bacterial culture, leave lid of universal
sample tube slightly loose to enable good oxygenation of sample.
The Following Day
1. The overnight culture should now appear turbid. Remove 1.5ml from each
sample and spin at 4,000rpm for 5 minutes on a desktop microfuge (Sanyo).
2. Carefully remove and discard all LB supernatant and add lOOpl of ice cold
Resuspension Buffer to remaining pellet. Vortex vigorously to ensure
complete resuspension of pellet.
3. Add 200pl of freshly prepared Lysis Buffer and gently invert sample tube
several times to mix. The bacterial suspension should clear.
4. Add 150p,l of Neutralisation Buffer and again gently invert sample tube
several times to mix. A cloudy white precipitate should form.
N.B. - Do not vortex sample tubes at stages 3 and 4, as this will shear
bacterial genomic DNA which could cause contamination of final plasmid
DNA prep.
5. Incubate samples from stage 4 on ice for 5 minutes before spinning at full
speed (13,000 rpm) on a desktop microfuge for 20 minutes.
6. Carefully remove and transfer supernatant to a clean 1,5ml eppendorf tube.
7. To remove protein from plasmid DNA sample, add 300|il of Tris-buffered
phenol and 300)ll of chloroform: iso-amyl alcohol mix (24 parts: 1 part
respectively). Vortex each sample thoroughly, before spinning at full speed
(13,000 rpm) on a desktop microfuge for 5 minutes.
8. Carefully remove aqueous (upper) phase to a clean 1.5ml eppendorf tube,
ensuring that no organic phase is carried over.
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9. Add 150(il of 3M Sodium Acetate (CH3COONa), pH 5.5 and 1ml of absolute
ethanol to precipitate plasmid DNA. Vortex thoroughly and place at -80°C for
1 hour.
10. Remove samples from -80°C freezer and spin at full speed (13,000 rpm) on a
desktop microfuge at 4°C for 20 minutes. A blue/white DNA pellet should
now be visible at the base of the eppendorf tube. Carefully remove and
discard supernatant without disturbing pellet.
11. To remove excess salt from plasmid DNA prep add 1ml of 70% ethanol,
gently invert tube several times and spin at full speed (13,000 rpm) on a
desktop microfuge for 5 minutes. Again, carefully remove and discard
supernatant without disturbing DNA pellet
12. All traces of ethanol must be removed from each sample prior to resuspension
of DNA pellet. Either, open and invert sample tubes on the bench to air-dry
for several hours, or place open sample tubes in a vacuum dryer for 5-10
minutes. To ensure resuspension of high-quality plasmid DNA, care should
be taken not to over-dry pellets.
13. The dried plasmid DNA pellets are finally resuspended in a 50pl volume of
either dH20 or TE buffer. Plasmid DNA prepared in this manner will be
stable long term at -20°C.
SOLUTIONS
LB Media (per litre)
lOg-NaCl
lOg - Bacto-Tryptone













60mls 5M Potassium Acetate
(C2H3K02)
11,5mls Glacial Acetic Acid
28.5mls dH20
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TE Buffer (pH 7.5)
lOmM Tris.Cl (pH=7.5)
ImM EDTA (pH=8.0)
N.B. - Final pH of solution is dependent upon the initial pH of Tris.Cl
Maxi-Prep
The preparation of plasmid DNA by this method should be sufficient to produce
between 200-500p.g DNA. This method employs the use of QIAGEN columns to
produce very high quality plasmid DNA in large quantities, suitable for the
purposes ofmammalian cell transfection and DNA sequencing.
1. Using a sterile 500ml conical flask, inoculate lOOmls of LB media
(supplemented with appropriate antibiotic) with a single bacterial colony
previously grown on a LB-agar plate (see section MM1.1).
2. Loosely cover the top of the conical flask with tinfoil and incubate sample at
37°C overnight with vigorous shaking (~225rpm).
The Following Day
All subsequent protocol steps and buffer compositions are detailed in the
"QIAGEN Plasmid Purification Handbook, January 1995", which is included with
every batch ofQIAGEN plasmid purification kits.
MM1.3
Restriction Digestion ofDNA
Examples of typical restriction digest reaction volumes are detailed below. These
include typical volumes for the analysis of plasmid DNA, for the cloning of
plasmid DNA and for the analysis of genomic DNA. Although total reaction
volumes and incubation times differ for each application of this technique, the
relative volume of restriction enzyme(s) should be consistent and never exceed
10% of the total reaction volume.
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Analysis of Plasmid DNA
lpl appropriate 10X React buffer (Gibco-BRL)
lpl of plasmid DNA (at an approximate concentration of lpg/pl)
0.5pl ofRNase A
6.5jll1 ofdH20
1 pi (or 10 units) of appropriate restriction enzyme(s) (Gibco-BRL)
* 1Opl total reaction volume
{Incubate at appropriate temperature for 1 hour}
Cloning of Plasmid DNA
3pl appropriate 10X React buffer (Gibco-BRL)
5pl of plasmid DNA (at concentration of lpg/pl)
0.5pl ofRNase A
18.5pl of dLLO
3pi (or 30 units) of appropriate restriction enzyme(s) (Gibco-BRL)
*3Opl total reaction volume
{Incubate at appropriate temperature for 3 hours}
Analysis of Genomic DNA
6pl appropriate 1 OX React buffer (Gibco-BRL)
1 Opg of genomic DNA
0.5pl ofRNase A
Sufficient dH20 to increase total reaction volume to 57pl
3pi (or 30 units) of appropriate restriction enzyme (Gibco-BRL)
*60pl total reaction volume
(Incubate at appropriate temperature over-night}
MM1.4
Southern Analysis of Genomic DNA
1. Digest 1 Opg genomic DNA overnight as detailed in section MM1.3
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2. Run out genomic digest on a 0.8% agarose gel until 500bp DNA marker
reaches the foot of the gel. Photograph gel and DNA markers beside a ruler to
enable accurate sizing of bands which subsequently hybridise to P32
radiolabeled probe.
3. (Optional) If fragment of interest is greater than 10Kb, depurination of DNA
within the gel prior to denaturation reportedly increases the efficiency of
DNA transfer to nylon filter.
Transfer gel to a tray containing several volumes of Depurination Solution.
Soak the gel, with gentle agitation, for 10 minutes. Rinse briefly with dITO.
4. Transfer gel to a tray containing several volumes of Denaturation Solution.
Soak the gel, with gentle agitation, for 45 minutes. Rinse briefly with dTfiO.
5. Transfer gel to a tray containing several volumes of Neutralisation solution.









1M Tris-HCl, pH 7
Capillary Transfer ofDNA from Gel to Nylon Filter
1. Fill a tray with lOx SSC.
2. Rest a piece of plastic on the sides of the tray to form a platform over the 10 x
SSC solution. Wrap the platform with a piece ofWhatmann 3MM filter paper
soaked in 2 x SSC, ensuring that all trapped air bubbles that arise between
paper and platform are removed and that the edges of the 3MM paper rest
within the 10 x SSC solution in the tray.
3. Place the neutralised gel on top of the 2 x SSC soaked 3MM paper. Cut
pieces of para-film to cover all wet areas of the 2 x SSC soaked 3MM paper
not already covered by the gel.
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4. Cut a piece Hybond N+ (Amersham) nylon filter to size, wet in dffO and
place on top of gel. Ensure the complete removal of all air bubbles that may
arise between gel and Hybond N+ filter.
N.B. - Marking one side of the nylon filter with pencil facilitates subsequent
orientation of the autoradiogram to the filter.
5. Cut two pieces of Whatmann 3MM paper to the size of the gel, wet in 2 x SSC
and place on top of Hybond N+ filter. Ensure the complete removal of all air
bubbles that may arise between 3MM paper and Hybond N+.
6. Place a stack of dry paper towels on top of the wet 3MM paper. Place a glass
plate over the top of the paper towel stack and weigh down with a large book
(or equivalent!). Cover the edges of the tray with cling-film to minimise the
evaporation of 10 x SSC and leave to transfer overnight.
This procedure should set up a flow of liquid from the reservoir in the tray,
through the gel and into the paper towels, transferring the digested DNA
fragments from within the gel onto the nylon membrane.
7. The following day, dismantle stack and dry Hybond N+ filter between two
sheets of 3MM Whatmann filter paper.
N.B. - the filter must dry completely to ensure fixation of the DNA to the
nylon membrane.
Hybridisation of Radio-Labelled Probe to DNA Immobilised on Nylon Membrane
1. Wet the dry DNA bound nylon filter membrane in 2 x SSC solution and place
on top of a piece of nylon gauze, wetted in dHaO. The layer of gauze ensures
even distribution of probe over the entire surface of the DNA bound nylon
membrane
2. Roll the two pieces of nylon together to form a tube and place inside of a
Hybaid hybridisation tube.
3. Add 25mls of pre-hybridisation solution (with 500pl boiled Salmon Sperm
DNA (Sigma; 10mg/ml)) to the hybridisation tube and incubate membrane at
65°C in a rolling incubator for 3 hours.
4. Boil P32 radiolabeled probe (see section MM1.5) for 10 minutes and pipette
into blue-capped Falcon tube. Immediately decant pre-hybridisation solution
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into Falcon tube containing probe, invert to mix, then quickly pour back into
Hybaid tube containing membrane. Incubate the probe with the membrane at
65°C, in a rolling incubator, overnight.
SOLUTIONS
Dextran Sulphate Stock Solution Pre-Hybridisation Solution
50g Dextran Sulphate dissolved in 15mls 20x SSC
300mls of dH20 5mls 10% SDS
30mls Dextran Sulphate Stock Solution
5. The following morning, decant probe/hybridisation solution from Hybaid tube
and rinse twice with 2 x SSC.
6. Add lOOmls Wash Solution I (pre-warmed to 65°C) to hybaid tube and
incubate at 65°C in the rolling incubator for 20 minutes before decanting.
7. Repeat this step a further four times by sequentially adding lOOmls pre-
warmed Wash Solution II through to V. In theory, this step removes non-
hybridised and non-specifically hybridised probe from the nylon filter
membrane.
Wash Solution I 2x SSC + 1% SDS in dH20 Lowest Stringency
Wash Solution II lx SSC + 1% SDS in dH20 i
Wash Solution III 0.5x SSC + 1% SDS in dH20 i
Wash Solution IV 0.25x SSC + 0.1% SDS in dH20 I
Wash Solution V O.lx SSC + 0.1% SDS in dH20 Highest Stringency
8. Following the last wash, remove filter membrane from Hybaid tube and gently
blot dry with a piece of Whatmann 3MM paper.
9. Seal filter into polythene bag and tape securely into auto-rad cassette (with
enhancer screens).
10. Overlay a piece of KODAK Biomax MS film (Amersham) over hybridised




Radiolabelling Probe with P by Random Priming
All probes were labelled with Stratagene's "Prime-it RmT Random Prier
Labelling Kit".
1. Add 50ng of probe DNA and dELO to a volume of 42pl in a single reaction
tube.
2. Boil sample tube for 5 minutes before briefly centrifuging to collect
condensation.
3. Add 3|Ltl of Magenta DNA polymerase and 5jil of P32 labelled dCTP (ICN).
Mix thoroughly and place reaction tube at 37°C for a minimum of 1 hour.
4. At end of labelling reaction add 2jll1 of stop reaction buffer.
Determination of Radio-Nucleotide Incorporation
1. Empty the contents of a Sephadex G50 column (Amersham) and wash resin
by allowing a minimum of 2mls TE buffer to pass through column.
2. Add 20pl of Salmon Sperm DNA to stopped probe labelling reaction tube,
mix thoroughly and add total volume directly onto Sephadex resin (take care
not to splash any volume of probe labelling mixture on column walls).
3. Add 400pil TE directly onto resin and collect flow through. This volume of
TE should not be significantly radioactive.
4. Add a further 400pl of TE directly onto resin and collect flow through. This
volume of TE should contain probe.
5. Compare residual counts in Sephadex column with those present in the
fraction of TE containing labelled probe. 50% label incorporation is achieved
if counts from both sources are approximately equal. This is the minimum





The following section details my lab protocols used to clone fragments of DNA
into plasmid vector backbones.
"Sticky" End Cloning
This technique is applicable when the restriction enzyme(s) used in the
preparation of DNA vector and insert are either identical and thus generate
identical 5' or 3' overhangs, or are different but generate compatible 5' or 3'
overhangs, (e.g. Bglll and BamHI recognise and cut at different sites, but
generate identical 5' overhangs).
1. Cut both insert and vector with the appropriate restriction enzyme(s) as
detailed in section MM1.3.
2. Following digestion, supplement the restriction digest of intended vector
sequence only with:
- lpl appropriate lOx reaction buffer
- 8(il dH20
- lpl Shrimp Alkaline Phosphate (S.A.P.)
Vortex sample tube to mix thoroughly and place reaction at 37°C for a further
hour.
N.B. - This step is optional but reduces the frequency of background cloning
products considerably by preventing the recircularisation of vector sequences
in the absence of insert. Enzymatic treatment with S.A.P. removes the
terminal-end phosphate groups from linearised vector sequence and thus
prevents the ligation of free vector ends in the absence of insert sequence.
3. Stop restriction digest and de-phosphorylation by adding 10% volume of
Loading Buffer.
218
4. Run DNA on a 0.8% agarose gel (or appropriate) to separate desired DNA
fragments from all non-required or undigested sequences present in the
sample.
5. Excise the appropriate digested vector and insert bands from the gel with a
scalpel blade and purify using QIAquick Gel extraction kit (Qiagen). See
manual provided with kit for protocol.
6. Run 10% of the gel-purified vector and insert fragments on a 0.8% agarose gel
beside known DNA standards. This step enables evaluation of both the
integrity and concentration of the purified DNA fragments.
N.B. - do not attempt to clone DNA fragments that appear as a slightly
diffuse or "smeary" band on an agarose gel. Anything other than a tight band
with little background at this stage of the cloning procedure indicates poor
integrity and/or degradation of the desired DNA fragment.
7. Set up ligation reaction using 50ng vector DNA and an approximate 3:1 molar
ratio (insert: vector) ofDNA fragments.
Ligation reaction
- 2pl 1 Ox Ligase buffer
- x)il DNA vector (equivalent to 50ng)
- xjllI DNA insert (to generate 3:1 molar ratio of insert to vector)
- xpl dhEO to adjust total reaction volume
Total reaction volume = 20|il.
8. Incubate ligation reaction at 16°C overnight.
9. The following day, transform CaCE competent bacteria with 10% of ligation
reaction as detailed in section MM1.1.
"Blunt" End Cloning
This technique is applicable when the restriction enzyme(s) used in the
preparation ofDNA vector and insert sequences either generate 5' or 3' overhangs
that are not compatible or cut to generate blunt ended DNA.
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1. Cut both insert and vector with the appropriate restriction enzyme(s) as
detailed in section MM1.3.
2. (a) If enzymes cut to generate non-compatible 5' overhangs, proceed to step 3.
(b) If enzymes cut to generate non-compatible 3' overhangs, proceed to step 4.
(c) If enzymes cut to generate a blunt ended DNA fragment, proceed to step 5.
3. Blunt ending DNA Fragments with 5' overhangs using Klenow Fragment
Supplement restriction digestion with the following components:
1 pi appropriate 1 Ox reaction buffer
4pl lOmM dNTP's (final reaction concentration = ImM)
- 4pl dH20
lpl Klenow fragment (Large)
Vortex to mix thoroughly and incubate sample for a further hour at 37°C.
(Proceed to step 5).
4. Blunt ending DNA Fragments with 3' overhangs using T4 DNA Polymerase
Supplement restriction digestion with the following components:
lpl appropriate lOx reaction buffer
4pl lOmM dNTP's (final reaction concentration = ImM)
- 4pl dH20
lpl T4 DNA Polymerase
Vortex to mix thoroughly and incubate sample for a further hour at 37°C.
(Proceed to step 5).
5. Supplement the restriction digest of intended vector sequence only with:
- lpl appropriate lOx reaction buffer
- 8pl dH20
- lpl Shrimp Alkaline Phosphate (S.A.P.)
220
Vortex sample tube to mix thoroughly and place reaction at 37°C for a further
hour.
6. Exactly follow protocol steps 4, 5 and 6 detailed in the previous protocol for
the cloning of "Sticky" ended fragments ofDNA.
7. Set up ligation reaction using 50ng vector DNA and an approximate 1:1 molar
ratio (insert: vector) ofDNA fragments.
Ligation reaction
- 2|li1 1 Ox Ligase buffer
- xpl DNA vector (equivalent to 50ng)
- xp,l DNA insert (to generate 1:1 molar ratio of insert to vector)
- x|Ltl dH20 to adjust total reaction volume
*Total reaction volume = 20pl.
8. Incubate ligation reaction at 16°C overnight.
9. The following day, transform CaCl2 competent bacteria with 10% of ligation
reaction as detailed in section MM1.1.
MM1.7
Construction of Vectorette Genomic DNA Libraries
The Vectorette genomic DNA libraries were constructed from 129/OLA ES cell
DNA (extracted as detailed in section MM4.1) by digesting total genomic DNA
with BamHI, Clal, EcoRI, Hindlll, EcoRV, XhoII restriction enzymes and
ligating the appropriate compatible vectorette tag.
1. Digest 1 jag of 129/OLA ES cell genomic DNA with 20 units of restriction
enzyme for 1 hour at 37°C (as detailed in section MM1.3), in a total reaction
volume of 50 |il.
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2. Add the following to restriction digest:
5jil Vectorette units (3pmol)
l(ll lOOmM ATP
l|ll lOOmM DTT
1 unit T4 DNA ligase
3. Incubate ligation reaction at 20°C for 1 hour, then 37°C (or appropriate) for 30
minutes. Repeat 3 times.
N.B. this repeated thermocycling enables optimal ligation efficiency of
synthetic tags to genomic DNA by enabling the digestion of tag: tag ligation
products and not tag: Genomic DNA products at 37°C.
If using a compatible 4-cutter enzyme, do not thermocycle and incubate
sample tube at a constant 20°C for 5 hours.
4. Following ligation, add 200jil dfUO and divide total reaction volume into
1 Opl aliquots. Store at-20°C.
5. Use l(il of Vectorette library as template per PCR amplification reaction, in
conjunction with sequence specific and synthetic DNA tag specific primers, as
detailed in section MM1.8
Synthetic Vectorette Primer Sequence:
5' CGA ATC GTA ACC GTT CGT ACG AGA A 3'
MM1.8
PCR amplification of DNA
The following reaction mix was standard for all PCR amplifications detailed
within this thesis. Only Mg2+ concentration and cycle conditions were varied to
enable optimisation of specific template amplification for each individual primer
pair (detailed at each relevant section throughout thesis).
The following reagents were prepared in a template free area:
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1 to 3mM MgCl2
dH20 to 98|ll
Once prepared, individual reaction tubes were transferred to a dedicated template
loading area where 1 jil of template was added to each sample, excepting negative
control (approx. 300ng genomic DNA or 1 (0,1 of a 10"6 plasmid dilution). 60|il of
paraffin oil was then overlaid to reduce sample evaporation during thermocycling.
All PCR reactions were "hot-started" to reduce the potential amplification of
background templates. Samples were pre-heated to 94°C for 1 minute prior to 1st
cycle and lpl Taq DNA polymerase (Advanced Biotechnologies) was added to
each sample tube below level of paraffin oil.
SOLUTIONS
1 OX Reaction Buffer IV
200mM (NH4)2S04
750mM Tris-HCl, pH 9.0
0.1. Tween 20
MM1.9
Dideoxy-Sequencing of Plasmid DNA with Sequenase
For best sequencing results, use plasmid DNA of the highest quality, preferably
prepared through a QIAGEN DNA column.
1. Take 10|LXg of plasmid DNA and add dH20 to a final volume of 45fil
2. Denature DNA by adding 5|ll of 2M NaOH, 2mM EDTA. Mix thoroughly by
inversion and keep at room temperature for 5 minutes.
223
3. Neutralise this strong alkali by adding 5|Ltl of 2M ammonium acetate, pH 4.6
and vortex.
4. To precipitate DNA, add 185|ul of ice-cold absolute ethanol, vortex and place
at -70°C for 30 minutes.
5. Spin sample tubes at 13,000 rpm for 10 minutes at 4°C and decant
supernatant. Wash pellet once with 200p.l ice-cold ethanol.
6. Dry DNA under vacuum for approximately 15 minutes then resuspend pellet
in 6|il of dHiO.
7. Anneal sequencing primer by adding 2|il 5X Annealing Buffer (Amersham)
and a 2pl volume (0.5pmol) of primer to resuspended DNA. Heat this mixture
to 65°C for 2 minutes, then allow temperature to drop slowly (approx. 30
minutes) to room temperature. Chill samples on ice.
8. Add 2.5pl of each dideoxy termination mix (Amersham) to 4 eppendorfs and
pre-warm to 37°C.
9. To the annealed reaction tube add:
l|il ofO.lMDTT
2pl Labelling Nucleotide Mix (Amersham)
0.5fil or 5(iCi radio-labelled dATP (cc-S35)
2|il of a 1:8 diluted stock of Sequenase Enzyme
(Addition of ljil 0.1M MnCB, 0.15M Sodium Isocitrate (optional) to the
labelling reaction will enable preferential sequencing ofDNA close to primer).
10.Mix total volume (approx. 1 5jll1) and incubate at room temperature for
between 2 to 5 minutes, depending on requirement to read sequence either
close or increasingly distant from the primer.
11. Transfer 3.5|il of labelling reaction to each of the four pre-warmed dideoxy
termination mixes.
12. Incubate termination reactions at 37°C for between 2-5 minutes before adding
4pl of Stop Solution (Amersham). Mix and either keep on ice prior to running
on sequencing gel, or store at -20°C.
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Preparation of a Polyacrylamide Sequencing Gel
1. Take two large sequencing plates and wash once with water and detergent,
then wash once with acetone. Coat the inner side of one plate with "Gel-slick"
(FMC BioProducts, USA) to facilitate the separation of both plates following
electrophoresis of samples. Ensure the inner sides of each plate are
completely clean, as any dust or residues remaining from previous gels will
trap air when pouring gel.
2. Mix the following in a 500ml beaker:
80mls 6%Acrylamide, 6M Urea, IX TBE
80pl 25% Ammonium Persulphate
80|ll TEMED
Immediately following the addition of TEMED pour gel-mix between glass
plates, place inverted sharks-tooth comb at the top of gel (so as to form a
single large well) and leave to polymerise at room temperature for between 45
to 60 minutes.
3. Following removal of comb, immediately transfer gel to electrophoresis rig,
ensuring that the smaller of the two glass plates is closest to rig apparatus. Fill
buffer tanks with IX TBE. Using a 50ml syringe, rinse out the single well
with buffer, ensuring that all non-polymerised gel is washed out.
4. Replace sharks tooth comb in the other orientation and apply pressure until the
tips of the "teeth" penetrate about 2-3mm into the gel. This will form
individual wells in which to load samples.
Denaturing PAGE of Sequencing Reactions
1. Immediately prior to the loading of the sequencing reactions, pre-run the
sequencing gel at 40W, or 1.7kV for 20 minutes or until the temperature of the
outer glass plate reaches approximately 50°C.
2. Heat samples to 80°C for 10 minutes, then place immediately on ice.
3. Load 2|ll of each reaction into one of the slots formed by the replaced sharks-
tooth comb. Try to ensure that the loading order of reactions is consistent
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(e.g. G, A, T, C from left to right) to enable subsequent ease and certainty in
the interpretation of sequencing results.
4. Run samples at 40W or 1,7kV until the bromophenol blue dye front from the
samples reaches the foot of the gel. The availability of free wells permitting,
stop the current and reload samples in spare wells. Re-apply electrical current
and run gel until either the bromophenol blue dye front of the newly loaded
samples, or the cyanol blue of the original samples, reaches the foot of the gel.
5. Dismantle electrophoresis rig, taking great care as the bottom TBE buffer
reservoir now contains S nucleotide. Separate the glass plates with a knife
and remove one to leave gel exposed.
6. Ensuring that the base plate upon which the gel rests is completely horizontal,
pour Gel Fix Solution over the entire surface area of the gel. Leave solution in
contact with the gel for 10 minutes (bromophenol blue dye turns yellow), then
drain by carefully tipping plate, ensuring that the gel does not become mobile
on plate surface.
7. To remove gel from the base plate, place a piece of Whatmann 3MM paper on
top of gel and press down firmly until the entire gel surface has come into
contact. Immediately pull the Whatmann 3MM paper away from the glass
plate in one rapid and constant movement. The gel should stick to the 3MM
paper and easily peel off from the surface of the plate.
8. Cover gel surface in cling film and dry in a Vacuum Dryer at 80°C for 2
hours, or until the gel is completely dry.
9. Place dried gel in an autoradiography cassette and overlay a piece of Bio-Max
MR film (Amersham). Expose film to gel at room temperature overnight and







Section 2 - RNA Techniques
MM2.0
Precautions that should be taken at All Times to avoid RNase contamination of
RNA samples
1. Gloves must be worn at all times.
2. Normal pipettes may be used ONLY in conjunction with RNase-free filter
tips.
3. All eppendorf or sample tubes must be removed from new bag with
gloved hands. Autoclave and dry tubes prior to use.
4. Dispense all solutions from dedicated "RNA only" stocks with a sterile
strippette into previously sealed 50ml blue-capped Falcon tubes.
5. Make up all solutions requiring dH20 with DEPC treated dH20.
MM2.1
Extraction of mRNA from Cultured Cells
1. Aspirate media from cells and wash lx in PBS.
2. Aspirate PBS from cells and add 1ml of TRIZOL Reagent (Gibco-BRL) per
10cm2 of culture dish.
N.B. TRIZOL is highly hazardous substance therefore read accompanying
health and safety information carefully prior to use and exercise great caution.
3. Leave at room temperature for approximately 2 minutes, and pass resultant
whole cell lysate several times through a blue (pi000) pipette tip.
4. Transfer cell lysate to a RNase-free eppendorf tube and add 200fll of
chloroform per 1ml TRIZOL.
5. Shake tubes vigorously for 15 seconds, then centrifuge samples at 13,000 rpm
for 15 minutes at 4°C. Remove the upper (colourless) aqueous phase and
transfer to a clean eppendorf.
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6. To precipitate RNA, add 500pil isopropyl alcohol per 1ml of TRIZOL reagent
used in the initial cell lysis. Mix thoroughly and incubate at room temperature
for 10 minutes. Centrifuge samples at 13,000 rpm for 10 minutes at 4°C, at
which time, RNA precipitate should be visible as a pellet at the base of the
sample tube.
7. To wash the RNA, remove supernatant from pellet and add 1ml of 70%
ethanol per 1ml of TRIZOL reagent used in the initial cell lysis. Vortex
sample thoroughly and centrifuge at 10,000 rpm for 5 minutes at 4°C. Discard
ethanol supernatant and briefly air-dry RNA pellet for between 5 to 10
minutes.
8. Resuspend pellet in an appropriate volume of RNase-free water by passing the
solution several times through a yellow (p200) tip and incubating at 55°C for
10 minutes.
MM2.2
Extraction of RNA from Fresh Tissue
1. For this technique it is essential that all samples of fresh tissue are
immediately frozen in liquid nitrogen following removal from host animal,
then rapidly transferred to -80°C storage prior to use.
2. Add 1ml of TRIZOL per lOOmg fresh tissue and homogenise thoroughly
using a "drill-bit" homogeniser.
For all subsequent instructions, follow steps 3 to 8 of section MM2.1.
MM2.3
Agarose Gel Analysis to Determine Integrity of Prepared RNA
1. To prepare agarose gel, melt the appropriate amount of agarose in DEPC
treated dFLO. Cool to approx. 60°C then add 5X formaldehyde gel-running
buffer and formaldehyde to generate a mix of:
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3.5 parts molten agarose/dHhO
1 part 12.3M formaldehyde stock solution
1.1 parts 5X formaldehyde gel-running buffer
Gel should be cast in a fume cabinet
2. To prepare RNA sample mix the following:
4.5|il RNA sample (up to 30p,g)
2.0|il 5X formaldehyde gel-running buffer
3.5|ll Formaldehyde
lO.Ojil Formamide
(Optional: add lpl of Ethidium Bromide at lmg/ml in DEPC treated dEEO to
enable visualisation ofRNA under UV light)
3. Incubate sample tube at 65°C for 15 minutes, then chill immediately on ice.
(briefly centrifuge to collect tube contents)
4. Add 2pl of Formaldehyde gel-loading buffer to each sample.
5. Run gel in IX formaldehyde gel-running buffer until dye-front reaches the
foot of the gel
6. The presence of well resolved and strong 28S and 18S rRNA bands infers




5X Formaldehyde Gel-Running Buffer
0.1M MOPS, pH 7.0 (pH adjusted with
Leave to stir over-night at room 2MNaOH)
temperature, with bottle cap slightly 40mM Sodium Acetate
open to equalise gas pressure.
Autoclave solution prior to use
5mM EDTA, pH 8.0
Filter sterilise (0.2|im) prior to use
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Formaldehyde Gel Loading Buffer
50% Glycerol
ImM EDTA, pH 8.0
0.25% Bromophenol Blue
0.25. Xylene Cyanol FF
MM2.4
Generation of cDNA from RNA Template with Reverse Transcriptase
First Strand cDNA Synthesis
1. To a PCR tube add the following:
lpl Oligo (dT)i2-i8 at 500fig/ml
l-5|ag total RNA
Make up volume to 12pl with DEPC treated dFBO
2. Fleat mixture to 70°C for 10 minutes, then quickly chill on ice. Briefly
centrifuge to collect contents of tube.
3. Now add:
4pl 5X First Strand Buffer (Gibco BRL; supplied with enzyme)
2pl 0.1MDTT
1 |il 1 OmM dNTP mix
4. Gently mix tube contents and incubate at 42°C for 2 minutes.
5. Add lpl (200 units) of Superscript II (Gibco BRL) and gently mix. Incubate
samples at 42°C for 50 minutes.
6. Following inactivation of reaction by incubating at 70°C for 15 minutes,
sample is ready to be used as template in conventional PCR reaction (see
section MM1.8).
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Section 3 - Protein and Immunological Techniques
MM3.1
Western Analysis of Protein
Extraction of Protein from Cultured Cells
It should be possible to extract lOOpg protein/per 106 cells via this method.
1. Trypsinise cells as detailed in section MM4.1 and wash cells once in ice cold
PBS.
2. Spin cells at 1,200 rpm for 5 minutes, discard supernatant and slightly loosen
cell pellet by flicking sample tube several times. Resuspend cell pellet in an
appropriate aliquot of ice-cold NP-40 Lysis Buffer (use approximately 5X
volume buffer: pellet). Invert tube several times and pipette up and down
several times with a blue (pi000) tip to ensure total cell lysis. Keep samples
on ice at all times.
3. To reduce viscosity of protein preparation, pass sample several times through
a 25-gauge syringe needle to shear chromosomal DNA.
4. Samples may be stored at -20°C prior to use.
Extraction of Protein from Fresh Tissue
1. For this technique it is essential that all samples of fresh tissue are
immediately frozen in liquid nitrogen following removal from host animal,
then rapidly transferred to -80°C storage prior to use.
2. Add the equivalent of 5X volume of NP-40 lysis buffer to each sample of
fresh tissue (i.e. 500jll lysis buffer per lOOmg fresh tissue) and homogenise
thoroughly using a "drill-bit" homogeniser.




50mM Tris/HCl pH 8.0
150mM NaCl
1% NP-40
1:1000 protease inhibitor cocktail stock (add immediately prior to use)
1:1000 PMSF stock (add immediately prior to use)
1000X Protease Inhibitor Cocktail
(Leupeptin; Pepstatin; Antipain Dihydrochloride; Chymostatin} at lmg/ml in
DMSO.
1000X PMSF (Phenylmethyl-sulfonyl Fluoride)
lOOmM PMSF in Ethanol
Quantitation of Sample Protein Concentration
Quantitation of sample protein concentration was achieved by Bradford Assay
using the "Bio-Rad Protein Assay" kit (Bio-Rad).
1. Dilute an appropriate volume of 5X assay reagent to IX with dPLO, sufficient
to provide 1ml reagent per protein standard /protein sample.
2. Measure and record the absorbance of known protein standards (ie 0|ig, 5}ig,
lOjig, 15|lg, 20jag, 25p.g and 50(_lg B.S.A.) at 595nm on a spectrophotometer.
3. Add 5|il from each sample to each 1ml aliquot of IX assay reagent, mix by
inversion and record absorbence at 595nm on a spectrophotometer.
4. Calculate the protein concentration of each sample by comparing recorded
absorbance with the recorded absorbencies of the known protein standards.
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Preparation of SDS-Polyacrylamide Gels
All SDS-PAGE of protein samples was performed using Bio-rad mini-PROTEAN
II equipment and gel multi-caster. The solution volumes described below are
sufficient to pour ten 12.5% mini-gels (0.75mm thickness) using gel multi-caster
apparatus.
1. To pour the separating phase (or the Running Gel) of the SDS-PAGE gel, mix
the following reagents in a 100ml conical flask:
25mls Monomer Solution
15mls 4X Running Gel buffer
0.6mls 10% SDS
19.1mis dH20
300JJ.1 10% Ammonium Persulphate
Finally add 20|ll TEMED, mix thoroughly and pour into the multi-gel caster
until level of fluid reaches approximately _ of the way from the top of the
plates.
2. Immediately overlay the un-polymerised gel mix with water-saturated butanol
and leave gel to polymerise at room temperature for between 45-60 minutes.
3. Pour offwater saturated butanol and wash polymerised gel once with dH20.
4. To pour the stacking phase of the SDS-PAGE gel, mix the following reagents
in a 100ml conical flask:
2.66mls Monomer Solution
5mls 4X Stacking Gel Buffer
0.2mls 10% SDS
12mls dH20
lOOp.1 10% Ammonium Persulphate
Finally add lOpl TEMED, mix thoroughly and pour into the multi-gel caster
until level of fluid reaches the top of the glass plates.
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5. Immediately insert 0.75mm combs into the un-polymerised stacking gel mix,
ensuring that no air becomes trapped and leave to polymerise at room
temperature for between 45-60 minutes.
6. Gels can be stored at 4°C for up to 1 month, providing they are kept moist
with TBS and sealed in clingfilm.
SOLUTIONS
Monomer Solution 4X Running Gel Buffer
40% acrylamide: bis-acrylamide mix 1,5M Tris.Cl, pH 8.8
(19:1); [Instagel]
4X Stacking Gel Buffer




(use upper phase only)
Preparation ofProtein Samples Prior to SDS-PAGE
1. Choose to run amount of sample equivalent to either 10 or 20|ig protein per
lane.
2. Add equivalent volume of 2X Sample Buffer to each protein sample.
3. Boil samples for 2 minutes, briefly centrifuge to collect tube contents and
place immediately on ice prior to loading onto gel.
SOLUTIONS
2X Sample Buffer






Running Protein Samples by SDS-PAGE
1. Rinse out the wells of the SDS-PA gel several times with dH20 and fix gel in
PROTEAN II electrophoresis tank, filled to approximately 1/3 capacity with
IX Running Buffer.
2. Fill the top compartment of gel tank with IX Running Buffer and carefully
load prepared protein samples, attempting to place entire sample as near to the
base of the well as possible.
3. Run at 30mA per gel for 50 minutes, or until bromophenol blue dye front
reaches base of the gel (PROTEAN II rig can accommodate a maximum of 2
gels).
Semi-Dry Transfer of Protein from SDS-PA to Nitrocellulose Membrane
1. Remove gel from between glass plates and place in IX Transfer Buffer for 5
to 10 minutes.
2. Assemble a stack of Whatmann 3MM filter paper (pre-wet in transfer buffer),
nitrocellulose membrane [Hybond ECL; Amersham] (pre-wet in dH20),
"soaked" gel and Whatmann 3MM filter paper (pre-wet in transfer buffer) on
top of the base plate of a semi-dry electrophoretic transfer unit (Fastblot B34,
Biometra).
3. If transferring one gel, run unit at 220mA for 25 minutes; transferring 2 gels,
run unit at 400mA for 30 minutes.
4. Stain nitrocellulose with Ponceau's Reagent for 5 minutes and rinse several
times in dH20 to determine the success of both PAGE and protein transfer.
SOLUTIONS
IX Running Buffer






IX Towbin Transfer Buffer
0.1% SDS
(final pH should be between 8.2 and 8.4)
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Immuno-Detection of p53 Fixed on Nitrocellulose
1. Pre-block nitrocellulose filter with 5% powdered milk (Marvel) in IX TTBS,
for 30 minutes.
2. Add 1° antibody (BMG-1; anti-p53 sheep polyclonal [Boehringer Mannheim])
at a concentration of lmg/ml in 5% powdered milk/ IX TTBS for 1 hour.
3. Wash filter three times in IX TTBS, for 10 minutes each wash, then add 2°
antibody (Rabbit anti-sheep, conjugated to peroxidase [DAKO]) diluted
1/1000 in 5% powdered milk/ IX TTBS. Leave 2° on for 30 minutes.
4. Wash filter three times in IX TTBS, for 10 minutes each wash. Leave last




lOOmM Tris.Cl, pH 7.5
0.9% NaCl
0.1% Tween-20
IX TTBS; 5% Powdered Milk
5g Marvel
lOOmls TTBS
ECL Detection of 10 Antibody
Follow protocol as detailed in the literature accompanying ECL detection kit
(Amersham). Once detected, place film optimised for ECL detection over filter
[Hyperfilm ECL; Amersham] and seal in an autoradiography cassette for between
5 minutes to 1 hour (film laid down initially for 5 minutes to determine strength of
signal).
MM3.2
P53 Immuno-analysis of Cultured Cells on Chamber Slides
1. Grow cells on Nunc 2-well (4.2cm2 per well), permanox coated, chamber
slides (Gibco BRL).
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2. At the appropriate time, aspirate media from cells, separate the microscope
slide (with cells adherent) from the culture wells and immerse slide in a
solution of 50% Acetone: 50% Methanol for 5 minutes at room temperature to
fix cells.
3. Remove cells from fix, air-dry and store at -70°C prior to immunostaining.
4. Following storage at -70°C, leave slides at room temperature for 30 minutes to
defrost. All subsequent steps are carried out at room temperature unless
specified.
5. Cover fixed cells with PBS for 10 minutes.
6. Shake off PBS and cover cells with a solution of 1% FfCF for 10 minutes to
block endogenous peroxidase activity.
7. Shake off H2O2 solution and cover cells with PBS for 5 minutes. Shake off
PBS from cells and repeat a further two times.
8. Cover cells with solution containing 20% Normal Rabbit Serum (NRS) and
0.5% Tween 20 in PBS for 10 minutes.
9. Shake off NRS/PBS/Tween and cover cells in PBS for 5 minutes
10. Shake off PBS and cover cells with Avidine D solution (from Biotin blocking
kit, SP 2001, Vector Laboratories) for 15 minutes to block endogenous biotin.
11. Shake off Avidine D and cover cells in PBS for 5 minutes. Shake off PBS and
repeat one further time.
12. Cover cells with Biotin solution (from Biotin blocking kit, SP 2001, Vector
Laboratories) for 15 minutes.
13. Shake off Biotin solution and cover cells with solution containing the primary
anti-p53 monoclonal antibody Pab421 (p53 (Ab-1) from Calbiochem, ref.
OP03) at a 1/1000 dilution in 5% NRS/ 0.5% Tween 20 in PBS. Leave cells
covered in this solution, in a humid chamber at 4°C overnight.
14.Shake off 1° antibody and cover cells in PBS for 5 minutes at room
temperature. Shake off PBS and repeat a further two times.
15.Cover cells with solution containing 2° antibody (Rabbit anti mouse
biotinylated F(ab')2 fragment, Rambio) at a 1/400 dilution in 5% NRS/ 0.5%
Tween 20 in PBS. Leave cells covered in this solution for 30 minutes at room
temperature.
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16. Shake off 2° antibody and cover cells in PBS for 5 minutes. Shake off and
repeat a further two times.
17.Incubate samples in ABComplex/HRP (DAKO) for 30 minutes at room
temperature
18. Shake off HRP-conjugated AB and cover cells in PBS for 5 minutes. Shake
off PBS and repeat one further time.
19. Visualise antibody binding by covering cells with DAB (Diaminobenzidine)
for approximately 5 minutes. Do not exceed 5 minutes to prevent non¬
specific background staining.
20. Wash samples immediately under running water to stop DAB staining.
21. Counter stain lightly with haematoxyline and light green. Dehydrate samples
in ascending grades of alcohol and mount cover slip.
SOLUTIONS
1 % H2Oz






(Adjust pH to 7.6)
MM3.3
P53 Immuno-histochemistry of Fixed Tissue on Microscope Slides
1. De-wax paraffin fixed samples in xylene for 1 minute, then re-hydrate samples
in descending grades of alcohol (i.e. from absolute ethanol through 74op to
64op; 1 minute in each). Wash samples in tap water after last ethanol
incubation.
2. Cover all samples in citrate buffer and microwave in a 700W oven at full
power for 3 x 5 minutes. Ensure that samples remain covered by buffer for
the entire duration of this treatment.
3. Cool samples to room temperature then wash in running tap water.
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4. Block endogenous peroxidase by covering samples in 0.5% H2O2 in methanol
for 15 minutes only. (This step appears to be critical).
5. Wash samples in tap water, then cover in TTBS buffer (see solutions section
MM3.1) for 5 minutes at room temperature twice.
6. Cover all samples in 20% Normal Swine Serum (NSS) in TTBS for 20
minutes at room temperature.
7. Incubate samples in 1° antibody (CM5; Rabbit polyclonal) at a dilution of
1:750 in 20% NSS in TTBS for either 1 hour at room temperature or at 4°C
overnight in a humid chamber.
8. Wash samples 5 times in TTBS for 2 minutes per wash.
9. Incubate samples in 2° antibody (swine anti-rabbit IgG Biotinylated; DAKO)
at a concentration of 1:400 in 20% NSS in TTBS for 30 minutes at room
temperature.
10. Wash samples 5 times in TTBS for 2 minutes per wash.
11.Incubate samples in ABComplex/HRP (DAKO) for 30 minutes at room
temperature.
12. Wash samples 5 times in TTBS for 2 minutes per wash.
13. Visualise antibody binding by covering cells in DAB for approximately 5
minutes. To reduce non-specific background staining do not exceed 5
minutes.
14. Wash samples immediately under running water to stop DAB staining.
15. Counter stain lightly with haematoxyline. Dehydrate samples in ascending
grades of alcohol and mount cover slip.
SOLUTIONS
Citrate Buffer
300mM Trisodium Citrate, pH 6.0
0.5% H7O? in Methanol
1.5mls of lOOvols stock H2O2
98.5mls of high-grade methanol
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MM3.4
Immuno-FIow Detection of p53
1. Trypisinize a minimum of lxlO^ cells and centrifuge at 1,200 rpm for 5
minutes. Wash the pellet once in PBS then repeat centrifugation step.
2. Aspirate PBS and add 1ml of 0.4% formaldehyde directly to the pellet.
Incubate the pellet with formaldehyde for 15 minutes on ice.
3. Pour off formaldehyde and resuspend pellet in 500|il of PBS. Centrifuge cells
at 3000 rpm for 5 minutes.
4. Pour off PBS and add 500jil of Permeabilisation Buffer to the pellet. Incubate
the pellet at 37°C for 15 minutes.
5. Pour off Permeabilisation Buffer and resuspend pellet in 500pl of PBS.
Centrifuge cells at 3000 rpm for 5 minutes.
6. Pour off PBS and add 100|il of normal sheep serum to pellet. Incubate pellet
for 5 minutes on ice with normal serum. Resuspend pellet in 500jil of PBS.
Centrifuge cells at 3000 rpm for 5 minutes.
7. Pour off PBS and resuspend pellet in 200pl of PBS. Split this total volume
between 2 wells of a 96 well plate. One well acts as a control for non-specific
FITC staining background. One well acts as the experimental sample.
8. Add 15pl of a 1/100 dilution (in Flow Buffer) of 1° anti-p53 (Ab-1) antibody
only to experimental sample. Incubate samples on ice for 1 hour.
9. Add 250jll1 of PBS and centrifuge on a plate-centrifuge at 300 G for 5 minutes.
10. Shake off PBS and add 1 5jll1 of a 1/50 dilution of 2° antibody (anti-mouse IgG
FITC conjugate) to both samples. Incubate on ice for 40 minutes.
11. Add 250|xl of PBS and centrifuge as detailed in step 9.
12. Shake off PBS and resuspend cells in 200pl of Flow Buffer. Run samples on
gated flow cytometer.
SOLUTIONS
Permeabilisation Buffer Flow Buffer




Section 4 - Cell Culture Techniques
MM4.1
ES cell culture
ES cells were routinely cultured at 37°C in CM media supplemented with 5%
(v/v) fetal calf serum, 5% (v/v) newborn calf serum (selected batches), (3-
mercaptoethanol and LIF (Leukaemia Inhibiting Factor) upon gelatinised tissue
culture plates.
Gelatinisation of Tissue Culture Plates
Gelatin (Sigma) is made up to 1% in dFLO, double autoclaved and stored at 4°C
This is equivalent to a 1 Ox stock solution.
Make up lx (0.1%) Gelatin solution and add sufficient volume to cover entire
base of tissue culture plate. Leave the gelatin solution on the tissue culture plate
for a minimum of 30 minutes at room temperature. Tissue plate is now
gelatinised and is ready for plating with ES cells.
Complete Media (CM)
500mls G-MEM (BHK-21) media (Gibco-BRL)
50mls Serum (25mls Fetal Calf Serum: 25mls Newborn Calf Serum)
5mls lOOx Non-Essential Amino Acids (Gibco-BRL)
5mls lOOx Sodium Pyruvate (Gibco-BRL)
500jil LIF (prepared and titred in lab as per standard protocols)
500)lx1 IOOOx [3-mercaptoethanol solution
1 OOOx (3-mercaptoethanol solution
1 OOp.1 pure (3-mercaptoethanol
14.1mis dFfO
(Filter sterilise solution through 0.2[im filter. Store at 4°C)
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Trypsinisation of ES Cells
ES cells should be routinely passaged 1 in 5 upon reaching approximately 70-80%
confluence.
1. Aspirate media from cells and wash once in PBS
2. Add appropriate volume of (IX) Trypsin-EDTA (Gibco-BRL) to cover entire
base of tissue culture plate.
3. Incubate cells at 37°C for 5 minutes, with occasional agitation of plate. This
should provide sufficient time to ensure that ES cells have detached from
tissue culture plate and have formed a single cell suspension. N.B. - monitor
ES cell detachment carefully and avoid over-trypsinisation as this can result in
cell lysis and a reduction in overall ES cell viability.
4. Neutralise Trypsin by adding a minimum of 2 volumes CM. ES cells are now
ready to be directly transferred to an area of gelatinised tissue culture plate or
for any of the further manipulations detailed in this section.
Freezing ES Cells
1. Following trypsinisation of ES cells, centrifuge cells at 1,200 rpm for 5
minutes.
2. Aspirate media and resuspend pellet in an appropriate volume of Freezing
Media (FM).
Plate area Volume of FM To Fill No. ofCryovials Area to Re-thaw Into
24-well 800|il 1 24-well
6-well 800pl 1 6-well
25cm2 1.6mls 2 6-well
75cm2 6.5mls 8 6-well
175cm2 13mls 16 6-well
3. Aliquot 800|ll of FM ES cell resuspension into appropriate number of
cryovials as detailed in table MM.4.1.
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4. Wrap rack of cryovials in paper towel and place at -80°C freezer overnight.
The following day, store cryovials in liquid nitrogen.
Freeze Media (FM)
80% CM
10% Serum (50% FCS: 50% NCS)
10% DMSO (Di-methyl Sulphoxide)
Thawing Frozen Stocks of ES Cells
1. Remove cryovial-containing cells from liquid nitrogen or -80°C storage and
thaw rapidly (with agitation) in 37°C waterbath.
2. Dilute contents of cryovial in lOx volume of CM media and spin immediately
at 1,200 rpm for 5 minutes.
3. Aspirate pellet and resuspend in volume of CM media appropriate to the area
of tissue culture plate to be used (lml=24-well plate; 3mls=6-well plate;
5mls=25cm2 flask)
Electroporation of ES Cells
1. Following trypsinisation of ES cells, centrifuge volume equivalent to 108 cells
at 1,200 rpm for 5 minutes.
2. Resuspend pellet in 0.7mls of PBS and transfer to electroporation cuvette
(Bio-Rad) containing 150pg of linearised vector DNA (suspended in 100p.l
PBS).
3. Pipette volume of cells up and down in electroporation cuvette once, to ensure
good mix of cells with DNA. Place cap on cuvette and pulse with a charge of
0.8kV, 3pF capacitance, resulting in a time constant of 0.1 seconds (Bio-Rad
Gene-Pulser).
4. Allow cells to recover for 20 minutes before adding 20mls ofCM.
5. Plate out cells on 10cm gelatinised plates in non-selective media at an
appropriate density to permit selection the following day (1x10s per plate for
FIAT selection; lxl06 per plate for all other antibiotic selections)
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HAT Selection and Picking of ES Cell Clones
1. 24 hours after transfection, replace non-selective CM with selective CM
containing 1 x HAT; 0.1 mM hypoxanthine, 0.4|aM aminopterin, 16|aM
thymidine (50x stock available from Boehringer Mannheim).
2. Refresh selective media on cells every 3 or 4 days until colonies of HAT
resistant clones become visible to the eye (usually within 12-13 days post-
transfection).
3. Prepare a 96 well plate containing lOOpd of trypsin-EDTA in each well.
Aspirate selective media from 10cm plate, wash lx in PBS and partially
aspirate leaving residual volume PBS sufficient to cover base of tissue culture
plate. This measure prevents dehydration of clones.
4. Place a p200 (yellow) tip over the HAT resistant ES cell clone and apply
gentle suction, thus taking the clone up into the pipette.
5. Pipette clone into a trypsin-EDTA containing well of the 96-well plate and
leave for 5 minutes at room temperature.
6. Pipette contents of well gently up and down once before transferring to a
single gelatinised well of a 24-well plate, containing 1ml of non-selective CM.
7. Refresh media the following day and replace with CM containing HAT
(optional).
Extraction of ES Cell DNA to Enable Subsequent Genetic Analysis
This protocol is essentially identical to that published by Laird et al, Nucleic
Acids Research, Vol. 19, no. 15, page 4293, 1991.
1. Following trypsinisation of ES cells, centrifuge cells at 1,200 rpm for 5
minutes. Wash cells once in PBS and re-centrifuge at 1,200 rpm for a further
5 minutes.
2. Partially aspirate PBS, leaving sufficient residual PBS to cover the pellet.
Flick the side of the tube until pellet has resuspended in this volume.
3. Add 600|itl of Lysis Buffer and either incubate at 55°C for 3 hours, or at 37°C
overnight.
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4. Add 500|il of isopropanol and shake on an orbital shaker for 15 minutes. The
DNA precipitate should now become visible.
5. Carefully remove DNA precipitate using a fine glass hook made from a
Pasteur pipette, and wash once in 70% ethanol.
6. Transfer DNA to an eppendorf tube containing 50p,l TE buffer and resuspend.
Incubation at 60°C for 30 minutes should aid resuspension in addition to
evaporating any trace residual ethanol.
Lysis Buffer




1 OOpg Proteinase K per ml
MM4.2
Sarcoma Cell Line (SL) Culture
Media Requirements
Media used for first 3 passages
500ml bottle of D-MEM-12 (Gibco
BRL)
50mls FCS
500pl Fungizone (50 mg/ml)
500pl Gentamycin (50mg/ml)
Media used for subsequent passages
500ml bottle of BHK-21 (Gibco BRL)
50mls FCS
500|_l1 Gentamycin (50mg/ml)
Following transfection of p6-16Lp53-
HYG add:-
800pl Hygromycin B (50mg/ml)
Using the above media, SL cells were passaged, trypsinised, frozen and thawed as
detailed for ES cells in section MM.4.1.
N.B. Gelatin treatment of tissue culture plates was not required prior to the plating
of SL cells.
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Derivation of SL Cell Lines from p53 Deficient Mice
1. Carefully remove sarcomas from p53 -/- mice and immerse each one in a
solution of 70% ethanol for 5 seconds to minimise risk of microbial infection.
2. Finely dissect sarcomas with a pair of sterile scalpel blades in a 10cm petri
dish. Drizzle resultant tumour pieces with a small volume (approximately
4mls) of culture medium to prevent dehydration.
3. Remove this volume of media from the mechanically sheared tumour pieces
and filter through a fine wire mesh sieve to produce a mix of single and small
aggregates of cells.
4. Plate 50% of these cells directly onto a 10cm petri dish.
5. To the remaining 50%, add several millilitres of medium containing
collagenase (concentration lOOU/ml; Gibco BRL). Place cells in a sealed
white capped universal and incubate at 37°C with gentle agitation for
approximately 30 minutes.
6. Centrifuge cells at l,200rpm for 5 minutes twice, aspirating and replacing
media both times, before plating as before at point 4.
7. Further dissect the remaining tumour pieces in the initial petri dish with sterile
scalpel blades as before. Drizzle tumour pieces with several millilitres of
medium containing 1 OOU/ml collagenase.
8. Remove this volume of media from the mechanically sheared and
enzymatically treated tumour pieces and filter through a fine wire mesh sieve
to produce a mix of single and small aggregates of cells. Centrifuge cells at
l,200rpm for 5 minutes twice, aspirating and replacing media both times,
before plating as before at point 4.
9. Place the remaining pieces of tumour into a white capped universal tube and
several millilitres of medium containing collagenase at a concentration of
1 OOU/ml. Incubate these cells at 37°C for 30 minutes with gentle agitation.
10.Centrifuge cells at l,200rpm for 5 minutes twice, aspirating and replacing
media both times, before plating as before at point 4.
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Transfection of SL Cells via Liposomes
1. Plate 6 x 104 cells per 2cm2 (single well of a 24 well plate) on the evening
prior to transfection.
2. The following day, dilute DNA in normal serum containing media
(approximately 1 pig plasmid DNA in 250|il medium per 2cm2). N.B. It is
possible to transfect cells in both serum containing and serum free media
conditions. Determine optimal transfection conditions empirically
3. Vigorously vortex stock solution of Tfx-50 (Promega) for 30 seconds, then
add an appropriate volume to diluted DNA to generate optimal charge ratio of
lipid: DNA (see section 2.vi.l).
4. Vortex Tfx/DNA/medium mix thoroughly and leave at room temperature for a
minimum of 10-15 minutes. Do not leave longer than 30 minutes.
5. Immediately prior to transfection, aspirate medium from cells. Vortex
Tfx/DNA/medium mix again and add 250pl of mix to each 24 well.
6. Leave Tfx/DNA/medium mix on cells for 2 hours at 37°C.
7. Following this 2 hour exposure, add 1ml of normal serum containing medium
to each well and return plates to 37°C incubator.
8. Collect cell lysates 48 hours after transfection and store at -20°C prior to
reporter gene analysis. N.B. Reporter cell lysis buffer comes included with
both the (3-Galactosidase Enzyme Assay System (Promega, Cat. # E2000) and
the Luciferase Assay System (Promega, Cat. #E4030). The protocols
describing both [3-Gal and Luciferase reporter assays can be found at
[http://www.promega.com]. The extent of [3-Gal expression was quantitated
using an ELISA plate reader (Dynatech MR5000) and Biolinx v2.20 software.
The extent of luciferase expression was quantitated by standard luminometer
detection.
Selection and Picking of SL Clones
1. The day following transfection with p6-16Lp53-HYG, SL cells were cultured
in media supplemented with 80|Xg/ml Hygromycin B (Boehringer Mannheim).
2. Individual clones were visible by the 12th day of selection. Clones grew as
monolayers and therefore could not be picked by the p200 pipette tip method
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as described for the picking of ES cell clones. All hygromycin resistant clones
were picked using a cloning "ring" method.
3. To prepare cloning rings, slice off and collect the wide ends of pi000 (blue)
pipette tips using a red-hot scalpel blade. Autoclave rings prior to use.
4. Aspirate culture dish containing clones and wash once with PBS. Using fine
forceps, dip each cloning ring in sterile paraffin wax and place over each
individual clone to form a series of small wells.
5. Add 150|ll of (IX) Trypsin-EDTA (Gibco BRL) to each cloning well and
incubate at 37°C for 5 minutes.
6. Add 500pl culture medium to each well to neutralise trypsin and pipette up
and down several times to ensure single cell suspension.
7. Transfer total volume to a single well of a 24 well plate and culture normally.
Induction of Transgene Expression
5 2
1. Plate 2x10 cells per 10cm on the day preceding induction.
2. The following day, cells should be approaching 70% confluence. Aspirate
medium from cells and refresh in media containing either 500 or 1000 I.R.U.
(International Reference Units) of interferon a/|3 (SIGMA, cat no. 11258).
MM4.3
Flow Cytometric DNA Analysis of Cultured SL Cells
1. Following trypsinisation of cells as detailed in section MM4.1, centrifuge a
minimum of 1 x 105 cells at 1,200 rpm for 5 minutes, wash once in PBS and
centrifuge again as before.
2. Aspirate PBS until a small volume remains covering the pellet of cells. Flick
sample tube wall to resuspend pellet in this small volume.
3. Add 225pl of Solution A to cells. Leave at room temperature for 15 minutes.
4. Add 163.5jil of Solution B to cells. Leave at room temperature for 15
minutes. At this stage, samples can be stored at 4°C overnight.
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5. Immediately prior to analysing samples on flow cytometer, add 125(il of
Solution C. Briefly vortex sample to mix and leave at room temperature for 5
minutes before running on flow cytometer.
N.B. Samples must be run rapidly following addition of Solution C as they







Make up to 1 litre in dbfO and pH to 7.6
Solution A
15mg Trypsin (SIGMA)










in 500ml Stock Solution
N.B. All the above solutions should be made up in the volumes specified and
stored as 10ml aliquots at -20°C prior to use.
MM4.4
Visualisation of Apoptosis by Acridine Orange Staining
1. Trypsinise cells as detailed in section MM4.1, spin at 1,200 rpm for 5 minutes
and wash pellet lx in PBS.
2. Aspirate PBS until a small volume remains covering the pellet of cells. Flick
sample tube wall to resuspend pellet in this volume. Add 100|al of Fix
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Solution (90% ethanol: 10% formalin) and leave at room temperature for 5
minutes.
3. Take up 20pl of the fixed single cell suspension and add 20jitl of Acridine
Orange solution (10pg/ml in PBS). Visualise cells by fluorescence
microscopy and score the numbers of apoptotic cells in relation to total cell
number.
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Section 5 - Whole Animal Techniques
MM5.1
Subcutaneous Injection of SL Cells
1 . Trypsinise cells as detailed in section MM4.1 and count using
haemocytometer.
2. Centrifuge cells at 1,200 rpm for 5 minutes and resuspend in sufficient volume
of PBS to provide 1 x 107 cells per ml.
3. Inject 500pl of cells sub-cutaneously into each flank of a SCID animal.
MM5.2
In vivo Induction of Type I Interferons with plrpC
1. Resuspend lyophilised pI:pC (Pharmacia, cat.# 27-4729) in PBS to a final
concentration of lmg/ml.
2. Inject between 50(Hg to 250pg plrpC intra-peritoneally per SCID mouse.
N.B. - Both the sub-cutaneous injections of SL cells and the IP injections of
plrpC were undertaken by the animal handling staff (John Verth, Will
Mungall and Linda Clark) of the University of Edinburgh Medical School.
MM5.3
Apoptotic Analysis of Whole Length Small Intestine
1. Sacrifice animal and remove an approximate 10cm length of intact small
intestine.
2. Using a 50ml Syringe with a yellow (p200) tip attached, flush out contents of
intestine with dKfiO.
3. Place intestine on a piece of dry Whatmann 3MM paper. Once stretched out,
drizzle with dffiO to prevent dehydration.
4. Using a fine pair of dissection scissors, carefully cut the entire length of
intestine longitudinally to form a single flat strip of exposed lumen
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5. To fix section, transfer intestine on Whatmann 3MM paper to a glass tray
containing Methocarn Solution. Leave intestine in methocarn for a minimum
of 1 hour at room temperature.
6. Using two pairs of watchmaker's forceps, gently lift intestine from Whatmann
3MM paper and roll to form a moderately packed spiral of tissue. Hold
structure together by piercing through with a hypodermic syringe needle and





1 part Concentrated Acetic Acid
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